<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":4.19667,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpFDgMTC1IAC1xcX0tKVBQWCAVfBhcfGRdUFV0HEE9UA1FVHgUPB1UFVU0HE18P","queueTime":0,"ttGuid":"cc622d0c4af6db48"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/full">
<meta property="description" name="description" content="Aims The short QT syndrome type 1 (SQT1) is linked to hERG channel mutations (e. g. N588K). Drug effects on hERG channel gating kinetics in SQT1-cells have n...">
<meta property="og:title" name="title" content="Frontiers | Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1">
<meta property="og:description" name="description" content="Aims The short QT syndrome type 1 (SQT1) is linked to hERG channel mutations (e. g. N588K). Drug effects on hERG channel gating kinetics in SQT1-cells have n...">
<meta name="keywords" content="short QT syndrome,arrhythmias,Antiarrhythmic drugs,Human-induced pluripotent stem cell-derived cardiomyocytes,HERG channel">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="12">
<meta name="citation_journal_title" content="Frontiers in Pharmacology">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Pharmacol.">
<meta name="citation_issn" content="1663-9812">
<meta name="citation_doi" content="10.3389/fphar.2021.675003">
<meta name="citation_firstpage" content="675003">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1">
<meta name="citation_keywords" content="short QT syndrome; arrhythmias; Antiarrhythmic drugs; Human-induced pluripotent stem cell-derived cardiomyocytes; HERG channel">
<meta name="citation_abstract" content="Aims The short QT syndrome type 1 (SQT1) is linked to hERG channel mutations (e. g. N588K). Drug effects on hERG channel gating kinetics in SQT1-cells have not been investigated. Methods This study used hiPSC-CMs of a healthy donor and a SQT1-patient carrying the N588K mutation and patch clamp to examine the drug effects on hERG channel gating kinetics. Results   Ajmaline, amiodarone, ivabradine, flecainide, quinidine, mexiletine and ranolazine inhibited the hERG channel current (IKr) less strongly in hiPSC-CMs from the SQTS1-patient (SQT1-hiPSC-CMs) comparing with cells from the healthy donor (donor-hiPSC-CMs). Quinidine and mexiletine reduced, but ajmaline, amiodarone, ivabradine and ranolazine increased the time to peak of IKr similarly in SQT1-hiPSC-CMs and donor-hiPSC-CMs. Although regarding the shift of activation and inactivation curves, tested drugs showed differential effects in donor- and SQT1-hiPSC-CMs, quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine reduced the window current in SQT1-hiPSC-CMs. Quinidine, ajmaline, ivabradine and mexiletine differentially changed the time constant of recovery from inactivation, but all of them increased the time constant of deactivation in SQT1-hiPSC-CMs. Conclusion The window current-reducing and deactivation-slowing effects may be important for the antiarrhythmic effect of ajmaline, ivabradine, quinidine and mexiletine in SQT1-cells. This information may be helpful for selecting drugs for treating SQT1-patients with hERG channel mutation.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2021/04/26">
<meta name="citation_publication_date" content="2021/05/07">
<meta name="citation_author" content="Huang, Mengying ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Liao, Zhenxing ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Li, Xin ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Yang, Zhen ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Fan, Xuehui ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Li, Yingrui ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Zhao, Zhihan ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Lang, Siegfried ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Cyganek, Lukas ">
<meta name="citation_author_institution" content="DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G?ttingen, Germany">
<meta name="citation_author" content="Zhou, Xiaobo ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Akin, Ibrahim ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="Borggrefe, Martin ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="citation_author" content="El-Battrawy, Ibrahim ">
<meta name="citation_author_institution" content="First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany">
<meta name="dc.identifier" content="doi:10.3389/fphar.2021.675003">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1","author":[{"@type":"Person","name":"Mengying Huang","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany"]},{"@type":"Person","name":"Zhenxing Liao","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","North Sichuan Medical College, China"]},{"@type":"Person","name":"Xin Li","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","College of Medical Technology, Chengdu University of Traditional Chinese Medicine, China"]},{"@type":"Person","name":"Zhen Yang","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","North Sichuan Medical College, China"]},{"@type":"Person","name":"Xuehui Fan","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, China"]},{"@type":"Person","name":"Yingrui Li","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany"]},{"@type":"Person","name":"Zhihan Zhao","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany"]},{"@type":"Person","name":"Siegfried Lang","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G?ttingen, Germany"]},{"@type":"Person","name":"Lukas Cyganek","affiliation":["DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G?ttingen, Germany","Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center G?ttingen, Germany"]},{"@type":"Person","name":"Xiaobo Zhou","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, China","DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G?ttingen, Germany"]},{"@type":"Person","name":"Ibrahim Akin","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G?ttingen, Germany"]},{"@type":"Person","name":"Martin Borggrefe","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G?ttingen, Germany"]},{"@type":"Person","name":"Ibrahim El-Battrawy","affiliation":["First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany","DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G?ttingen, Germany"]}],"datePublished":"2021-05-07","dateModified":"2025-11-26","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2021","isPartOf":{"@type":"PublicationVolume","volumeNumber":"12","isPartOf":{"@type":"Periodical","name":"Frontiers in Pharmacology"}}},"citation":["https://doi.org/10.3389/fphar.2021.675003"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/pharmacology" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Pharmacology</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=62&amp;specialtyid=0&amp;entitytype=2&amp;entityid=176" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/pharmacology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Pharmacology</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/cardiovascular-and-smooth-muscle-pharmacology" data-event="iBarJournal-sections-a_id_182">Cardiovascular and Smooth Muscle Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drug-metabolism-and-transport" data-event="iBarJournal-sections-a_id_199">Drug Metabolism and Transport</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drugs-outcomes-research-and-policies" data-event="iBarJournal-sections-a_id_202">Drugs Outcomes Research and Policies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/ethnopharmacology" data-event="iBarJournal-sections-a_id_184">Ethnopharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/experimental-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_183">Experimental Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/gastrointestinal-and-hepatic-pharmacology" data-event="iBarJournal-sections-a_id_186">Gastrointestinal and Hepatic Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/inflammation-pharmacology" data-event="iBarJournal-sections-a_id_188">Inflammation Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/integrative-and-regenerative-pharmacology" data-event="iBarJournal-sections-a_id_178">Integrative and Regenerative Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/neuropharmacology" data-event="iBarJournal-sections-a_id_26">Neuropharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/obstetric-and-pediatric-pharmacology" data-event="iBarJournal-sections-a_id_196">Obstetric and Pediatric Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacoepidemiology" data-event="iBarJournal-sections-a_id_2186">Pharmacoepidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-infectious-diseases" data-event="iBarJournal-sections-a_id_2216">Pharmacology of Infectious Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-ion-channels-and-channelopathies" data-event="iBarJournal-sections-a_id_179">Pharmacology of Ion Channels and Channelopathies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/predictive-toxicology" data-event="iBarJournal-sections-a_id_195">Predictive Toxicology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/renal-pharmacology" data-event="iBarJournal-sections-a_id_1357">Renal Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/respiratory-pharmacology" data-event="iBarJournal-sections-a_id_190">Respiratory Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/translational-pharmacology" data-event="iBarJournal-sections-a_id_1251">Translational Pharmacology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=62&amp;specialtyid=0&amp;entitytype=2&amp;entityid=176" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/pharmacology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Pharmacology</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/cardiovascular-and-smooth-muscle-pharmacology" data-event="iBarJournal-sections-a_id_182">Cardiovascular and Smooth Muscle Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drug-metabolism-and-transport" data-event="iBarJournal-sections-a_id_199">Drug Metabolism and Transport</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drugs-outcomes-research-and-policies" data-event="iBarJournal-sections-a_id_202">Drugs Outcomes Research and Policies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/ethnopharmacology" data-event="iBarJournal-sections-a_id_184">Ethnopharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/experimental-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_183">Experimental Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/gastrointestinal-and-hepatic-pharmacology" data-event="iBarJournal-sections-a_id_186">Gastrointestinal and Hepatic Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/inflammation-pharmacology" data-event="iBarJournal-sections-a_id_188">Inflammation Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/integrative-and-regenerative-pharmacology" data-event="iBarJournal-sections-a_id_178">Integrative and Regenerative Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/neuropharmacology" data-event="iBarJournal-sections-a_id_26">Neuropharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/obstetric-and-pediatric-pharmacology" data-event="iBarJournal-sections-a_id_196">Obstetric and Pediatric Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacoepidemiology" data-event="iBarJournal-sections-a_id_2186">Pharmacoepidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-infectious-diseases" data-event="iBarJournal-sections-a_id_2216">Pharmacology of Infectious Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-ion-channels-and-channelopathies" data-event="iBarJournal-sections-a_id_179">Pharmacology of Ion Channels and Channelopathies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/predictive-toxicology" data-event="iBarJournal-sections-a_id_195">Predictive Toxicology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/renal-pharmacology" data-event="iBarJournal-sections-a_id_1357">Renal Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/respiratory-pharmacology" data-event="iBarJournal-sections-a_id_190">Respiratory Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/translational-pharmacology" data-event="iBarJournal-sections-a_id_1251">Translational Pharmacology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/pharmacology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Pharmacology</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/cardiovascular-and-smooth-muscle-pharmacology" data-event="iBarJournal-sections-a_id_182">Cardiovascular and Smooth Muscle Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drug-metabolism-and-transport" data-event="iBarJournal-sections-a_id_199">Drug Metabolism and Transport</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/drugs-outcomes-research-and-policies" data-event="iBarJournal-sections-a_id_202">Drugs Outcomes Research and Policies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/ethnopharmacology" data-event="iBarJournal-sections-a_id_184">Ethnopharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/experimental-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_183">Experimental Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/gastrointestinal-and-hepatic-pharmacology" data-event="iBarJournal-sections-a_id_186">Gastrointestinal and Hepatic Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/inflammation-pharmacology" data-event="iBarJournal-sections-a_id_188">Inflammation Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/integrative-and-regenerative-pharmacology" data-event="iBarJournal-sections-a_id_178">Integrative and Regenerative Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/neuropharmacology" data-event="iBarJournal-sections-a_id_26">Neuropharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/obstetric-and-pediatric-pharmacology" data-event="iBarJournal-sections-a_id_196">Obstetric and Pediatric Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacoepidemiology" data-event="iBarJournal-sections-a_id_2186">Pharmacoepidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-infectious-diseases" data-event="iBarJournal-sections-a_id_2216">Pharmacology of Infectious Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/pharmacology-of-ion-channels-and-channelopathies" data-event="iBarJournal-sections-a_id_179">Pharmacology of Ion Channels and Channelopathies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/predictive-toxicology" data-event="iBarJournal-sections-a_id_195">Predictive Toxicology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/renal-pharmacology" data-event="iBarJournal-sections-a_id_1357">Renal Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/respiratory-pharmacology" data-event="iBarJournal-sections-a_id_190">Respiratory Pharmacology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/pharmacology/sections/translational-pharmacology" data-event="iBarJournal-sections-a_id_1251">Translational Pharmacology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/pharmacology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=62&amp;specialtyid=0&amp;entitytype=2&amp;entityid=176" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Pharmacol.</span><span>, 07 May 2021</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Pharmacology of Ion Channels and Channelopathies</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 12 - 2021 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fphar.2021.675003">https://doi.org/10.3389/fphar.2021.675003</a></p><!----></div><!----><!----></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract"><a id="h1" name="h1"></a><div class="authors"><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1251801" class="user-id-1251801"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1251801/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Mengying Huang&#x;">Mengying Huang</a><sup>1</sup><sup>&#x02020;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Zhenxing Liao,&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Zhenxing Liao<sup>1,2</sup><sup>&#x02020;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Xin Li,&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Xin Li<sup>1,3</sup><sup>&#x02020;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Zhen Yang," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Zhen Yang<sup>1,2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1252911" class="user-id-1252911"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1252911/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Xuehui Fan,">Xuehui Fan</a><sup>1,4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Yingrui Li" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Yingrui Li<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Zhihan Zhao" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Zhihan Zhao<sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/701611" class="user-id-701611"><img class="pr5" src="https://loop.frontiersin.org/images/profile/701611/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Siegfried Lang,">Siegfried Lang</a><sup>1,5</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/822000" class="user-id-822000"><img class="pr5" src="https://loop.frontiersin.org/images/profile/822000/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Lukas Cyganek,">Lukas Cyganek</a><sup>5,6</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/815918" class="user-id-815918"><img class="pr5" src="https://loop.frontiersin.org/images/profile/815918/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Xiaobo Zhou,,&#xa;">Xiaobo Zhou</a><sup>1,4,5</sup>&#x0002a;</span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Ibrahim Akin," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Ibrahim Akin<sup>1,5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Martin Borggrefe," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Martin Borggrefe<sup>1,5</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/368363" class="user-id-368363"><img class="pr5" src="https://loop.frontiersin.org/images/profile/368363/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Ibrahim El-Battrawy,">Ibrahim El-Battrawy</a><sup>1,5</sup></span></div><ul class="notes"><li><span><sup>1</sup></span>First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Mannheim, Germany</li><li><span><sup>2</sup></span>North Sichuan Medical College, Nanchong, China</li><li><span><sup>3</sup></span>College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China</li><li><span><sup>4</sup></span>Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China</li><li><span><sup>5</sup></span>DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G&#x000f6;ttingen, Mannheim, Germany</li><li><span><sup>6</sup></span>Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center G&#x000f6;ttingen, G&#x000f6;ttingen, Germany</li></ul><p class="mb15"><strong>Aims:</strong> The short QT syndrome type 1 (SQT1) is linked to hERG channel mutations (e.g., N588K). Drug effects on hERG channel gating kinetics in SQT1-cells have not been investigated.</p><p class="mb15"><strong>Methods:</strong> This study used hiPSC-CMs of a healthy donor and a SQT1-patient carrying the N588K mutation and patch clamp to examine the drug effects on hERG channel gating kinetics.</p><p class="mb15"><strong>Results:</strong> Ajmaline, amiodarone, ivabradine, flecainide, quinidine, mexiletine and ranolazine inhibited the hERG channel current (I<sub>Kr</sub>) less strongly in hiPSC-CMs from the SQTS1-patient (SQT1-hiPSC-CMs) comparing with cells from the healthy donor (donor-hiPSC-CMs). Quinidine and mexiletine reduced, but ajmaline, amiodarone, ivabradine and ranolazine increased the time to peak of I<sub>Kr</sub> similarly in SQT1-hiPSC-CMs and donor-hiPSC-CMs. Although regarding the shift of activation and inactivation curves, tested drugs showed differential effects in donor- and SQT1-hiPSC-CMs, quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine reduced the window current in SQT1-hiPSC-CMs. Quinidine, ajmaline, ivabradine and mexiletine differentially changed the time constant of recovery from inactivation, but all of them increased the time constant of deactivation in SQT1-hiPSC-CMs.</p><p class="mb15"><strong>Conclusion:</strong> The window current-reducing and deactivation-slowing effects may be important for the antiarrhythmic effect of ajmaline, ivabradine, quinidine and mexiletine in SQT1-cells. This information may be helpful for selecting drugs for treating SQT1-patients with hERG channel mutation.</p><div class="clear"></div></div><div class="JournalFullText"><a id="h2" name="h2"></a><h2>Introduction</h2><p class="mb15">Short QT syndrome (SQTS), described initially by Gussak et al., in 2000 (<a href="#B30">Gussak et al., 2000</a>), is a rare, inheritable heart disease associated with abbreviated corrected QT interval (QTc) and sudden cardiac death (SCD). So far, genes reported to be associated with SQTS include KCNH2 (SQTS1), KCNQ1 (SQTS2) and KCNJ2 (SQTS3) (<a href="#B11">Campuzano et al., 2018</a>). In addition, a mutation in the cardiac Cl/HCO3 exchanger AE3 has also been reported in patients with SQTS (<a href="#B68">Thorsen et al., 2017</a>).</p><p class="mb15">The therapeutic approaches for SQTS are challenging for physicians because of the low prevalence and rare cases. Until now, a small number of drugs including disopyramide, nifekalant, quinidine, flecainide, sotalol, ibutilide and propafenone have been tested by <em>in vivo</em> studies on SQTS1 (<a href="#B1">Abriel and Rougier, 2013</a>), among which only quinidine has shown profit effect in the treatment (<a href="#B50">Mizobuchi et al., 2008</a>; <a href="#B27">Giustetto et al., 2011</a>; <a href="#B42">Mazzanti et al., 2017</a>; <a href="#B19">El-Battrawy et al., 2018</a>; <a href="#B20">El-Battrawy et al., 2019</a>). In human-induced stem cell-derived cardiomyocytes (hiPSC-CMs) from a patient with SQTS type 1, besides quinidine, disopyramide, ajmaline, ivabradine and mexiletine but not sotalol, amiodarone, flecainide and ranolazine showed profitable (APD-prolonging and antiarrhythmic) effects (<a href="#B65">Shinnawi et al., 2019</a>; <a href="#B84">Zhao et al., 2019</a>; <a href="#B39">Lan et al., 2020</a>).</p><p class="mb15">Since SQT1 is caused by an enhanced (a gain-of-function) hERG channel current, hERG channel blockers should be effective for prolonging QT interval or reducing the chance of arrhythmias in SQT1-patients. Surprisingly, some classical hERG channel blockers like sotalol and ibutilide failed to prolong QTc interval in SQT1-patients (<a href="#B26">Gaita et al., 2004</a>; <a href="#B20">El-Battrawy et al., 2019</a>), suggesting that the mutation in the hERG channel changed the sensitivity of the channel to drugs. Indeed, it was found that some drugs mainly affect hERG channels in the inactivated state and the SQTS1 is caused by a mutation in the hERG channel, which impairs inactivation of the channel and hence reduce the channel sensitivity to those drugs (<a href="#B43">McPate et al., 2008</a>). Quinidine affects both the open and inactivated hERG channels and can still inhibit hERG channels even when the inactivation is impaired. This could be an explanation for the failure of some drugs in treating SQTS1. Therefore, numerous studies focused on influences of mutations on channel sensitivity and/or affinity of hERG channels to drugs. However, the sensitivity change cannot explain some phenomena, for example, amiodarone, propafenone and quinidine inhibited N588K-hERG channels in a similar intensity, but only quinidine is effective in prolonging QTc or action potential duration (APD) and suppressing arrhythmic events in SQT1-patients or SQT1-cells (<a href="#B43">McPate et al., 2008</a>; <a href="#B84">Zhao et al., 2019</a>). This suggests other mechanisms may also play important roles for the efficacy of drugs for SQTS-patients. In our recent studies, using hiPSC-CMs from a patient carrying N588K mutation in hERG channels, we tested the APD-prolonging and antiarrhythmic effects of quinidine, sotalol, ajmaline, amiodarone, ivabradine, flecainide, mexiletine and ranolazine, which are known to be able to inhibit hERG channels. We found that quinidine, ajmaline, ivabradine and mexiletine but not sotalol, amiodarone, flecainide and ranolazine prolonged APD and reduced arrhythmic events in SQT1-hiPSC-CMs (<a href="#B17">El-Battrawy et al., 2018</a>; <a href="#B84">Zhao et al., 2019</a>), although all of them could inhibit hERG channel currents. Therefore, we hypothesize that not only the channel sensitivity bot also the channel gating kinetics in presence of a drug is important for the efficacy of the drug and the observed differential drug effects may also result from different effects on hERG channel gating kinetics in SQT1-cells. The current study was designed to analyze in detail the effects of quinidine, ajmaline, amiodarone, ivabradine, flecainide, mexiletine and ranolazine on hERG channel gating kinetics in SQT1-hiPSC-CMs.</p><a id="h3" name="h3"></a><h2>Methods</h2><h3 class="pt0">Ethics Statement and Clinical Data</h3><p class="mb0">A skin biopsy from a SQTS1 patient was obtained with written informed consent from the patient and the Ethics Committee of the Medical Faculty Mannheim, University of Heidelberg (approval numbers: 2018-565N-MA) and the Ethics Committee of University Medical Center G&#x000f6;ttingen (approval number: 10/9/15). The study was carried out in accordance with the Helsinki Declaration of 1975 (<a href="https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/">https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/</a>), revised in 2013.</p><h3 class="pt0">Generation of Human iPS Cells</h3><p class="mb0">The patient with familial SQTS1 carries the N588K mutation in hERG channel. The clinical data of the patient has been provided in our recent publication (<a href="#B17">El-Battrawy et al., 2018</a>).</p><p class="mb0">The methods for the generation of iPS cells (hiPSCs) have been described in our previous study (<a href="#B17">El-Battrawy et al., 2018</a>). Briefly, skin fibroblasts from a skin biopsy of the patient and a healthy subject (here defined as donor) were reprogrammed into hiPSC cell line in feeder free culture conditions using the integration-free CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific, &#x00023;A16517) and the reprogramming factors OCT4, KLF4, SOX2 and c-MYC. The pluripotency and <em>in vitro</em> differentiation potential of generated hiPSCs were examined as described before (<a href="#B17">El-Battrawy et al., 2018</a>). The detailed information is provided in the <a href="#SM1">Supplementary Material</a>.</p><h3 class="pt0">Generation of hiPSC-CMs</h3><p class="mb0">The hiPSCs were differentiated into cardiomyocytes (hiPSC-CMs) as described in our previous studies (<a href="#B13">Cyganek et al., 2018</a>; <a href="#B17">El-Battrawy et al., 2018</a>; <a href="#B18">El-Battrawy et al., 2018</a>). Briefly (the detailed information is provided in the <a href="#SM1">Supplementary Material</a>), culture dishes were coated with Matrigel (Corning). The medium of TeSR-E8 (Stemcell Technologies) was used for hiPSCs culture and the medium of RPMI1640 Glutamax (Life Technologies) consisting of 1% sodium pyruvate, 1% Penicillin/Streptomycin, ascorbic acid (Sigma Aldrich) and B27 (Life Technologies) was used for hiPSC-CM culture (basic cardiac medium). In the first two weeks, CHIR99021 (Stemgent), BMP-4 (R&#x00026;DSystems), FGF-2 (MiltenyiBiotec), Activin A (R&#x00026;D Systems), and IWP-4 (Stemgent) were applied to induce hiPSCs to differentiate into hiPSC-CMs. Normally, on day 8 of differentiation some cells start to beat. In the third week, a selection medium containing sodium lactate (Sigma, Germany) and RPMI medium without glucose and glutamine (WKS, Germany) was used to select cardiomyocytes. Afterward, the selected cells were cultured with basic cardiac medium. After 40 to 60 days of differentiation, the cardiomyocytes were dissociated from 6 well plates and plated on Matrigel-coated 3.5&#x000a0;cm petri dishes as single cells for patch clamp tests. In our lab, the differentiation of hiPS cells into iPSC-CMs is regularly carried out every 2&#x02013;3&#x000a0;weeks. The hiPSC-CMs from several differentiations were used for studies and the data were combined. Two clones of the hiPSCs were alternately differentiated into hiPSC-CMs.</p><h3 class="pt0">Patch-Clamp</h3><p class="mb0">Standard patch-clamp whole-cell recording techniques were used to measure the hERG channel currents at room temperature. Patch electrodes were pulled from borosilicate glass capillaries (MTW 150F; world Precision Instruments, Inc., Sarasota, FL) using a DMZ-Universal Puller (Zeitz-Instrumente Vertriebs GmbH, Martinsried, Germany) and filled with pre-filtered pipette solution (see below). Pipette resistance ranged from 1&#x02013;2&#x000a0;M&#x003a9;. Signals were acquired at 10&#x000a0;kHz and filtered at 2&#x000a0;kHz with the EPC10 Patch-master digitizer hardware (HEKA Germany) and Fit-master software (HEKA Germany).</p><p class="mb0">To separate the hERG channel current from other currents, the Cs<sup>&#x0002b;</sup> currents conducted by hERG channels (I<sub>Kr</sub>) were measured. External solution contains (mM): 140 CsCl, 2 MgCl2, 10 HEPES, 10 Glucose, pH &#x0003d; 7.4 (CsOH). Pipette solution: 140 CsCl, 2 MgCl2, 10 HEPES, 10 EGTA, pH&#x0003d;7.2 (CsOH).</p><h3 class="pt0">Drugs</h3><p class="mb0">Ivabradine, flecainide, amiodarone, mexiletine, quinidine, and ranolazine were from Sigma, ajmaline from MP Biomedicals. The tested concentrations were selected according to literatures and our previous studies in hiPSC-CMs (<a href="#B76">Wu et al., 2004</a>; <a href="#B17">El-Battrawy et al., 2018</a>; <a href="#B59">Salvage et al., 2018</a>; <a href="#B84">Zhao et al., 2019</a>). Our previous studies showed that 10&#x000a0;&#x000b5;M quinidine, 10&#x000a0;&#x000b5;M ivabradine, 30&#x000a0;&#x000b5;M ajmaline, 100&#x000a0;&#x000b5;M mexiletine, prolonged APD, 10&#x000a0;&#x000b5;M amiodarone inhibited I<sub>Kr</sub> (<a href="#B17">El-Battrawy et al., 2018</a>; <a href="#B84">Zhao et al., 2019</a>). Ranolazine (5&#x02013;30&#x000a0;&#x000b5;M) significantly reduced episodes of EADs and VT produced by ATX-II (<a href="#B76">Wu et al., 2004</a>). Flecainide of 3&#x02013;30&#x000a0;&#x000b5;M was shown to inhibit Na and K channel currents (<a href="#B59">Salvage et al., 2018</a>). Therefore, the concentrations of 10&#x000a0;&#x000b5;M quinidine, 30&#x000a0;&#x000b5;M ajmaline, 10&#x000a0;&#x000b5;M amiodarone, 10&#x000a0;&#x000b5;M ivabradine, 30&#x000a0;&#x000b5;M flecainide, 100&#x000a0;&#x000b5;M mexiletine and 30&#x000a0;&#x000b5;M ranolazine were chosen for the study. Of note, all these drugs can affect other channel currents besides hERG channel currents (<a href="#SM1">Supplementary Table 1</a>).</p><h3 class="pt0">Statistical Analysis</h3><p class="mb0">Data are shown as mean &#x000b1; SEM and were analyzed using InStat<sup>&#x000a9;</sup> (GraphPad, San Diego, United States) and SigmaPlot 11.0 (Systat GmbH, Germany). The t-test was used for comparison between two independent groups. Paired t-test was used for comparisons of data in the same cells before and after application of a drug. One way ANOVA was used for comparison among multiple groups (more than two groups). <em>p</em> &#x0003c; 0.05 (two-tailed) was considered significant.</p><a id="h4" name="h4"></a><h2>Results</h2><h3 class="pt0">Drug Effects on hERG Channel Currents in hiPSC-CMs</h3><p class="mb0">In our recent study, we demonstrated that quinidine, ajmaline, amiodarone, ivabradine, and mexiletine but not amiodarone, flecainide and ranolazine prolonged APD and reduced epinephrine induced arrhythmic events in hiPSC-CMs from the SQT1-patient (SQT1-hiPSC-CMs) (<a href="#B84">Zhao et al., 2019</a>).To check whether these drugs affect hERG channel currents (I<sub>Kr</sub>) differentially in hiPSC-CMs from healthy donor and the SQTS1-patient, drug effects on I<sub>Kr</sub> were analyzed in both the healthy and diseased cells. I<sub>Kr</sub> amplitudes and current-voltage relationship (I-V) curves in the same cells before and after application of a drug were analyzed. <a href="#F1">Figures 1A&#x02013;D</a> showed effects of quinidine as examples of drug effects. Quinidine reduced the peak and steady state current of I<sub>Kr</sub> (<a href="#F1">Figures 1,B</a>) at different potentials (<a href="#F1">Figures 1C,D</a>). All the tested seven drugs inhibited I<sub>Kr</sub> in both donor- and SQT1-hiPSC-CMs. However, the inhibition induced by drugs was reduced in SQT1-hiPSC-CMs. Especially, the effect of amiodarone, flecainide, mexiletine and ranolazine was more severely reduced in SQT1-hiPSC-CMs (<a href="#F1">Figure 1E</a>, <a href="#T1">Table 1</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg" name="Figure1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg" alt="www.frontiersin.org" id="F1" loading="lazy">
  </picture>
</a><p><strong>FIGURE 1</strong>. Drug effects on I<sub>Kr</sub> in SQTS1-hiPSC-CMs. I<sub>Kr</sub> was evoked by 2&#x000a0;s pulses from &#x02212;80 to 60&#x000a0;mV (10&#x000a0;mV increments) with a holding potential of &#x02212;80&#x000a0;mV. The steady state currents were measured at the end of pulses as indicated by arrows in <strong>(A)</strong> and <strong>(B)</strong> in the same cells before and after application of a drug. <strong>(A)</strong> The protocol <strong>(right side)</strong> and representative I<sub>Kr</sub> traces <strong>(left side)</strong> in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a SQT1-hiPSC-CM (SQT). <strong>(B)</strong> Representative I<sub>Kr</sub> traces in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a donor-hiPSC-CM (Healthy). <strong>(C)</strong> Current-voltage relationship (I-V) curves of I<sub>Kr</sub> in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in SQT1-hiPSC-CMs (SQT). <strong>(D)</strong> I-V curves of I<sub>Kr</sub> in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in donor-hiPSC-CMs (Healthy). <strong>(E)</strong> Averaged values of percent inhibition of I<sub>Kr</sub> at 40&#x000a0;mV by quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M) in hiPSC-CMs from a healthy subject (Donor) and the patient (SQT). The inhibition was calculated by: Inhibition &#x0003d; (I<sub>ctr</sub>&#x02212;I<sub>drug</sub>)/I<sub>ctr</sub>&#x0002a;100, where I<sub>ctr</sub> is the current before application of a drug, I<sub>drug</sub> is the steady state current in presence of a drug. Shown are mean &#x000b1; SEM, <em>n</em> represents number of measured cells. The statistical significance was examined by paired t-test <strong>(C, D)</strong> or unpaired t-test <strong>(E)</strong>, &#x0002a;<em>p</em> &#x0003c; 0.05.</p></div><div class="clear"></div><div class="Imageheaders">TABLE 1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg" name="Table1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a><p><strong>TABLE 1</strong>. Summary of drug effects on I<sub>Kr</sub> and APD/QT.</p></div><div class="clear"></div><div class="DottedLine"></div><h3 class="pt0">Drug Effects on Activation of I<sub>Kr</sub> in hiPSC-CMs</h3><p class="mb0">To examine the effects of drugs on I<sub>Kr</sub> activation, the time to peak (T-p) and activation curves were analyzed (<a href="#T1">Table 1</a>). Quinidine (<a href="#F2">Figures 2A,H,I,P</a>) and mexiletine (<a href="#F2">Figures 2F,H,N,P</a>) accelerated (T-p was reduced), while ajmaline (<a href="#F2">Figures 2B,H,J,P</a>), amiodarone (<a href="#F2">Figures 2C,H,K,P</a>), ivabradine (<a href="#F2">Figures 2D,H,L,P</a>) and ranolazine (<a href="#F2">Figures 2G,H,O,P</a>) decelerated (T-p was increased) the I<sub>Kr</sub> activation in donor- and SQTS1-hiPSC-CMs. Flecainide showed no effect in SQT1-hiPSC-CMs (<a href="#F2">Figures 2E,H</a>), but increased T-p in donor-hiPSC-CMs (<a href="#F2">Figures 2M,P</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg" name="Figure2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg" alt="www.frontiersin.org" id="F2" loading="lazy">
  </picture>
</a><p><strong>FIGURE 2</strong>. Drug effects on the time to peak of I<sub>Kr</sub> in SQTS1-hiPSC-CMs. The time to peak (the time between the start of a pulse to the highest peak current point) of I<sub>Kr</sub> was measured in current traces from 10 to 80&#x000a0;mV and plotted against voltages. The same cells before and after application of a drug were measured. <strong>(A&#x02013;G)</strong> Representative curves of time to peak in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(H)</strong> Averaged values of time to peak at 20&#x000a0;mV in SQT1-hiPSC-CMs in absence (Ctr) and presence of drugs. <strong>(I&#x02013;O)</strong> Representative curves of time to peak in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(P)</strong> Averaged values of time to peak at 20&#x000a0;mV in donor-hiPSC-CMs in absence (Ctr) and presence of drugs. Shown are mean &#x000b1; SEM, <em>n</em> represents number of cells. The statistical significance was examined by paired t-test, &#x0002a;<em>p</em> &#x0003c; 0.05 versus Control.</p></div><div class="clear"></div><div class="DottedLine"></div><p class="mb0">In SQT1-hiPSC-CMs, quinidine, ajmaline and ivabradine shifted the activation curve of I<sub>Kr</sub> to more positive potentials (<a href="#F3">Figures 3A,B,D,H</a>), whereas ranolazine shifted the activation curve to more negative potentials (<a href="#F3">Figures 3G,H</a>). Amiodarone, flecainide and mexiletine showed no effect (<a href="#F3">Figures 3C,E&#x02013;H</a>). In donor cells, quinidine, ajmaline, amiodarone, ivabradine and mexiletine shifted the activation curves to more positive potentials (<a href="#F3">Figures 3I&#x02013;L,N,P</a>), while ranolazine showed an opposite effect (<a href="#F3">Figures 3O,P</a>). Flecainide showed no significant effect (<a href="#F3">Figures 3M,P</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg" name="Figure3" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg" alt="www.frontiersin.org" id="F3" loading="lazy">
  </picture>
</a><p><strong>FIGURE 3</strong>. Drug effects on voltage-dependent activation of I<sub>Kr</sub> in SQTS1-hiPSC-CMs. I<sub>Kr</sub> was evoked by 2&#x000a0;s pulses from &#x02212;80 to 60&#x000a0;mV (10&#x000a0;mV increments) with a holding potential of &#x02212;80&#x000a0;mV. The steady state currents were measured at the end of pulses as indicated by arrows in <a href="#F1">Figures 1A,B</a> before and after application of a drug. The conductance was calculated with the equation: G &#x0003d; I/V, where I is the measured current, V is the voltage of pulses and G is the conductance. The conductance was normalized to the maximum (G/Gmax) and plotted against voltage to obtain the activation (G-V) curves. The curves were fitted by Boltzmann equation to obtain the voltage value at half maximal activation (V0.5). <strong>(A&#x02013;G)</strong> Activation curves of I<sub>Kr</sub> in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(H)</strong> Averaged values of half maximal activation potential (V0.5) in SQT1-hiPSC-CMs in absence (Ctr) and presence of drugs. <strong>(I&#x02013;O)</strong> Activation curves of I<sub>Kr</sub> in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(P)</strong> Averaged values of half maximal activation potential (V0.5) in donor-hiPSC-CMs in absence (Ctr) and presence of drugs. Shown are mean &#x000b1; SEM, <em>n</em> represents number of cells. The statistical significance was examined by paired t-test, &#x0002a;<em>p</em> &#x0003c; 0.05 versus Control.</p></div><div class="clear"></div><div class="DottedLine"></div><h3 class="pt0">Drug Effects on Inactivation of I<sub>Kr</sub> in hiPSC-CMs</h3><p class="mb0">To examine drug effects on I<sub>Kr</sub> inactivation, the inactivation curves of I<sub>Kr</sub> and the time constant (&#x003c4;) of the current decay due to channel inactivation were analyzed (<a href="#T1">Table 1</a>). The inactivation curves were shifted to more negative potentials by quinidine (<a href="#F4">Figures 4A,H</a>), ajmaline (<a href="#F4">Figures 4B,H</a>), ivabradine (<a href="#F4">Figures 4D,H</a>), mexiletine (<a href="#F4">Figures 4F,H</a>), and ranolazine (<a href="#F4">Figures 4G,H</a>) but not significantly influenced by amiodarone (<a href="#F4">Figures 4C,H</a>) and flecainide (<a href="#F4">Figures 4E,H</a>) in SQT1-hiPSC-CMs. In donor cells, the inactivation curves were shifted to more negative potentials by quinidine (<a href="#F4">Figures 4I,P</a>), ajmaline (<a href="#F4">Figures 4J,P</a>), flecainide (<a href="#F4">Figures 4M,P</a>), mexiletine (<a href="#F4">Figures 4N,P</a>) and ranolazine (<a href="#F4">Figures 4O,P</a>) and to more positive potentials by amiodarone (<a href="#F4">Figures 4K,P</a>) and ivabradine (<a href="#F4">Figures 4L,P</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 4</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg" name="Figure4" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg" alt="www.frontiersin.org" id="F4" loading="lazy">
  </picture>
</a><p><strong>FIGURE 4</strong>. Drug effects on voltage-dependent inactivation of I<sub>Kr</sub> in SQTS1-hiPSC-CMs. I<sub>Kr</sub> was evoked by the protocol shown in A <strong>(right panel)</strong>. A pre-pulse of 1&#x000a0;s from &#x02212;80&#x000a0;mV (the holding potential) to &#x0002b;60&#x000a0;mV followed by a short (20&#x000a0;ms) repolarization to &#x02212;100&#x000a0;mV was given for channel activation, inactivation and recovery of inactivated channels to open state. Before deactivation occurs, test pulses of 1&#x000b0;s from &#x02212;50 to &#x0002b;80&#x000a0;mV (10&#x000a0;mV increments) were started to evaluate the inactivation of channels. I<sub>Kr</sub> was measured at the beginning (peak current, a) and end (steady current, b) of test pulses as shown in A <strong>(right panel)</strong>. The currents in same cells before and after application of a drug were measured. The current of inactivated channels (I<sub>inact</sub>) was calculated as: I<sub>inact</sub> &#x0003d;Ia-Ib, where Ia is the peak current, Ib is the steady current. When I<sub>inact</sub> is larger than zero, it means inactivation occurred. When I<sub>inact</sub> equals or is smaller than zero, it means no inactivation occurred. I<sub>inact</sub> at different potentials were measured and normalized to the maximal current (I<sub>inactMax</sub>). To plot the inactivation curves as usually shown (the curve decays with increasing voltages), the relative current was calculated by I&#x0003d;1 &#x02212; I<sub>inact</sub>/I<sub>inactMax</sub>. Finally, I was normalized to the maximal value I<sub>max</sub> and plotted against voltages to obtain an inactivation curve. The inactivation curves were then fitted by Boltzmann equation to obtain the voltage value at half maximal inactivation (V0.5). <strong>(A&#x02013;G)</strong> Inactivation curves of I<sub>Kr</sub> in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(H)</strong> Averaged values of half maximal inactivation potential (V0.5) in SQT1-hiPSC-CMs in absence (Ctr) and presence of drugs. <strong>(I&#x02013;O)</strong> Inactivation curves of I<sub>Kr</sub> in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(P)</strong> Averaged values of half maximal inactivation potential (V0.5) in donor-hiPSC-CMs in absence (Ctr) and presence of drugs. Shown are mean &#x000b1; SEM, <em>n</em> represents number of cells. The statistical significance was examined by paired t-test, &#x0002a;<em>p</em> &#x0003c; 0.05 versus Control.</p></div><div class="clear"></div><div class="DottedLine"></div><p class="mb0">In addition, it was detected that in SQT1-hiPSC-CMs, ajmaline (<a href="#F5">Figure 5C</a>), flecainide (<a href="#F5">Figure 5F</a>) and ranolazine (<a href="#F5">Figure 5H</a>) decelerated the inactivation (time constant was increased), while amiodarone (<a href="#F5">Figure 5D</a>) and ivabradine (<a href="#F5">Figure 5E</a>) accelerated it. Quinidine (<a href="#F5">Figure 5B</a>) and mexiletine (<a href="#F5">Figure 5G</a>) had no significant effects. In donor-hiPSC-CMs, quinidine (<a href="#F5">Figure 5J</a>), ajmaline (<a href="#F5">Figure 5K</a>), amiodarone (<a href="#F5">Figure 5L</a>) and flecainide (<a href="#F5">Figure 5N</a>) decelerated the inactivation, while ivabradine (<a href="#F5">Figure 5M</a>), mexiletine (<a href="#F5">Figure 5O</a>) and ranolazine (<a href="#F5">Figure 5P</a>) accelerated it. <a href="#F5">Figures 5A,I</a> show examples of current inactivation in absence and presence of a drug (quinidine).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 5</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg" name="Figure5" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg" alt="www.frontiersin.org" id="F5" loading="lazy">
  </picture>
</a><p><strong>FIGURE 5</strong>. Drug effects on the time constant of I<sub>Kr</sub> inactivation in SQTS1-hiPSC-CMs. To examine drug effects on the fast phase of inactivation, I<sub>Kr</sub> was evoked by a 1&#x000a0;s-long pre-pulse from &#x02212;80 to 60&#x000a0;mV to let hERG channels be activated and returned to &#x02212;100&#x000a0;mV for 20&#x000a0;ms, and then the pre-pulse was followed by 500&#x000a0;ms test-pulses [P4 in the protocol shown by the inset in <strong>(A)</strong> and <strong>(I)</strong>] from 20 to 80&#x000a0;mV (10&#x000a0;mV increments). Currents evoked by test pulses were fitted by single exponential decay to obtain the time constant (&#x003c4;) of I<sub>Kr</sub> fast inactivation. <strong>(A)</strong> Representative traces of I<sub>Kr</sub> evoked by pulses from 20 to 80&#x000a0;mV in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a SQT1-hiPSC-CM. <strong>(B&#x02013;H)</strong> Mean values of time constants (&#x003c4;) of I<sub>Kr</sub> inactivation in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(I)</strong> Representative traces of I<sub>Kr</sub> evoked by pulses from 20 to 80&#x000a0;mV in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a donor-hiPSC-CM. <strong>(J&#x02013;P)</strong> Mean values of time constants (&#x003c4;) of I<sub>Kr</sub> inactivation in donor-hiPSC-CMs in absence (Ctr) and presence of each drug. Shown are mean &#x000b1; SEM, <em>n</em> represents number of cells. The statistical significance was examined by paired t-test, &#x0002a;<em>p</em> &#x0003c; 0.05 versus Control.</p></div><div class="clear"></div><div class="DottedLine"></div><h3 class="pt0">Drug Effects on I<sub>Kr</sub> Window Currents in hiPSC-CMs</h3><p class="mb0">Since the shift of activation or inactivation curves may change the window current, we assessed the I<sub>Kr</sub> window current in the same cells in absence and presence of a drug. Quinidine, ivabradine, ajmaline and mexiletine reduced the I<sub>Kr</sub> window current, but amiodarone, flecainide and ranolazine failed to do so in SQTS1-hiPSC-CMs (<a href="#F6">Figures 6A&#x02013;G</a>). In donor cells, quinidine, ajmaline and mexiletine also reduced the window current, whereas ivabradine, ranolazine, amiodarone and flecainide showed no effects (<a href="#F6">Figures 6 H&#x02013;N</a>) (<a href="#T1">Table 1</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 6</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg" name="Figure6" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg" alt="www.frontiersin.org" id="F6" loading="lazy">
  </picture>
</a><p><strong>FIGURE 6</strong>. Drug effects on window currents of I<sub>Kr</sub> in SQTS1-hiPSC-CMs. The activation and inactivation curves were plotted in the same figure. The window current was defined as the current under the crossover of activation and inactivation curves. The activation curves are the same curves as in <a href="#F3">Figure 3</a>. To obtain the inactivation curves, a pulse of 1&#x000a0;s from &#x02212;80 to &#x0002b;60&#x000a0;mV was applied to activate and inactivate hERG channels. Then, the pulse was set to &#x02212;100&#x000a0;mV for 20&#x000a0;ms to let the inactivated channels recover to open state. Before the deactivation occurs, a test pulse to &#x0002b;60&#x000a0;mV for 500&#x000a0;ms was applied and the peak current at the test potential was measured. The voltage of recovery pulses was changed from &#x02212;100 to &#x0002b;80&#x000a0;mV. The currents at test pulse versus respective voltages of the recovery pulses were normalized to the maximal current and plotted against voltages of the recovery pulses to obtain the inactivation curves (availability-voltage curves). The cell numbers of activation curves are same as that in <a href="#F3">Figure 3</a>. The cells numbers of inactivation curves are nine for each drug experiments. For comparison, the window currents in absence (black points and lines) and presence (grey points and lines) of drugs were overlapped in the same plot. <strong>(A&#x02013;G)</strong> Overlapped activation and inactivation curves showing the widow currents in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(H&#x02013;N)</strong> Overlapped activation and inactivation curves showing the widow currents in donor-hiPSC-CMs in absence (Ctr) and presence of each drug.</p></div><div class="clear"></div><div class="DottedLine"></div><h3 class="pt0">Drug Effects on Recovery From Inactivation of I<sub>Kr</sub> in hiPSC-CMs</h3><p class="mb0">To examine drug effect on the recovery of hERG channel from inactivation, the time constant (&#x003c4;) of tail currents representing recovery of hERG channels from inactivation was analyzed (<a href="#F7">Figures 7E,F</a>) (<a href="#T1">Table 1</a>). In SQTS1-hiPSC-CMs, ajmaline, amiodarone and mexiletine speeded up the recovery, whereas flecainide and quinidine slowed it down. Ivabradine and ranolazine showed no significant effect (<a href="#F7">Figure 7E</a>). In donor cells, the recovery speed was reduced by quinidine (<a href="#F7">Figures 7B,F</a>), ivabradine and ranolazine, increased by amiodarone but not significantly affected by ajmaline, flecainide and mexiletine (<a href="#F7">Figure 7F</a>). <a href="#F7">Figures 7A,D</a> show examples of current recovery from inactivation in absence and presence of a drug (quinidine).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 7</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg" name="Figure7" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg" alt="www.frontiersin.org" id="F7" loading="lazy">
  </picture>
</a><p><strong>FIGURE 7</strong>. Drug effects on time constants of I<sub>Kr</sub> recovery from inactivation and deactivation in SQTS1-hiPSC-CMs. I<sub>Kr</sub> was evoked by a 1&#x000a0;s-long pre-pulse from &#x02212;80 to 60&#x000a0;mV to let hERG channels be activated and some of them to be inactivated. The pre-pulse was followed by 500&#x000a0;ms test-pulses from &#x02212;20 to &#x02212;100&#x000a0;mV (10&#x000a0;mV increments). The protocol is shown in <strong>(B)</strong> (inset). Currents evoked by test pulses (tail currents) were used for analyzing the recovery from inactivation or deactivation of the currents. When the tail current increased, i.e., &#x0201c;b&#x0201d; is larger (more negative) than &#x0201c;a&#x0201d;, the current was defined as recovered current. The curves were fitted by single exponential decay to obtain time constants of recovery from inactivation. From &#x02212;50 to &#x02212;100&#x000a0;mV, deactivation became obvious. i.e., the current decrease again (the current at &#x0201c;d&#x0201d; is smaller than that at &#x0201c;c&#x0201d;. The change point &#x0201c;b/c&#x0201d; is defined as the end of recovered current and the start of the deactivation. <strong>(A)</strong> Representative traces of I<sub>Kr</sub> evoked by test pulses from &#x02212;20 to &#x02212;100&#x000a0;mV in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a donor-hiPSC-CM. <strong>(B)</strong> Mean values of time constants (&#x003c4;) of I<sub>Kr</sub> recovery from inactivation at different voltages in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine. <strong>(C)</strong> Mean values of time constants (&#x003c4;) of I<sub>Kr</sub> deactivation at different voltages in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine. <strong>(D)</strong> Representative traces of I<sub>Kr</sub> at &#x02212;60&#x000a0;mV taken as recovered currents from inactivation in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in donor-hiPSC-CMs. <strong>(E)</strong> Mean values of time constants (&#x003c4;) of I<sub>Kr</sub> recovery from inactivation at &#x02212;60&#x000a0;mV in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(F)</strong> Mean values of time constants (&#x003c4;) of I<sub>Kr</sub> recovery from inactivation at &#x02212;60&#x000a0;mV in donor-hiPSC-CMs in absence (Ctr) and presence of each drug. <strong>(G)</strong> Representative traces of I<sub>Kr</sub> at &#x02212;80&#x000a0;mV taken as deactivated currents in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a donor-hiPSC-CM. <strong>(H)</strong> Mean values of time constants (&#x003c4;) of I<sub>Kr</sub> deactivation at &#x02212;80&#x000a0;mV in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). <strong>(I)</strong> Mean values of time constants (&#x003c4;) of I<sub>Kr</sub> deactivation at &#x02212;80&#x000a0;mV in donor-hiPSC-CMs in absence (Ctr) and presence of each drug. Shown are mean &#x000b1; SEM, n represents number of cells. The n-numbers given in <strong>(F)</strong> are also for <strong>(E)</strong>, <strong>(H)</strong> and <strong>(I)</strong>. The statistical significance was examined by paired t-test, &#x0002a;<em>p</em> &#x0003c; 0.05 <em>vs.</em> Control.</p></div><div class="clear"></div><div class="DottedLine"></div><h3 class="pt0">Drug Effects on Deactivation of I<sub>Kr</sub> in hiPSC-CMs</h3><p class="mb0">Finally, the deactivation of I<sub>Kr</sub> was analyzed in hiPSC-CMs (<a href="#T1">Table 1</a>, <a href="#F7">Figures 7A,G&#x02013;I</a>). In SQT1-hiPSC-CMs, quinidine, ajmaline, ivabradine and mexiletine reduced the speed of deactivation of hERG channels (the time constant &#x003c4; was increased), but amiodarone, flecainide and ranolazine failed to change it (<a href="#F7">Figure 7H</a>). In donor cells, amiodarone accelerated the deactivation (<a href="#F7">Figure 7I</a>), while quinidine (<a href="#F7">Figures 7C,I</a>), ivabradine and mexiletine decelerated it (<a href="#F7">Figure 7I</a>). Ajmaline, flecainide and ranolazine did not influence the channel deactivation (<a href="#F7">Figure 7I</a>). <a href="#F7">Figures 7A,G</a> show examples of current deactivation in absence and presence of a drug (quinidine).</p><a id="h5" name="h5"></a><h2>Discussion</h2><p class="mb15">In this study, we investigated the effects of quinidine, ajmaline, amiodarone, ivabradine, flecainide, mexiletine and ranolazine on gating kinetics of hERG channels in hiPSC-CMs from a SQT1-patient with N588k mutation. The study demonstrated that 1) these drugs affected differentially the hERG channel gating kinetics in donor- and SQT1-hiPSC-CMs, 2) quinidine, ajmaline, ivabradine and mexiletine reduced the window current of hERG channels and 3) quinidine, ajmaline, ivabradine and mexiletine decelerated deactivation of hERG channels. The latter two may be important for their antiarrhythmic effects previously observed in SQTS-patients (reduction of the occurrence of life-threatening arrhythmic events) or SQTS-hiPSC-CMs (reduction of epinephrine-induced arrhythmic events) (<a href="#B42">Mazzanti et al., 2017</a>; <a href="#B84">Zhao et al., 2019</a>).</p><p class="mb15">In our previous study, we generated hiPSC-CMs from a patient with STQS1 carrying the hERG (KCNH2) gene mutation of N588K and characterized the phenotypic features (APD-shortening and arrhythmic events) (<a href="#B17">El-Battrawy et al., 2018</a>). Using the cellular model of SQT1 (SQT1-hiPSC-CMs) we tested the APD-prolonging and antiarrhythmic effect of different drugs (<a href="#B17">El-Battrawy et al., 2018</a>; <a href="#B84">Zhao et al., 2019</a>; <a href="#B39">Lan et al., 2020</a>). We have demonstrated that the SQTS1-hiPSC-CMs displayed shortened APD and increased arrhythmic events. Quinidine, disopyramide, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide or ranolazine prolonged APD and reduced the arrhythmic episodes in SQT1-hiPSC-CMs (<a href="#B17">El-Battrawy et al., 2018</a>; <a href="#B84">Zhao et al., 2019</a>; <a href="#B39">Lan et al., 2020</a>). Although we found that the inhibition of the N588K-hERG channel current by drugs is different, whether these drugs exert also different effects on N588K-hERG channel gating kinetics, which may help clarify the effect difference of drugs, is so far unknown. The current study was designed to address this open question and look for hints for selecting possible effective drugs for SQT1-treatment.</p><p class="mb15">Quinidine is a multiple channel blocker with a high affinity to hERG and was a frequently used antiarrhythmic drug. It can inhibit I<sub>Na</sub> (Na channel current), I<sub>Ca-L</sub> (L-type Ca current), I<sub>to</sub> (transient outward K current), I<sub>Kr</sub> (hERG channel current), I<sub>Ks</sub> (slowly activating delayed rectifier K current), I<sub>K1</sub> (inward rectifier K current) and I<sub>KATP</sub> (ATP-sensitive-K channel current) (<a href="#SM1">Supplementary Table 1</a>) (<a href="#B55">Pugsley et al., 2005</a>; <a href="#B46">Michel et al., 2002</a>; <a href="#B52">Paul et al., 2002</a>; <a href="#B77">Yang et al., 2009</a>; <a href="#B32">Imaizumi and Giles, 1987</a>; <a href="#B37">Koepple et al., 2017</a>; <a href="#B70">Undrovinas et al., 1990</a>). The I<sub>Na</sub>-inhibiting effect can reduce the speed of depolarization and excitation conduction, and hence reduce occurrence of some arrhythmias. The inhibition of I<sub>Ca-L</sub> may shorten APD, whereas the inhibition of K currents can prolong APD. In fact, quinidine prolongs APD in wild-type (healthy) and SQTS-cells (<a href="#T1">Table 1</a>) (<a href="#B14">Davidenko et al., 1989</a>; <a href="#B29">Guo et al., 2019</a>), indicating that its effect on K currents is larger than that on I<sub>Ca-L</sub>. The APD-prolonging effect can be antiarrhythmic and also proarrhythmic. Quinidine was clinically used as an antiarrhythmic drug, but the severe side effects of quinidine reduced its clinical relevance for arrhythmia-treatment. However, when it was shown to be effective for SQT-patients, it absorbed again interests of physicians and researchers. It was found that although the mutation N588K in hERG channel rendered hERG channel resistant to many drugs including typical hERG channel blockers, the channel remains still sensitive to quinidine. One reason for the efficacy of quinidine is that quinidine affects hERG channels in both open and closed (inactivated) state, different from other drugs that affect only or mainly inactivated hERG channels. The N588K mutation reduced the inactivation of hERG channel and hence reduced the effects of inactivation-affecting drugs like E-4031, sotalol, dofetilide and terfenadine (<a href="#B43">McPate et al., 2008</a>; <a href="#B53">Perrin et al., 2008</a>). Quinidine effect is only partially changed by N588K mutation because its open-channel-affecting effect is not influenced by the mutation. Therefore, quinidine is effective for SQT-patients with N588K mutation and recommended for application in SQT-patients (<a href="#B54">Priori et al., 2015</a>). Since previously reported studies focused on the change of channel sensitivity (shift of dose-response curve) induced by N588K-mutation, the influence of N588K on drug effects regarding the hERG channel gating kinetic parameters was not analyzed in detail. In the current study, we found out that the quinidine effects on the time to peak and activation curve, on the time constant of inactivation and inactivation curve, on the time constants of recovery from inactivation and the deactivation as well as on the window current of the hERG channel were similar in donor- and SQT1-hiPSC-CMs, suggesting that quinidine effects on hERG channel gating are not severely changed by N588K.</p><p class="mb15">The class Ia anti-arrhythmic drug ajmaline is frequently applied to induce phenotypic changes of Brugada syndrome (BrS) in ECG for diagnostic aim. Studies reported that ajmaline inhibits various currents, including I<sub>Na</sub>, I<sub>Ca-L</sub>, I<sub>to</sub>, I<sub>Kr</sub>, I<sub>K1</sub> and I<sub>KATP</sub> (<a href="#SM1">Supplementary Table 1</a>) (<a href="#B48">Miller et al., 2017</a>; <a href="#B5">B&#x000e9;barov&#x000e1; et al., 2005a</a>; <a href="#B35">Khodorov and Zaborovskaya, 1983</a>; <a href="#B6">B&#x000e9;barov&#x000e1; et al., 2005b</a>; <a href="#B36">Kiesecker et al., 2004</a>). The inhibition of I<sub>to</sub>, I<sub>Kr</sub>, I<sub>K1</sub> and I<sub>KATP</sub> can prolong APD and hence APD-prolongation induced by ajmaline was observed in both wild-type cells and an SQT-model (<a href="#T1">Table 1</a>) (<a href="#B6">B&#x000e9;barov&#x000e1; et al., 2005b</a>; <a href="#B34">J&#x000e6;ger et al., 2021</a>). This led us to assume that it may inhibit the hERG channel current in SQTS1-hiPSC-CMs. Indeed, ajmaline inhibited the hERG channel current, prolonged APD and reduced arrhythmic events in SQTS1-cells (<a href="#B84">Zhao et al., 2019</a>). In HEK cells and Xenopus oocytes expressing hERG channels, ajmaline inhibited the hERG current and the Y652A and F656A mutations abolished the ajmaline effect (<a href="#B36">Kiesecker et al., 2004</a>). Ajmaline shifted slightly the half-maximal activation voltage toward more negative potentials but did not significantly influence hERG inactivation curve, although it reduced the &#x003c4; value of inactivation (<a href="#B36">Kiesecker et al., 2004</a>). The influence of N588K on ajmaline effects was not examined in that study. Here in the current study, we add novel data about ajmaline effects on the gating parameters of wild-type and N588K-hERG channels in hiPSC-CMs. The effects of ajmaline on hERG channel current data including the time to peak, &#x003c4; of inactivation, activation and inactivation curves and the window current are similar (changes in the same direction) in donor- and SQT1-hiPSC-CMs, while its effects on the time constants of recovery from inactivation and deactivation were observed only in SQT1-hiPSC-CMs. These data may be helpful for understanding the anti- or pro-arrhythmic feature of the drug. Since ajmaline can inhibit other ion channel currents, its inhibitory effect on I<sub>to</sub>, I<sub>K1</sub> and I<sub>KATP</sub> may also contribute its APD-prolonging and antiarrhythmic effects in SQTS.</p><p class="mb15">Amiodarone alone showed no QTc-prolonging effect, but amiodarone together with metoprolol prolonged QTc in a SQTS-patient (<a href="#B27">Giustetto et al., 2011</a>). The benefit of amiodarone for SQTS-patients is still questionable. In our hiPS-CMs from the patient with SQTS1, amiodarone failed to prolong APD and to reduce arrhythmic events. Amiodarone is similar to quinidine in inhibiting hERG current conducted by the mutant (N588K) hERG channel (<a href="#B43">McPate et al., 2008</a>). Since the influence of N588K on amiodarone effects regarding gating kinetics of hERG channels was not investigated, it is difficult to understand why quinidine but not amiodarone is effective in SQT1-patients. Our current study detected the difference, i.e., quinidine reduced the window current, decelerated the recovery from inactivation and deactivation, while amiodarone showed no or opposite effects on those parameters. Besides hERG current, I<sub>Na</sub>, I<sub>Ca-L</sub>, I<sub>NCX</sub>, I<sub>to</sub>, I<sub>Ks</sub>, I<sub>K1</sub> and I<sub>KATP</sub> can be inhibited by amiodarone (<a href="#SM1">Supplementary Table 1</a>) (<a href="#B51">Nishida et al., 2011</a>; <a href="#B67">Suzuki et al., 2013</a>; <a href="#B33">Iwamoto et al., 2007</a>; <a href="#B75">Watanabe, 2019</a>). The inhibition of I<sub>Ca-L</sub> may shorten APD, while the inhibition of I<sub>to</sub>, I<sub>Ks</sub>, I<sub>K1</sub> and I<sub>KATP</sub> can prolong APD. In wild-type cells, amiodarone prolonged or showed no effect on APD (<a href="#T1">Table 1</a>) (<a href="#B4">Aomine, 1988</a>; <a href="#B61">Sasaki et al., 2014</a>). In our experiments, amiodarone failed to changed APD significantly, implying that its effects on inward currents and outward currents are similar.</p><p class="mb15">Ivabradine could prolong QT interval and suppress the arrhythmic events in rabbit models of SQTS induced by an ATP-sensitive potassium channel activator pinacidil (<a href="#B24">Frommeyer et al., 2017</a>). Ivabradine is a well-known funny channel (I<sub>f</sub>) blocker. Since it displayed no negative inotropic effects and is useful to maintain stable hemodynamics, it is clinically administered to reduce heart rate in patients with heart failure. Ivabradine also inhibits hERG channel currents (<a href="#B40">Lees-Miller et al., 2015</a>). In a study, hERG channels, either WT or mutated, were expressed by transfection into HEK393 cells and ivabradine effects on the channels were investigated (<a href="#B44">Melgari et al., 2015</a>). In that study, Melgari et al. demonstrated that ivabradine inhibited the WT- and mutated hERG channel current. N588K and S624A variants slightly reduced ivabradine effect, while Y652A and F656A strongly reduced its effect. In addition, the authors also showed that ivabradine shifted both the activation and inactivation curve to a more negative potential without effect on the speed (&#x003c4;) of inactivation of the WT-hERG channel. In the current study, we demonstrated that the inhibition of hERG current by ivabradine was reduced and the inactivation curve was shifted to a more negative potential, consistent with the previous study. However, we found that ivabradine shifted the activation curve to a more positive potential, which differs from the results of the Melgari study. Moreover, we observed that ivabradine prolonged the time to peak, reduced the time constant of inactivation and increased the time constant of deactivation in both donor and SQT1-cells, reduced the window current in SQT1-cells but not in donor-cells, and increased the time constant of recovery in donor-cells but not in SQT1-cells. These data are new because previous studies including Melgari study did not investigate ivabradine effects on these parameters in N588K-hERG channels or in SQT1-cells. Besides hERG current, I<sub>Na</sub>, but not I<sub>Ca-L</sub>, I<sub>Ks</sub> and I<sub>K1</sub> can be inhibited by ivabradine (<a href="#SM1">Supplementary Table 1</a>) (<a href="#B31">Haechl et al., 2019</a>; <a href="#B15">Demontis et al., 2009</a>). The inhibition of I<sub>Na</sub> may contribute to antiarrhythmic but not APD-prolonging effect. In previous studies, ivabradine showed no effect or prolonging or shortening effect on APD in wild type cells (<a href="#T1">Table 1</a>) (<a href="#B38">Koncz et al., 2011</a>; <a href="#B31">Haechl et al., 2019</a>). It seems that ivabradine effect on APD mainly resulted from its effect on I<sub>Kr</sub>.</p><p class="mb15">Mexiletine, a sodium channel blocker, was shown to be effective for suppressing arrhythmias in a rabbit model of SQTS and atrial fibrillation (AF) (<a href="#B25">Frommeyer et al., 2018</a>). In our recent study, using the SQT1-hiPSC-CMs we also observed profitable results of mexiletine, prolonging APD and reducing arrhythmic events. Although mexiletine inhibited I<sub>Kr</sub> in SQTS1-hiPSC-CMs, its effect on I<sub>Kr</sub> gating kinetic parameter has not been assessed. In a previous study from Gualdani et al., WT and mutant hERG channels were expressed in HEK293 or CHO cells and mexiletine effects were assessed (<a href="#B28">Gualdani et al., 2015</a>). The study demonstrated that i) Mexiletine inhibited the hERG channel current in a time- and voltage-dependent way; ii) Its inhibitory effect was strongly reduced by Y652A and F656A mutants; iii) It reduced the time constant of activation but increased the time constant of deactivation, meaning that it accelerated activation and decelerated deactivation; iv) Mexiletine did not influence the channel inactivation. The effects of mexiletine on gating kinetics of N588K-hERG channels were not investigated. Our current study detected that the inhibitory effect of mexiletine was strongly reduced in SQT1-hiPSC-CMs carrying the N588K mutation. Mexiletine reduced the time to peak in both donor and SQT1-cells, suggesting an increase in activation speed, consistent with the Gualdani study. In our study, mexiletine increased the time constant of deactivation (consistent with the previous study) but reduced the time constant of inactivation (different from the previous study) in both donor and SQT1-cells. The differences between our and the previous study may result from using different cell types. Further, mexiletine reduced the time constant of recovery from inactivation and the window current as well, which have not been shown before. In addition, mexiletine can inhibit I<sub>Na</sub>, I<sub>Ca-L</sub>, I<sub>NCX</sub>, I<sub>Ks</sub> and I<sub>to,</sub> and activate I<sub>KATP</sub> (<a href="#SM1">Supplementary Table 1</a>) (<a href="#B72">Wang et al., 1996</a>; <a href="#B78">Yonemizu et al., 2019</a>; <a href="#B57">Rahm et al., 2020</a>; <a href="#B49">Mitcheson and Hancox, 1997</a>). The I<sub>Ca-L</sub>-inhibiting and I<sub>KATP</sub>-activation can explain the APD-shortening effect of mexiletine in wild-type cardiomyocytes (<a href="#T1">Table 1</a>) (<a href="#B41">Matsuo et al., 1985</a>; <a href="#B62">Sato et al., 1995</a>). The I<sub>Kr</sub>-, I<sub>Ks</sub>- and I<sub>to</sub>-inhibiting effects can be the reason for APD-prolonging effect observed in SQT-cells (<a href="#B25">Frommeyer et al., 2018</a>). Whether mexiletine prolongs or shortens APD in cells, probably depends on its net effect on the inward and outward currents. In our hiPSC-CMs, mexiletine prolonged APD, suggesting that its effect on outward current is predominant.</p><p class="mb15">Flecainide has been shown to prolong APD and refractory period but did not reduce the rate of inducibility of ventricular fibrillation in a rabbit model of SQTS (<a href="#B47">Milberg et al., 2007</a>). In a clinical study, it was shown to be ineffective for prolonging QT interval and reducing arrhythmias (<a href="#B26">Gaita et al., 2004</a>). In our recent study, it inhibited slightly the hERG channel current, but failed to prolong APD or to reduce arrhythmic events in SQT1-hiPSC-CMs (<a href="#B84">Zhao et al., 2019</a>). Before, it was shown that flecainide inhibited hERG channel currents in HEK cells and N588K reduced flecainide effect (<a href="#B45">Melgari et al., 2015</a>). Flecainide did not influence the voltage-dependent inactivation curve but increased the time constant of inactivation of wild-type hERG channels (<a href="#B45">Melgari et al., 2015</a>). Flecainide shifted activation curve to a more negative potential but did not influence the time constant of deactivation of wild-type hERG channels (<a href="#B52">Paul et al., 2002</a>). Flecainide effects on gating kinetics of N588K-hERG channel have not been reported. Our current study showed that i) The inhibitory effect of flecainide was largely reduced in SQT1-cells, ii) The time to peak of hERG current was prolonged in donor but not in SQT1-cells and iii) The inactivation curve was shifted to a more negative potential in donor but not in SQT1-cells. The latter may help us understand the reduced inhibitory effect of flecainide in SQT1-hiPSC-CMs. Flecainide did not change the window current of hERG channels. It decelerated the recovery from inactivation in SQT1-hiPSC-CMs and showed no effect on the channel deactivation. These data may help explain why flecainide showed no antiarrhythmic effects in SQT1-hiPSC-CMs and SQT-patients because these effects are different from that of quinidine, ajmaline, ivabradine and mexiletine, which prolonged APD and reduced epinephrine-induced arrhythmic events in SQT1-hiPSC-CMs. Flecainide can inhibit I<sub>Na</sub>, I<sub>Ca-L</sub>, I<sub>to</sub>, I<sub>KATP</sub>, and enhance I<sub>NCX</sub> and I<sub>K1</sub> but has no effect on I<sub>Ks</sub> (<a href="#SM1">Supplementary Table 1</a>) (<a href="#B75">Watanabe, 2019</a>; <a href="#B72">Wang et al., 1996</a>; <a href="#B71">Wang et al., 1993</a>; <a href="#B21">Follmer and Colatsky, 1990</a>; <a href="#B10">Caballero et al., 2010</a>; <a href="#B80">Yunoki et al., 2001</a>). The inhibition of I<sub>to</sub> and I<sub>KATP</sub> can prolong APD, which may contribute to the APD-prolongation observed in healthy cardiomyocytes (<a href="#T1">Table 1</a>) (<a href="#B8">Borchard and Boisten, 1982</a>; <a href="#B71">Wang et al., 1993</a>). In the current study, we did not examine the effect of flecainide on these currents. The fact that flecainide failed to prolong APD in SQT1-hiPSC-CMs suggests that its effect on I<sub>to</sub> and I<sub>KATP</sub> is probably also attenuated in SQT1-cells.</p><p class="mb15">Ranolazine, an antianginal drug, possesses also antiarrhythmic effects (<a href="#B22">Frommeyer et al., 2012</a>; <a href="#B9">Burashnikov et al., 2012</a>). It showed potent antiarrhythmic properties in the rabbit model of pinacidil-induced SQTS (<a href="#B23">Frommeyer et al., 2016</a>). Ranolazine was shown to block I<sub>Kr</sub> in dog cardiomyocytes (<a href="#B2">Antzelevitch et al., 2004a</a>; <a href="#B64">Schram et al., 2004</a>). In HEK cells expressing WT- and mutant hERG channels, ranolazine inhibited the hERG channel current and its effect was reduced by different mutants including N588K<sup>69</sup>. It shifted the activation curve of WT hERG channels to a more negative potential (<a href="#B16">Du et al., 2014</a>; <a href="#B58">Rajamani et al., 2008</a>). It was also shown that ranolazine reduced the time constant of inactivation and showed no effect on the time constant of recovery from inactivation of hERG channels in HEK cells (<a href="#B58">Rajamani et al., 2008</a>). Effects of ranolazine on gating kinetic parameters of mutant hERG channels have not been shown. Our study analyzed in detail the effects of ranolazine on the activation, inactivation, recovery from inactivation and deactivation of hERG channel currents in both healthy donor and SQT1-hiPSC-CMs. The main findings are that both the activation and inactivation curves were shifted in the same direction and hence the window current was not changed. The time to peak and time constant of deactivation were similar in donor and SQT1-hiPSC-CMs. The time constant of inactivation and time constant of recovery from inactivation were differentially affected by ranolazine in donor- and SQT1-hiPSC-CMs. Besides hERG current, ranolazine can inhibit I<sub>Na</sub>, I<sub>Ca-L</sub>, I<sub>NCX</sub>, I<sub>to</sub> and I<sub>Ks</sub> without effect onI<sub>K1</sub> (<a href="#SM1">Supplementary Table 1</a>) (<a href="#B3">Antzelevitch et al., 2004b</a>; <a href="#B56">Qian et al., 2012</a>). Action potential prolongation and shortening induced by ranolazine were observed in wild-type cells (<a href="#T1">Table 1</a>) (<a href="#B2">Antzelevitch et al., 2004a</a>; <a href="#B76">Wu et al., 2004</a>; <a href="#B23">Frommeyer et al., 2016</a>). The inhibition of I<sub>Ca-L</sub> can shorten APD, while inhibition of I<sub>Kr</sub> and I<sub>Ks</sub> can explain the APD-prolongation. In our SQT1-hiPSC-CMs, ranolazine did not prolong APD, probably, its effect on I<sub>Ks</sub> was also attenuated or its inhibitory effect on I<sub>Ca-L</sub> was enhanced, which counteracted the APD-prolonging effect of inhibition of I<sub>Kr</sub> and I<sub>Ks</sub>.</p><p class="mb15">Taking all the data together, all the examined drugs inhibited the hERG channel current in both donor- and SQT1-hiPSC-CMs. The inhibition by each drug was reduced in SQT1-cells. Though the tested drugs displayed some differences regarding effects on the hERG channel gating kinetics in donor or SQT1-hiPSC-CMs, we observed important features, i.e., 1) quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine reduced the window current in SQT1-hiPSC-CMs, 2) quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine increased the time constant of deactivation (the speed of deactivation was reduced). Since quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine showed APD-prolonging and antiarrhythmic effects in SQT1-hiPSC-CMs (<a href="#B84">Zhao et al., 2019</a>), we assume that the window current-reducing and deactivation-slowing effect may be important for antiarrhythmic effects of drugs in SQT1-paptient with hERG mutation, at least with a N588K mutation.</p><p class="mb15">Notably, all the seven drugs tested in this study have effects on multiple ion channels (<a href="#SM1">Supplementary Table 1</a>). Theoretically, either an enhancement of inward current or a suppression of outward current or both can prolong APD/QTc. Therefore, the effects of quinidine, ajmaline, ivabradine and mexiletine on ion channel currents other than I<sub>Kr</sub> may also contribute to their APD/QTc-prolonging and antiarrhythmic effects.</p><p class="mb15">The concentrations of drugs used in the study were higher than that used in patients. The concentrations were selected because they showed noticeable effects (either on I<sub>Kr</sub> or APD or arrhythmic events) in hiPSC-CMs. The reason for requirement of higher concentration is not clear. Probably, the sensitivity of cells to drugs is reduced due to challenges in cell splitting, single cell isolation or unphysiological cell culture. The high concentration may enhance the toxicity or side effects of a drug and limit the drug application in patients. Besides, cells in other systems express also hERG channels, which may be also inhibited when the drug is used in a SQTS-patient. This may further limit the application of hERG-inhibiting drugs in patients. Therefore, the data from our study cannot be directly translated to clinical use, instead, provide information for designing clinical studies. On the other hand, it is possible that in patients lower concentrations of drugs are required to exert effects same with or similar to that observed in our study. Our hiPSC-CM platform for drug testing can provide possible candidate drugs, but the real efficacy and safe concentrations in patients need to be examined in clinical studies<strong>.</strong></p><p class="mb15">In summary, we analyzed effects of quinidine, ajmaline, amiodarone, ivabradine, flecainide, mexiletine and ranolazine on hERG channel gating kinetic parameters. We observed that all the tested drugs have some effects on hERG gating parameters in donor or SQT1-hiPSC-CMs (<a href="#T1">Table 1</a>), but constant effects on hERG window current and deactivation were detected only in the application of quinidine, ajmaline, ivabradine and mexiletine, which may be one of the reasons for their effective antiarrhythmic effects in SQT1-cells.</p><a id="h6" name="h6"></a><h2>Conclusion</h2><p class="mb15">From the results we conclude that the window current-reducing and deactivation-slowing effects may be important for the antiarrhythmic effects of drugs in SQT1-paptients with a hERG mutation, at least with a N588K mutation. These findings may help us to search for potential candidate drugs for treating SQT1-patients.</p><a id="h7" name="h7"></a><h2>Study Limitations</h2><p class="mb15">We recruited only one SQT1-patient and one healthy donor for this study. Differences among individuals cannot be ruled out. Due to the hurdle to find more SQT1-patients with the same mutation, the study focused on cell line from single patient. Therefore, the study may be relevant for personalized medicine, e.g., for planning a therapeutical strategy for this specific SQT-hiPSC-CM donor.</p><p class="mb15">Isogenic control cells were not used in the study. The possibility that the different gene background in heathy donor and SQT1 cells influenced the drug effects cannot be completely excluded.</p><p class="mb15">Since the concentration of drugs used in the study was higher than that used in patients, possible drug toxicity <em>in vivo</em> needs to be considered when interpreting the data of the current study.</p><p class="mb15">All the measurements were performed at room temperature. The possible influence of temperature on drug effects was not examined in this study. In previously reported studies with respect to hERG channel current or drug effect on the current, some were performed at room temperature (<a href="#B60">Sanguinetti et al., 1995</a>; <a href="#B69">Trudeau et al., 1995</a>; <a href="#B66">Snyders and Chaudhary, 1996</a>; <a href="#B73">Wang et al., 1997</a>; <a href="#B81">Zhang et al., 1999</a>; <a href="#B36">Kiesecker et al., 2004</a>; <a href="#B12">Cordeiro et al., 2005</a>; <a href="#B58">Rajamani et al., 2008</a>), some at physiological temperature (37&#x000b0;C) (<a href="#B52">Paul et al., 2002</a>; <a href="#B43">McPate et al., 2008</a>; <a href="#B44">Melgari et al., 2015</a>; <a href="#B45">Melgari et al., 2015</a>). It has been shown that hERG channel current is temperature-sensitive (<a href="#B85">Zhou et al., 1998</a>; <a href="#B74">Wang et al., 2003</a>). This may suggest a possible influence of temperature on drug effects. On the other hand, it is also possible that the temperature influence on drug effects is minor because the temperature-sensitivity of the channel does not mean the drug effect is also temperature-sensitive. The temperature may underestimate or overestimate (amplify) drug effects, but it is also possible that temperature does not change drug effect when temperature changes at certain range. Cs<sup>&#x0002b;</sup> instead of K<sup>&#x0002b;</sup> was used as the charge carrier for recording hERG current since Cs<sup>&#x0002b;</sup> can be conducted by hERG channel but not by other K<sup>&#x0002b;</sup> channels and hence can separate hERG channel current from other K<sup>&#x0002b;</sup> currents (<a href="#B63">Sch&#x000f6;nherr and Heinemann, 1996</a>; <a href="#B79">Youm et al., 2004</a>; <a href="#B83">Zhang, 2006</a>). It was reported that Cs<sup>&#x0002b;</sup> can slow hERG channel inactivation but has no effect on the channel activation (<a href="#B82">Zhang et al., 2003</a>). This suggests a possibility that Cs<sup>&#x0002b;</sup> may influence some drug effects. It is possible that Cs<sup>&#x0002b;</sup> may reduce or enhance drug effects, but it is also possible that it has no influence on some drug effects. Taken together, the drug effects shown in this study were detected under unphysiological conditions and therefore need to be examined in more physiological studies in future.</p><p class="mb15">Another limitation may be the immaturity of hiPSC-CMs. The immature hiPSC-CMs possess similarities but also differences compared with adult human cardiomyocytes. As shown before, the expression profile of some ion channels in hiPSC-CMs may be different from that in adult cardiomyocytes and even more, hiPSC-CMs from different cell lines may also show different expression profile of ion channels (<a href="#B7">Blinova et al., 2017</a>), which may influence drug effects in hiPSC-CMs. This should be taken into account when interpreting the data.</p><p class="mb15">I<sub>NCX</sub> is known to have both an inward and an outward component at different phases of APs. Although we reported in <a href="#SM1">Supplementary Table 1</a> the drug effects on I<sub>NCX</sub>, it is not simple speculating on how its activation/inhibition could affect APD following drug administration. This would require a more detailed analysis that is out of the scope of this manuscript.</p><a id="h8" name="h8"></a><h2>Data Availability Statement</h2><p class="mb15">The original contributions presented in the study are included in the article/<a href="#SM1">Supplementary Material</a>, further inquiries can be directed to the corresponding author.</p><a id="h9" name="h9"></a><h2>Author Contributions</h2><p class="mb0">MH, XL, ZL, XF, ZY, YL and ZZ performed experiments. SL analyzed data. LC, MB, XZ, IA and IE designed the study and wrote the paper.</p><a id="h10" name="h10"></a><h2>Funding</h2><p class="mb0">This study was supported by the Post-doc of German Center for Cardiovascular Research (DZHK) (81Z0500204) and shared expertise (81X2500208).</p><a id="h11" name="h11"></a><h2>Conflict of Interest</h2><p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><a id="h12" name="h12"></a><h2>Acknowledgments</h2><p class="mb0">We gratefully thank C. Liebetrau for excellent technical assistance. We thank the Chinese Scholarship Council (CSC) for the financial support for Mengying Huang, Zhihan Zhao, Xin Li and Xuehui Fan. Excellent technical support by the Stem Cell Unit G&#x000f6;ttingen is acknowledged.</p><a id="h13" name="h13"></a><h2>Supplementary Material</h2><p class="mb15" id="SM1">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fphar.2021.675003/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2021.675003/full&#x00023;supplementary-material</a></p><a id="h14" name="h14"></a><h2>References</h2><div class="References"><p class="ReferencesCopy1"><a name="B1" id="B1"></a>Abriel, H., and Rougier, J. S. (2013). &#x003b2;-Blockers in Congenital Short-QT Syndrome as Ion Channel Blockers. <em>J. Cardiovasc. Electrophysiol.</em> 24, 1172&#x02013;1174. doi:10.1111/jce.12204</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23890274/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/jce.12204">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=-Blockers+in+Congenital+Short-QT+Syndrome+as+Ion+Channel+Blockers&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B2" id="B2"></a>Antzelevitch, C., Belardinelli, L., Wu, L., Fraser, H., Zygmunt, A. C., Burashnikov, A., et al. (2004a). Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent. <em>J. Cardiovasc. Pharmacol. Ther.</em> 9 (Suppl. 1), S65&#x02013;S83. doi:10.1177/107424840400900106</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15378132/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1177/107424840400900106">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Electrophysiologic+Properties+and+Antiarrhythmic+Actions+of+a+Novel+Antianginal+Agent&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B3" id="B3"></a>Antzelevitch, C., Belardinelli, L., Zygmunt, A. C., Burashnikov, A., Di Diego, J. M., Fish, J. M., et al. (2004b). Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent with Antiarrhythmic Properties. <em>Circulation</em> 110, 904&#x02013;910. doi:10.1161/01.cir.0000139333.83620.5d</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15302796/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1161/01.cir.0000139333.83620.5d">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Electrophysiological+Effects+of+Ranolazine,+a+Novel+Antianginal+Agent+with+Antiarrhythmic+Properties&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B4" id="B4"></a>Aomine, M. (1988). Does Acute Exposure to Amiodarone Prolong Cardiac Action Potential Duration? <em>Gen. Pharmacol. Vasc. Syst.</em> 19, 615&#x02013;619. doi:10.1016/0306-3623(88)90173-5</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1016/0306-3623(88)90173-5">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Does+Acute+Exposure+to+Amiodarone+Prolong+Cardiac+Action+Potential+Duration?&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B5" id="B5"></a>B&#x000e9;barov&#x000e1;, M., Matejovic, P., P&#x000e1;sek, M., Simurdov&#x000e1;, M., and Simurda, J. (2005a). Effect of Ajmaline on Transient Outward Current in Rat Ventricular Myocytes. <em>Gen. Physiol. Biophys.</em> 24, 27&#x02013;45. doi:10.1113/expphysiol.2004.029439 </p><p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effect+of+Ajmaline+on+Transient+Outward+Current+in+Rat+Ventricular+Myocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B6" id="B6"></a>B&#x000e9;barov&#x000e1;, M., Matejovic, P., P&#x000e1;sek, M., Simurdov&#x000e1;, M., and Simurda, J. (2005b). Effect of Ajmaline on Action Potential and Ionic Currents in Rat Ventricular Myocytes. <em>Gen. Physiol. Biophys.</em> 24, 311&#x02013;325. doi:10.1113/expphysiol.2005.031096 </p><p class="ReferencesCopy2"><a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effect+of+Ajmaline+on+Action+Potential+and+Ionic+Currents+in+Rat+Ventricular+Myocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B7" id="B7"></a>Blinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre, M. P., et al. (2017). Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. <em>Toxicol. Sci.</em> 155, 234&#x02013;247. doi:10.1093/toxsci/kfw200</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27701120/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1093/toxsci/kfw200">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Comprehensive+Translational+Assessment+of+Human-Induced+Pluripotent+Stem+Cell+Derived+Cardiomyocytes+for+Evaluating+Drug-Induced+Arrhythmias&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B8" id="B8"></a>Borchard, U., and Boisten, M. (1982). Effect of Flecainide on Action Potentials and Alternating Current-Induced Arrhythmias in Mammalian Myocardium. <em>J. Cardiovasc. Pharmacol.</em> 4, 205&#x02013;212. doi:10.1097/00005344-198203000-00007</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/6175802/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1097/00005344-198203000-00007">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effect+of+Flecainide+on+Action+Potentials+and+Alternating+Current-Induced+Arrhythmias+in+Mammalian+Myocardium&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B9" id="B9"></a>Burashnikov, A., Belardinelli, L., and Antzelevitch, C. (2012). Atrial-selective Sodium Channel Block Strategy to Suppress Atrial Fibrillation: Ranolazine versus Propafenone. <em>J. Pharmacol. Exp. Ther.</em> 340, 161&#x02013;168. doi:10.1124/jpet.111.186395</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22005044/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1124/jpet.111.186395">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Atrial-selective+Sodium+Channel+Block+Strategy+to+Suppress+Atrial+Fibrillation:+Ranolazine+versus+Propafenone&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B10" id="B10"></a>Caballero, R., Dolz-Gait&#x000f3;n, P., G&#x000f3;mez, R., Amor&#x000f3;s, I., Barana, A., Gonz&#x000e1;lez de la Fuente, M., et al. (2010). Flecainide Increases Kir2.1 Currents by Interacting with Cysteine 311, Decreasing the Polyamine-Induced Rectification. <em>Proc. Natl. Acad. Sci.</em> 107, 15631&#x02013;15636. doi:10.1073/pnas.1004021107</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20713726/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1073/pnas.1004021107">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Flecainide+Increases+Kir2.1+Currents+by+Interacting+with+Cysteine+311,+Decreasing+the+Polyamine-Induced+Rectification&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B11" id="B11"></a>Campuzano, O., Sarquella-Brugada, G., Cesar, S., Arbelo, E., Brugada, J., and Brugada, R. (2018). Recent Advances in Short QT Syndrome. <em>Front. Cardiovasc. Med.</em> 5, 149. doi:10.3389/fcvm.2018.00149</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30420954/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.3389/fcvm.2018.00149">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Recent+Advances+in+Short+QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B12" id="B12"></a>Cordeiro, J., Brugada, R., Wu, Y., Hong, K., and Dumaine, R. (2005). Modulation of Inactivation by Mutation N588K in KCNH2: A Link to Arrhythmogenesis in Short QT Syndrome. <em>Cardiovasc. Res.</em> 67, 498&#x02013;509. doi:10.1016/j.cardiores.2005.02.018</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16039272/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.cardiores.2005.02.018">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modulation+of+Inactivation+by+Mutation+N588K+in+KCNH2:+A+Link+to+Arrhythmogenesis+in+Short+QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B13" id="B13"></a>Cyganek, L., Tiburcy, M., Sekeres, K., Gerstenberg, K., Bohnenberger, H., Lenz, C., et al. (2018). Deep Phenotyping of Human Induced Pluripotent Stem Cell-Derived Atrial and Ventricular Cardiomyocytes. <em>JCI insight</em> 3, e99941. doi:10.1172/jci.insight.99941</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29925689/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1172/jci.insight.99941">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Deep+Phenotyping+of+Human+Induced+Pluripotent+Stem+Cell-Derived+Atrial+and+Ventricular+Cardiomyocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B14" id="B14"></a>Davidenko, J. M., Cohen, L., Goodrow, R., and Antzelevitch, C. (1989). Quinidine-induced Action Potential Prolongation, Early Afterdepolarizations, and Triggered Activity in Canine Purkinje Fibers. Effects of Stimulation Rate, Potassium, and Magnesium. <em>Circulation</em> 79, 674&#x02013;686. doi:10.1161/01.cir.79.3.674</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/2917391/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1161/01.cir.79.3.674">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Quinidine-induced+Action+Potential+Prolongation,+Early+Afterdepolarizations,+and+Triggered+Activity+in+Canine+Purkinje+Fibers.+Effects+of+Stimulation+Rate,+Potassium,+and+Magnesium&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B15" id="B15"></a>Demontis, G. C., Gargini, C., Paoli, T. G., and Cervetto, L. (2009). Selective Hcn1 Channels Inhibition by Ivabradine in Mouse Rod Photoreceptors. <em>Invest. Ophthalmol. Vis. Sci.</em> 50, 1948&#x02013;1955. doi:10.1167/iovs.08-2659</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19060291/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1167/iovs.08-2659">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Selective+Hcn1+Channels+Inhibition+by+Ivabradine+in+Mouse+Rod+Photoreceptors&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B16" id="B16"></a>Du, C., Zhang, Y., El Harchi, A., Dempsey, C. E., and Hancox, J. C. (2014). Ranolazine Inhibition of hERG Potassium Channels: Drug-Pore Interactions and Reduced Potency against Inactivation Mutants. <em>J. Mol. Cell. Cardiol.</em> 74, 220&#x02013;230. doi:10.1016/j.yjmcc.2014.05.013</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24877995/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.yjmcc.2014.05.013">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ranolazine+Inhibition+of+hERG+Potassium+Channels:+Drug-Pore+Interactions+and+Reduced+Potency+against+Inactivation+Mutants&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B17" id="B17"></a>El-Battrawy, I., Lan, H., Cyganek, L., Zhao, Z., Li, X., Buljubasic, F., et al. (2018). Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <em>J. Am. Heart Assoc.</em> 7. doi:10.1161/JAHA.117.007394</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29574456/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1161/JAHA.117.007394">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modeling+Short+QT+Syndrome+Using+Human-Induced+Pluripotent+Stem+Cell-Derived+Cardiomyocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B18" id="B18"></a>El-Battrawy, I., Zhao, Z., Lan, H., Sch&#x000fc;nemann, J.-D., Sattler, K., Buljubasic, F., et al. (2018). Estradiol Protection against Toxic Effects of Catecholamine on Electrical Properties in Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes. <em>Int. J. Cardiol.</em> 254, 195&#x02013;202. doi:10.1016/j.ijcard.2017.11.007</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29407091/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.ijcard.2017.11.007">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Estradiol+Protection+against+Toxic+Effects+of+Catecholamine+on+Electrical+Properties+in+Human-Induced+Pluripotent+Stem+Cell+Derived+Cardiomyocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B19" id="B19"></a>El-Battrawy, I., Besler, J., Liebe, V., Schimpf, R., T&#x000fc;l&#x000fc;men, E., Rudic, B., et al. (2018). Long-Term Follow-Up of Patients with Short QT Syndrome: Clinical Profile and Outcome. <em>J. Am. Heart Assoc.</em> 7, e010073. doi:10.1161/JAHA.118.010073</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30571592/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1161/JAHA.118.010073">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Long-Term+Follow-Up+of+Patients+with+Short+QT+Syndrome:+Clinical+Profile+and+Outcome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B20" id="B20"></a>El-Battrawy, I., Besler, J., Li, X., Lan, H., Zhao, Z., Liebe, V., et al. (2019). Impact of Antiarrhythmic Drugs on the Outcome of Short QT Syndrome. <em>Front. Pharmacol.</em> 10, 771. doi:10.3389/fphar.2019.00771</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31427960/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.3389/fphar.2019.00771">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Impact+of+Antiarrhythmic+Drugs+on+the+Outcome+of+Short+QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B21" id="B21"></a>Follmer, C. H., and Colatsky, T. J. (1990). Block of Delayed Rectifier Potassium Current, Ik, by Flecainide and E-4031 in Cat Ventricular Myocytes. <em>Circulation</em> 82, 289&#x02013;293. doi:10.1161/01.cir.82.1.289</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/2114236/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1161/01.cir.82.1.289">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Block+of+Delayed+Rectifier+Potassium+Current,+Ik,+by+Flecainide+and+E-4031+in+Cat+Ventricular+Myocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B22" id="B22"></a>Frommeyer, G., Schmidt, M., Clauss, C., Kaese, S., Stypmann, J., Pott, C., et al. (2012). Further Insights into the Underlying Electrophysiological Mechanisms for Reduction of Atrial Fibrillation by Ranolazine in an Experimental Model of Chronic Heart Failure. <em>Eur. J. Heart Fail.</em> 14, 1322&#x02013;1331. doi:10.1093/eurjhf/hfs163</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23099358/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1093/eurjhf/hfs163">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Further+Insights+into+the+Underlying+Electrophysiological+Mechanisms+for+Reduction+of+Atrial+Fibrillation+by+Ranolazine+in+an+Experimental+Model+of+Chronic+Heart+Failure&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B23" id="B23"></a>Frommeyer, G., Ellermann, C., Dechering, D. G., Kochh&#x000e4;user, S., B&#x000f6;geholz, N., G&#x000fc;ner, F., et al. (2016). Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome. <em>J. Cardiovasc. Electrophysiol.</em> 27, 1214&#x02013;1219. doi:10.1111/jce.13029</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27283775/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/jce.13029">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ranolazine+and+Vernakalant+Prevent+Ventricular+Arrhythmias+in+an+Experimental+Whole-Heart+Model+of+Short+QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B24" id="B24"></a>Frommeyer, G., Weller, J., Ellermann, C., Kaese, S., Kochh&#x000e4;user, S., Lange, P. S., et al. (2017). Antiarrhythmic Properties of Ivabradine in an Experimental Model of Short-QT- Syndrome. <em>Clin. Exp. Pharmacol. Physiol.</em> 44, 941&#x02013;945. doi:10.1111/1440-1681.12790</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28556923/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/1440-1681.12790">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Antiarrhythmic+Properties+of+Ivabradine+in+an+Experimental+Model+of+Short-QT-+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B25" id="B25"></a>Frommeyer, G., Garthmann, J., Ellermann, C., Dechering, D. G., Kochh&#x000e4;user, S., Reinke, F., et al. (2018). Broad Antiarrhythmic Effect of Mexiletine in Different Arrhythmia Models. <em>Electrophysiol. Eur. Soc. Cardiol.</em> 20, 1375&#x02013;1381. doi:10.1093/europace/eux221</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1093/europace/eux221">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Broad+Antiarrhythmic+Effect+of+Mexiletine+in+Different+Arrhythmia+Models&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B26" id="B26"></a>Gaita, F., Giustetto, C., Bianchi, F., Schimpf, R., Haissaguerre, M., Cal&#x000f2;, L., et al. (2004). Short QT Syndrome: Pharmacological Treatment. <em>J. Am. Coll. Cardiol.</em> 43, 1494&#x02013;1499. doi:10.1016/j.jacc.2004.02.034</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15093889/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.jacc.2004.02.034">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Short+QT+Syndrome:+Pharmacological+Treatment&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B27" id="B27"></a>Giustetto, C., Schimpf, R., Mazzanti, A., Scrocco, C., Maury, P., Anttonen, O., et al. (2011). Long-term Follow-Up of Patients with Short QT Syndrome. <em>J. Am. Coll. Cardiol.</em> 58, 587&#x02013;595. doi:10.1016/j.jacc.2011.03.038</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21798421/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.jacc.2011.03.038">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Long-term+Follow-Up+of+Patients+with+Short+QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B28" id="B28"></a>Gualdani, R., Tadini-Buoninsegni, F., Roselli, M., Defrenza, I., Contino, M., Colabufo, N. A., et al. (2015). Inhibition of hERG Potassium Channel by the Antiarrhythmic Agent Mexiletine and its Metabolite M-Hydroxymexiletine. <em>Pharmacol. Res. Perspect.</em> 3, e00160. doi:10.1002/prp2.160</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26516576/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1002/prp2.160">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibition+of+hERG+Potassium+Channel+by+the+Antiarrhythmic+Agent+Mexiletine+and+its+Metabolite+M-Hydroxymexiletine&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B29" id="B29"></a>Guo, F., Sun, Y., Wang, X., Wang, H., Wang, J., Gong, T., et al. (2019). Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome. <em>Circ. Res.</em> 124, 66&#x02013;78. doi:10.1161/circresaha.118.313518</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30582453/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1161/circresaha.118.313518">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Patient-Specific+and+Gene-Corrected+Induced+Pluripotent+Stem+Cell-Derived+Cardiomyocytes+Elucidate+Single-Cell+Phenotype+of+Short+QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B30" id="B30"></a>Gussak, I., Brugada, P., Brugada, J., Wright, R. S., Kopecky, S. L., Chaitman, B. R., et al. (2000). Idiopathic Short QT Interval:A New Clinical Syndrome? <em>Cardiology</em> 94, 99&#x02013;102. doi:10.1159/000047299</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/11173780/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1159/000047299">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Idiopathic+Short+QT+Interval:A+New+Clinical+Syndrome?&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B31" id="B31"></a>Haechl, N., Ebner, J., Hilber, K., Todt, H., and Koenig, X. (2019). Pharmacological Profile of the Bradycardic Agent Ivabradine on Human Cardiac Ion Channels. <em>Cell Physiol Biochem</em> 53, 36&#x02013;48. doi:10.33594/000000119</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31169990/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.33594/000000119">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Pharmacological+Profile+of+the+Bradycardic+Agent+Ivabradine+on+Human+Cardiac+Ion+Channels&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B32" id="B32"></a>Imaizumi, Y., and Giles, W. R. (1987). Quinidine-induced Inhibition of Transient Outward Current in Cardiac Muscle. <em>Am. J. Physiology-Heart Circulatory Physiol.</em> 253, H704&#x02013;H708. doi:10.1152/ajpheart.1987.253.3.h704</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1152/ajpheart.1987.253.3.h704">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Quinidine-induced+Inhibition+of+Transient+Outward+Current+in+Cardiac+Muscle&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B33" id="B33"></a>Iwamoto, T., Watanabe, Y., Kita, S., and Blaustein, M. (2007). Na&#x0002b;/Ca2&#x0002b; Exchange Inhibitors: a New Class of Calcium Regulators. <em>Chddt</em> 7, 188&#x02013;198. doi:10.2174/187152907781745288</p><p class="ReferencesCopy2"><a href="https://doi.org/10.2174/187152907781745288">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Na+/Ca2++Exchange+Inhibitors:+a+New+Class+of+Calcium+Regulators&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B34" id="B34"></a>J&#x000e6;ger, K. H., Wall, S., and Tveito, A. (2021). Computational Prediction of Drug Response in Short QT Syndrome Type 1 Based on Measurements of Compound Effect in Stem Cell-Derived Cardiomyocytes. <em>Plos Comput. Biol.</em> 17, e1008089. doi:10.1371/journal.pcbi.1008089</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33591962/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1371/journal.pcbi.1008089">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Computational+Prediction+of+Drug+Response+in+Short+QT+Syndrome+Type+1+Based+on+Measurements+of+Compound+Effect+in+Stem+Cell-Derived+Cardiomyocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B35" id="B35"></a>Khodorov, B. I., and Zaborovskaya, L. D. (1983). Blockade of Sodium and Potassium Channels in the Node of Ranvier by Ajmaline and N-Propyl Ajmaline. <em>Gen. Physiol. Biophys.</em> 2, 233&#x02013;268.</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/6088360/">PubMed Abstract</a> | <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Blockade+of+Sodium+and+Potassium+Channels+in+the+Node+of+Ranvier+by+Ajmaline+and+N-Propyl+Ajmaline&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B36" id="B36"></a>Kiesecker, C., Zitron, E., L&#x000fc;ck, S., Bloehs, R., Scholz, E. P., Kath&#x000f6;fer, S., et al. (2004). Class Ia Anti-arrhythmic Drug Ajmaline Blocks HERG Potassium Channels: Mode of Action. <em>Naunyn-schmiedeberg&#x00027;s Arch. Pharmacol.</em> 370, 423&#x02013;435. doi:10.1007/s00210-004-0976-8</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15599706/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1007/s00210-004-0976-8">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Class+Ia+Anti-arrhythmic+Drug+Ajmaline+Blocks+HERG+Potassium+Channels:+Mode+of+Action&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B37" id="B37"></a>Koepple, C., Scherer, D., Seyler, C., Scholz, E., Thomas, D., Katus, H. A., et al. (2017). Dual Mechanism for Inhibition of Inwardly Rectifying Kir2.X Channels by Quinidine Involving Direct Pore Block and PIP2-Interference. <em>J. Pharmacol. Exp. Ther.</em> 361, 209&#x02013;218. doi:10.1124/jpet.116.238287</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28188270/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1124/jpet.116.238287">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Dual+Mechanism+for+Inhibition+of+Inwardly+Rectifying+Kir2.X+Channels+by+Quinidine+Involving+Direct+Pore+Block+and+PIP2-Interference&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B38" id="B38"></a>Koncz, I., Sz&#x000e9;l, T., Bitay, M., Cerbai, E., Jaeger, K., F&#x000fc;l&#x000f6;p, F., et al. (2011). Electrophysiological Effects of Ivabradine in Dog and Human Cardiac Preparations: Potential Antiarrhythmic Actions. <em>Eur. J. Pharmacol.</em> 668, 419&#x02013;426. doi:10.1016/j.ejphar.2011.07.025</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21821019/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.ejphar.2011.07.025">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Electrophysiological+Effects+of+Ivabradine+in+Dog+and+Human+Cardiac+Preparations:+Potential+Antiarrhythmic+Actions&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B39" id="B39"></a>Lan, H., Xu, Q., El-Battrawy, I., Zhong, R., Li, X., Lang, S., et al. (2020). Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1. <em>Front. Pharmacol.</em> 11, 554422. doi:10.3389/fphar.2020.554422</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33154722/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.3389/fphar.2020.554422">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ionic+Mechanisms+of+Disopyramide+Prolonging+Action+Potential+Duration+in+Human-Induced+Pluripotent+Stem+Cell-Derived+Cardiomyocytes+from+a+Patient+with+Short+QT+Syndrome+Type+1&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B40" id="B40"></a>Lees-Miller, J. P., Guo, J., Wang, Y., Perissinotti, L. L., Noskov, S. Y., and Duff, H. J. (2015). Ivabradine Prolongs Phase 3 of Cardiac Repolarization and Blocks the hERG1 (KCNH2) Current over a Concentration-Range Overlapping with that Required to Block HCN4. <em>J. Mol. Cell. Cardiol.</em> 85, 71&#x02013;78. doi:10.1016/j.yjmcc.2015.05.009</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25986146/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.yjmcc.2015.05.009">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ivabradine+Prolongs+Phase+3+of+Cardiac+Repolarization+and+Blocks+the+hERG1+(KCNH2)+Current+over+a+Concentration-Range+Overlapping+with+that+Required+to+Block+HCN4&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B41" id="B41"></a>Matsuo, S., Kishida, H., Munakata, K., and Atarashi, H. (1985). The Effects of Mexiletine on Action Potential Duration and its Restitution in guinea Pig Ventricular Muscles. <em>Jpn. Heart J.</em> 26, 271&#x02013;287. doi:10.1536/ihj.26.271</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/4009969/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1536/ihj.26.271">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=The+Effects+of+Mexiletine+on+Action+Potential+Duration+and+its+Restitution+in+guinea+Pig+Ventricular+Muscles&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B42" id="B42"></a>Mazzanti, A., Maragna, R., Vacanti, G., Kostopoulou, A., Marino, M., Monteforte, N., et al. (2017). Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients with Short QT Syndrome. <em>J. Am. Coll. Cardiol.</em> 70, 3010&#x02013;3015. doi:10.1016/j.jacc.2017.10.025</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29241489/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.jacc.2017.10.025">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Hydroquinidine+Prevents+Life-Threatening+Arrhythmic+Events+in+Patients+with+Short+QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B43" id="B43"></a>McPate, M. J., Duncan, R. S., Hancox, J. C., and Witchel, H. J. (2008). Pharmacology of the Short QT Syndrome N588K-hERG K&#x0002b; Channel Mutation: Differential Impact on Selected Class I and Class III Antiarrhythmic Drugs. <em>Br. J. Pharmacol.</em> 155, 957&#x02013;966. doi:10.1038/bjp.2008.325</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18724381/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1038/bjp.2008.325">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Pharmacology+of+the+Short+QT+Syndrome+N588K-hERG+K++Channel+Mutation:+Differential+Impact+on+Selected+Class+I+and+Class+III+Antiarrhythmic+Drugs&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B44" id="B44"></a>Melgari, D., Brack, K. E., Zhang, C., Zhang, Y., El Harchi, A., Mitcheson, J. S., et al. (2015). hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine. <em>J. Am. Heart Assoc.</em> 4, e001813. doi:10.1161/jaha.115.001813</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25911606/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1161/jaha.115.001813">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=hERG+Potassium+Channel+Blockade+by+the+HCN+Channel+Inhibitor+Bradycardic+Agent+Ivabradine&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B45" id="B45"></a>Melgari, D., Zhang, Y., El Harchi, A., Dempsey, C. E., and Hancox, J. C. (2015). Molecular Basis of hERG Potassium Channel Blockade by the Class Ic Antiarrhythmic Flecainide. <em>J. Mol. Cell. Cardiol.</em> 86, 42&#x02013;53. doi:10.1016/j.yjmcc.2015.06.021</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26159617/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.yjmcc.2015.06.021">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Molecular+Basis+of+hERG+Potassium+Channel+Blockade+by+the+Class+Ic+Antiarrhythmic+Flecainide&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B46" id="B46"></a>Michel, D., Wegener, J. W., and Nawrath, H. (2002). Effects of Quinine and Quinidine on the Transient Outward and on the L-type Ca2&#x0002b; Current in Rat Ventricular Cardiomyocytes. <em>Pharmacology</em> 65, 187&#x02013;192. doi:10.1159/000064342</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/12180412/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1159/000064342">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effects+of+Quinine+and+Quinidine+on+the+Transient+Outward+and+on+the+L-type+Ca2++Current+in+Rat+Ventricular+Cardiomyocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B47" id="B47"></a>Milberg, P., Tegelkamp, R., Osada, N., Schimpf, R., Wolpert, C., Breithardt, G., et al. (2007). Reduction of Dispersion of Repolarization and Prolongation of Postrepolarization Refractoriness Explain the Antiarrhythmic Effects of Quinidine in a Model of Short QT Syndrome. <em>J. Cardiovasc. Electrophysiol.</em> 18, 658&#x02013;664. doi:10.1111/j.1540-8167.2007.00813.x</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/17521304/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/j.1540-8167.2007.00813.x">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Reduction+of+Dispersion+of+Repolarization+and+Prolongation+of+Postrepolarization+Refractoriness+Explain+the+Antiarrhythmic+Effects+of+Quinidine+in+a+Model+of+Short+QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B48" id="B48"></a>Miller, D. C., Harmer, S. C., Poliandri, A., Nobles, M., Edwards, E. C., Ware, J. S., et al. (2017). Ajmaline Blocks I Na and I Kr without Eliciting Differences between Brugada Syndrome Patient and Control Human Pluripotent Stem Cell-Derived Cardiac Clusters. <em>Stem Cel. Res.</em> 25, 233&#x02013;244. doi:10.1016/j.scr.2017.11.003</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1016/j.scr.2017.11.003">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ajmaline+Blocks+I+Na+and+I+Kr+without+Eliciting+Differences+between+Brugada+Syndrome+Patient+and+Control+Human+Pluripotent+Stem+Cell-Derived+Cardiac+Clusters&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B49" id="B49"></a>Mitcheson, J. S., and Hancox, J. C. (1997). Modulation by Mexiletine of Action Potentials, L-type Ca Current and Delayed Rectifier K Current Recorded from Isolated Rabbit Atrioventricular Nodal Myocytes. <em>Pflugers Archiv Eur. J. Physiol.</em> 434, 855&#x02013;858. doi:10.1007/s004240050476</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/9306023/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1007/s004240050476">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modulation+by+Mexiletine+of+Action+Potentials,+L-type+Ca+Current+and+Delayed+Rectifier+K+Current+Recorded+from+Isolated+Rabbit+Atrioventricular+Nodal+Myocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B50" id="B50"></a>Mizobuchi, M., Enjoji, Y., Yamamoto, R., Ono, T., Funatsu, A., Kambayashi, D., et al. (2008). Nifekalant and Disopyramide in a Patient with Short QT Syndrome: Evaluation of Pharmacological Effects and Electrophysiological Properties. <em>Pacing Clin. Electrophysiol. : PACE</em> 31, 1229&#x02013;1232. doi:10.1111/j.1540-8159.2008.01169.x</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18834480/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/j.1540-8159.2008.01169.x">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Nifekalant+and+Disopyramide+in+a+Patient+with+Short+QT+Syndrome:+Evaluation+of+Pharmacological+Effects+and+Electrophysiological+Properties&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B51" id="B51"></a>Nishida, A., Takizawa, T., Matsumoto, A., Miki, T., Seino, S., and Nakaya, H. (2011). Inhibition of ATP-Sensitive K&#x0002b; Channels and L-type Ca2&#x0002b; Channels by Amiodarone Elicits Contradictory Effect on Insulin Secretion in MIN6 Cells. <em>J. Pharmacol. Sci.</em> 116, 73&#x02013;80. doi:10.1254/jphs.10294fp</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21512308/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1254/jphs.10294fp">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibition+of+ATP-Sensitive+K++Channels+and+L-type+Ca2++Channels+by+Amiodarone+Elicits+Contradictory+Effect+on+Insulin+Secretion+in+MIN6+Cells&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B52" id="B52"></a>Paul, A. A., Witchel, H. J., and Hancox, J. C. (2002). Inhibition of the Current of Heterologously Expressed HERG Potassium Channels by Flecainide and Comparison with Quinidine, Propafenone and Lignocaine. <em>Br. J. Pharmacol.</em> 136, 717&#x02013;729. doi:10.1038/sj.bjp.0704784</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/12086981/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1038/sj.bjp.0704784">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibition+of+the+Current+of+Heterologously+Expressed+HERG+Potassium+Channels+by+Flecainide+and+Comparison+with+Quinidine,+Propafenone+and+Lignocaine&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B53" id="B53"></a>Perrin, M. J., Kuchel, P. W., Campbell, T. J., and Vandenberg, J. I. (2008). Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-&#x000c0;-Go-Go-Related Gene Channels. <em>Mol. Pharmacol.</em> 74, 1443&#x02013;1452. doi:10.1124/mol.108.049056</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18701618/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1124/mol.108.049056">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Drug+Binding+to+the+Inactivated+State+Is+Necessary+but+Not+Sufficient+for+High-Affinity+Binding+to+Human+Ether--Go-Go-Related+Gene+Channels&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B54" id="B54"></a>Priori, S. G., Blomstr&#x000f6;m-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., et al. (2015). 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). <em>Europace</em> 17, 1601&#x02013;1687. doi:10.1093/europace/euv319</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26318695/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1093/europace/euv319">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=2015+ESC+Guidelines+for+the+Management+of+Patients+with+Ventricular+Arrhythmias+and+the+Prevention+of+Sudden+Cardiac+Death:+The+Task+Force+for+the+Management+of+Patients+with+Ventricular+Arrhythmias+and+the+Prevention+of+Sudden+Cardiac+Death+of+the+European+Society+of+Cardiology+(ESC)Endorsed+by:+Association+for+European+Paediatric+and+Congenital+Cardiology+(AEPC)&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B55" id="B55"></a>Pugsley, M. K., Walker, M. J., and Saint, D. A. (2005). Block of NA&#x0002b; and K&#x0002b; Currents in Rat Ventricular Myocytes by Quinacainol and Quinidine. <em>Clin. Exp. Pharmacol. Physiol.</em> 32, 60&#x02013;65. doi:10.1111/j.1440-1681.2005.04149.x</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15730436/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/j.1440-1681.2005.04149.x">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Block+of+NA++and+K++Currents+in+Rat+Ventricular+Myocytes+by+Quinacainol+and+Quinidine&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B56" id="B56"></a>Qian, C., Ma, J., Zhang, P., Luo, A., Wang, C., Ren, Z., et al. (2012). Resveratrol Attenuates the Na(&#x0002b;)-dependent Intracellular Ca(2&#x0002b;) Overload by Inhibiting H(2)O(2)-induced Increase in Late Sodium Current in Ventricular Myocytes. <em>PloS one</em> 7, e51358. doi:10.1371/journal.pone.0051358</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23272101/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1371/journal.pone.0051358">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Resveratrol+Attenuates+the+Na(+)-dependent+Intracellular+Ca(2+)+Overload+by+Inhibiting+H(2)O(2)-induced+Increase+in+Late+Sodium+Current+in+Ventricular+Myocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B57" id="B57"></a>Rahm, A.-K., M&#x000fc;ller, M. E., Gramlich, D., Lugenbiel, P., Uludag, E., Rivinius, R., et al. (2020). Inhibition of Cardiac Kv4.3 (Ito) Channel Isoforms by Class I Antiarrhythmic Drugs Lidocaine and Mexiletine. <em>Eur. J. Pharmacol.</em> 880, 173159. doi:10.1016/j.ejphar.2020.173159</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32360350/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.ejphar.2020.173159">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibition+of+Cardiac+Kv4.3+(Ito)+Channel+Isoforms+by+Class+I+Antiarrhythmic+Drugs+Lidocaine+and+Mexiletine&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B58" id="B58"></a>Rajamani, S., Shryock, J. C., and Belardinelli, L. (2008). Rapid Kinetic Interactions of Ranolazine with HERG K&#x0002b; Current. <em>J. Cardiovasc. Pharmacol.</em> 51, 581&#x02013;589. doi:10.1097/fjc.0b013e3181799690</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18520952/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1097/fjc.0b013e3181799690">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Rapid+Kinetic+Interactions+of+Ranolazine+with+HERG+K++Current&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B59" id="B59"></a>Salvage, S. C., Chandrasekharan, K. H., Jeevaratnam, K., Dulhunty, A. F., Thompson, A. J., Jackson, A. P., et al. (2018). Multiple Targets for Flecainide Action: Implications for Cardiac Arrhythmogenesis. <em>Br. J. Pharmacol.</em> 175, 1260&#x02013;1278. doi:10.1111/bph.13807</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28369767/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/bph.13807">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Multiple+Targets+for+Flecainide+Action:+Implications+for+Cardiac+Arrhythmogenesis&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B60" id="B60"></a>Sanguinetti, M. C., Jiang, C., Curran, M. E., and Keating, M. T. (1995). A Mechanistic Link between an Inherited and an Acquird Cardiac Arrthytmia: HERG Encodes the IKr Potassium Channel. <em>Cell</em> 81, 299&#x02013;307. doi:10.1016/0092-8674(95)90340-2</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/7736582/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/0092-8674(95)90340-2">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=A+Mechanistic+Link+between+an+Inherited+and+an+Acquird+Cardiac+Arrthytmia:+HERG+Encodes+the+IKr+Potassium+Channel&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B61" id="B61"></a>Sasaki, N., Watanabe, I., Kogawa, R., Sonoda, K., Takahashi, K., Okumura, Y., et al. (2014). Effects of Intravenous Amiodarone and Ibutilide on Action Potential Duration and Atrial Conduction Kinetics in Patients with Persistent Atrial Fibrillation. <em>Int. Heart J.</em> 55, 244&#x02013;248. doi:10.1536/ihj.13-254</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24806377/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1536/ihj.13-254">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effects+of+Intravenous+Amiodarone+and+Ibutilide+on+Action+Potential+Duration+and+Atrial+Conduction+Kinetics+in+Patients+with+Persistent+Atrial+Fibrillation&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B62" id="B62"></a>Sato, T., Shigematsu, S., and Arita, M. (1995). Mexiletine-induced Shortening of the Action Potential Duration of Ventricular Muscles by Activation of ATP-Sensitive K&#x0002b; Channels. <em>Br. J. Pharmacol.</em> 115, 381&#x02013;382. doi:10.1111/j.1476-5381.1995.tb16342.x</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/7582444/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/j.1476-5381.1995.tb16342.x">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Mexiletine-induced+Shortening+of+the+Action+Potential+Duration+of+Ventricular+Muscles+by+Activation+of+ATP-Sensitive+K++Channels&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B63" id="B63"></a>Sch&#x000f6;nherr, R., and Heinemann, S. H. (1996). Molecular Determinants for Activation and Inactivation of HERG, a Human Inward Rectifier Potassium Channel. <em>J. Physiol.</em> 493 (Pt 3), 635&#x02013;642. doi:10.1113/jphysiol.1996.sp021410</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/8799887/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1113/jphysiol.1996.sp021410">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Molecular+Determinants+for+Activation+and+Inactivation+of+HERG,+a+Human+Inward+Rectifier+Potassium+Channel&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B64" id="B64"></a>Schram, G., Zhang, L., Derakhchan, K., Ehrlich, J. R., Belardinelli, L., and Nattel, S. (2004). Ranolazine: Ion-Channel-Blocking Actions and In Vivo Electrophysiological Effects. <em>Br. J. Pharmacol.</em> 142, 1300&#x02013;1308. doi:10.1038/sj.bjp.0705879</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15277312/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1038/sj.bjp.0705879">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ranolazine:+Ion-Channel-Blocking+Actions+and+In+Vivo+Electrophysiological+Effects&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B65" id="B65"></a>Shinnawi, R., Shaheen, N., Huber, I., Shiti, A., Arbel, G., Gepstein, A., et al. (2019). Modeling Reentry in the Short QT Syndrome with Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets. <em>J. Am. Coll. Cardiol.</em> 73, 2310&#x02013;2324. doi:10.1016/j.jacc.2019.02.055</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31072576/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.jacc.2019.02.055">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modeling+Reentry+in+the+Short+QT+Syndrome+with+Human-Induced+Pluripotent+Stem+Cell-Derived+Cardiac+Cell+Sheets&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B66" id="B66"></a>Snyders, D. J., and Chaudhary, A. (1996). High Affinity Open Channel Block by Dofetilide of HERG Expressed in a Human Cell Line. <em>Mol. Pharmacol.</em> 49, 949&#x02013;955.</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/8649354/">PubMed Abstract</a> | <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=High+Affinity+Open+Channel+Block+by+Dofetilide+of+HERG+Expressed+in+a+Human+Cell+Line&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B67" id="B67"></a>Suzuki, T., Morishima, M., Kato, S., Ueda, N., Honjo, H., and Kamiya, K. (2013). Atrial Selectivity in Na&#x0002b;channel Blockade by Acute Amiodarone. <em>Cardiovasc. Res.</em> 98, 136&#x02013;144. doi:10.1093/cvr/cvt007</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23341577/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1093/cvr/cvt007">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Atrial+Selectivity+in+Na+channel+Blockade+by+Acute+Amiodarone&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B68" id="B68"></a>Thorsen, K., Dam, V. S., Kjaer-Sorensen, K., Pedersen, L. N., Skeberdis, V. A., Jurevicius, J., et al. (2017). Loss-of-activity-mutation in the Cardiac Chloride-Bicarbonate Exchanger AE3 Causes Short QT Syndrome. <em>Nat. Commun.</em> 8, 1696. doi:10.1038/s41467-017-01630-0</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29167417/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1038/s41467-017-01630-0">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Loss-of-activity-mutation+in+the+Cardiac+Chloride-Bicarbonate+Exchanger+AE3+Causes+Short+QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B69" id="B69"></a>Trudeau, M., Warmke, J., Ganetzky, B., and Robertson, G. (1995). HERG, a Human Inward Rectifier in the Voltage-Gated Potassium Channel Family. <em>Science</em> 269, 92&#x02013;95. doi:10.1126/science.7604285</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/7604285/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1126/science.7604285">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=HERG,+a+Human+Inward+Rectifier+in+the+Voltage-Gated+Potassium+Channel+Family&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B70" id="B70"></a>Undrovinas, A. I., Burnashev, N., Eroshenko, D., Fleidervish, I., Starmer, C. F., Makielski, J. C., et al. (1990). Quinidine Blocks Adenosine 5&#x00027;-Triphosphate-Sensitive Potassium Channels in Heart. <em>Am. J. Physiology-Heart Circulatory Physiol.</em> 259, H1609&#x02013;H1612. doi:10.1152/ajpheart.1990.259.5.h1609</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1152/ajpheart.1990.259.5.h1609">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Quinidine+Blocks+Adenosine+5'-Triphosphate-Sensitive+Potassium+Channels+in+Heart&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B71" id="B71"></a>Wang, Z., Fermini, B., and Nattel, S. (1993). Mechanism of Flecainide&#x00027;s Rate-dependent Actions on Action Potential Duration in Canine Atrial Tissue. <em>J. Pharmacol. Exp. Ther.</em> 267, 575&#x02013;581.</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/8246130/">PubMed Abstract</a> | <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Mechanism+of+Flecainide's+Rate-dependent+Actions+on+Action+Potential+Duration+in+Canine+Atrial+Tissue&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B72" id="B72"></a>Wang, D., Kiyosue, T., Sato, T., and Arita, M. (1996). Comparison of the Effects of Class I Anti-arrhythmic Drugs, Cibenzoline, Mexiletine and Flecainide, on the Delayed Rectifier K&#x0002b;Current of Guinea-pig Ventricular Myocytes. <em>J. Mol. Cell. Cardiol.</em> 28, 893&#x02013;903. doi:10.1006/jmcc.1996.0084</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/8762029/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1006/jmcc.1996.0084">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Comparison+of+the+Effects+of+Class+I+Anti-arrhythmic+Drugs,+Cibenzoline,+Mexiletine+and+Flecainide,+on+the+Delayed+Rectifier+K+Current+of+Guinea-pig+Ventricular+Myocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B73" id="B73"></a>Wang, S., Liu, S., Morales, M. J., Strauss, H. C., and Rasmusson, R. L. (1997). A Quantitative Analysis of the Activation and Inactivation Kinetics of HERG Expressed in <em>Xenopus</em> Oocytes. <em>J. Physiol.</em> 502 (Pt 1), 45&#x02013;60. doi:10.1111/j.1469-7793.1997.045bl.x</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/9234196/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/j.1469-7793.1997.045bl.x">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=A+Quantitative+Analysis+of+the+Activation+and+Inactivation+Kinetics+of+HERG+Expressed+in+Xenopus+Oocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B74" id="B74"></a>Wang, J., Della Penna, K., Wang, H., Karczewski, J., Connolly, T. M., Koblan, K. S., et al. (2003). Functional and Pharmacological Properties of Canine ERG Potassium Channels. <em>Am. J. Physiology-Heart Circulatory Physiol.</em> 284, H256&#x02013;H267. doi:10.1152/ajpheart.00220.2002</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/12388285/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1152/ajpheart.00220.2002">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Functional+and+Pharmacological+Properties+of+Canine+ERG+Potassium+Channels&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B75" id="B75"></a>Watanabe, Y. (2019). Cardiac Na&#x0002b;/Ca2&#x0002b; Exchange Stimulators Among Cardioprotective Drugs. <em>J. Physiol. Sci.</em> 69, 837&#x02013;849. doi:10.1007/s12576-019-00721-5</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31664641/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1007/s12576-019-00721-5">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Cardiac+Na+/Ca2++Exchange+Stimulators+Among+Cardioprotective+Drugs&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B76" id="B76"></a>Wu, L., Shryock, J. C., Song, Y., Li, Y., Antzelevitch, C., and Belardinelli, L. (2004). Antiarrhythmic Effects of Ranolazine in a guinea Pig In Vitro Model of Long-QT Syndrome. <em>J. Pharmacol. Exp. Ther.</em> 310, 599&#x02013;605. doi:10.1124/jpet.104.066100</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15031300/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1124/jpet.104.066100">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Antiarrhythmic+Effects+of+Ranolazine+in+a+guinea+Pig+In+Vitro+Model+of+Long-QT+Syndrome&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B77" id="B77"></a>Yang, T., Kanki, H., Zhang, W., and Roden, D. M. (2009). Probing the Mechanisms Underlying Modulation of Quinidine Sensitivity to Cardiac IKsblock by Protein Kinase A-Mediated IKsphosphorylation. <em>Br. J. Pharmacol.</em> 157, 952&#x02013;961. doi:10.1111/j.1476-5381.2009.00293.x</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19522859/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1111/j.1476-5381.2009.00293.x">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Probing+the+Mechanisms+Underlying+Modulation+of+Quinidine+Sensitivity+to+Cardiac+IKsblock+by+Protein+Kinase+A-Mediated+IKsphosphorylation&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B78" id="B78"></a>Yonemizu, S., Masuda, K., Kurata, Y., Notsu, T., Higashi, Y., Fukumura, K., et al. (2019). Inhibitory Effects of Class I Antiarrhythmic Agents on Na&#x0002b; and Ca2&#x0002b; Currents of Human iPS Cell-Derived Cardiomyocytes. <em>Regenerative Ther.</em> 10, 104&#x02013;111. doi:10.1016/j.reth.2018.12.002</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30766898/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/j.reth.2018.12.002">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibitory+Effects+of+Class+I+Antiarrhythmic+Agents+on+Na++and+Ca2++Currents+of+Human+iPS+Cell-Derived+Cardiomyocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B79" id="B79"></a>Youm, J. B., Earm, Y. E., and Ho, W. K. (2004). Modulation of HERG Channel Inactivation by External Cations. <em>Eur. Biophys. J. : EBJ</em> 33, 360&#x02013;369. doi:10.1007/s00249-003-0367-y</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/14586519/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1007/s00249-003-0367-y">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modulation+of+HERG+Channel+Inactivation+by+External+Cations&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B80" id="B80"></a>Yunoki, T., Teramoto, N., Naito, S., and Ito, Y. (2001). The Effects of Flecainide on ATP-Sensitive K&#x0002b; Channels in Pig Urethral Myocytes. <em>Br. J. Pharmacol.</em> 133, 730&#x02013;738. doi:10.1038/sj.bjp.0704109</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/11429398/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1038/sj.bjp.0704109">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=The+Effects+of+Flecainide+on+ATP-Sensitive+K++Channels+in+Pig+Urethral+Myocytes&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B81" id="B81"></a>Zhang, S., Zhou, Z., Gong, Q., Makielski, J. C., and January, C. T. (1999). Mechanism of Block and Identification of the Verapamil Binding Domain to HERG Potassium Channels. <em>Circ. Res.</em> 84, 989&#x02013;998. doi:10.1161/01.res.84.9.989</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/10325236/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1161/01.res.84.9.989">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Mechanism+of+Block+and+Identification+of+the+Verapamil+Binding+Domain+to+HERG+Potassium+Channels&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B82" id="B82"></a>Zhang, S., Kehl, S. J., and Fedida, D. (2003). Modulation of Human Ether-A-Go-Go-Related K&#x0002b; (HERG) Channel Inactivation by Cs&#x0002b; and K&#x0002b;. <em>J. Physiol.</em> 548, 691&#x02013;702. doi:10.1113/jphysiol.2003.039198</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/12626667/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1113/jphysiol.2003.039198">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modulation+of+Human+Ether-A-Go-Go-Related+K++(HERG)+Channel+Inactivation+by+Cs++and+K+&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B83" id="B83"></a>Zhang, S. (2006). Isolation and Characterization of IKr in Cardiac Myocytes by Cs&#x0002b; Permeation. <em>Am. J. Physiology-Heart Circulatory Physiol.</em> 290, H1038&#x02013;H1049. doi:10.1152/ajpheart.00679.2005</p><p class="ReferencesCopy2"><a href="https://doi.org/10.1152/ajpheart.00679.2005">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Isolation+and+Characterization+of+IKr+in+Cardiac+Myocytes+by+Cs++Permeation&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B84" id="B84"></a>Zhao, Z., Li, X., El&#x02010;Battrawy, I., Lan, H., Zhong, R., Xu, Q., et al. (2019). Drug Testing in Human&#x02010;Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1. <em>Clin. Pharmacol. Ther.</em> 106, 642&#x02013;651. doi:10.1002/cpt.1449</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30947366/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1002/cpt.1449">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Drug+Testing+in+Human%90Induced+Pluripotent+Stem+Cell-Derived+Cardiomyocytes+from+a+Patient+with+Short+QT+Syndrome+Type+1&amp;btnG=">Google Scholar</a></p></div><div class="References"><p class="ReferencesCopy1"><a name="B85" id="B85"></a>Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J. C., Robertson, G. A., et al. (1998). Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature. <em>Biophysical J.</em> 74, 230&#x02013;241. doi:10.1016/s0006-3495(98)77782-3</p><p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/9449325/">PubMed Abstract</a> &#x0007c; <a href="https://doi.org/10.1016/s0006-3495(98)77782-3">CrossRef Full Text</a> &#x0007c; <a href="https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Properties+of+HERG+Channels+Stably+Expressed+in+HEK+293+Cells+Studied+at+Physiological+Temperature&amp;btnG=">Google Scholar</a></p></div></div><div class="thinLineM20"></div><div class="AbstractSummary"><p><span>Keywords:</span> short QT syndrome, arrhythmias, antiarrhythmic drugs, human-induced pluripotent stem cell-derived cardiomyocytes, hERG channel</p><p><span>Citation:</span> Huang M, Liao Z, Li X, Yang Z, Fan X, Li Y, Zhao Z, Lang S, Cyganek L, Zhou X, Akin I, Borggrefe M and El-Battrawy I (2021) Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. <em>Front. Pharmacol.</em> 12:675003. doi: 10.3389/fphar.2021.675003</p><p id="timestamps"><span>Received:</span> 02 March 2021; <span>Accepted:</span> 26 April 2021;<br><span>Published:</span> 07 May 2021.</p><div><p>Edited by:</p><a href="https://loop.frontiersin.org/people/29508/overview">Eleonora Grandi</a>, University of California, Davis, United States</div><div><p>Reviewed by:</p><a href="https://loop.frontiersin.org/people/649436/overview">Luca Sala</a>, Istituto Auxologico Italiano, Italy<br><a href="https://loop.frontiersin.org/people/466033/overview">Michelangelo Paci</a>, Tampere University, Finland</div><p><span>Copyright</span> &#x000a9; 2021 Huang, Liao, Li, Yang, Fan, Li, Zhao, Lang, Cyganek, Zhou, Akin, Borggrefe and El-Battrawy. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY).</a> The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p><p><span>&#x0002a;Correspondence:</span> Xiaobo Zhou, <a id="encmail">WGlhb2JvLnpob3VAbWVkbWEudW5pLWhlaWRlbGJlcmcuZGU=</a></p><p><span><sup>&#x02020;</sup></span>These authors have contributed equally to this work</p><div class="clear"></div></div>
</div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fphar.2021.675003" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">3K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">1,6K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">12</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/675003#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fphar.2021.675003" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fphar.2021.675003" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/29508/overview" data-event="editorInfo-a-eleonoraGrandi" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">E</span><span class="notranslate">G</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Eleonora  Grandi</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">University of California, Davis, United States</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/466033/overview" data-event="editorInfo-a-michelangeloPaci" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">M</span><span class="notranslate">P</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Michelangelo  Paci</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Tampere University, Finland</div></div></a><a href="https://loop.frontiersin.org/people/649436/overview" data-event="editorInfo-a-lucaSala" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">L</span><span class="notranslate">S</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Luca  Sala</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Department of Biotechnology and Biosciences, University of Milano - Bicocca, Italy</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"><li><a href="#h1">Abstract</a></li><li><a href="#h2">Introduction</a></li><li><a href="#h3">Methods</a></li><li><a href="#h4">Results</a></li><li><a href="#h5">Discussion</a></li><li><a href="#h6">Conclusion</a></li><li><a href="#h7">Study Limitations</a></li><li><a href="#h8">Data Availability Statement</a></li><li><a href="#h9">Author Contributions</a></li><li><a href="#h10">Funding</a></li><li><a href="#h11">Conflict of Interest</a></li><li><a href="#h12">Acknowledgments</a></li><li><a href="#h13">Supplementary Material</a></li><li><a href="#h14">References</a></li></ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fphar.2021.675003" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/pharmacology/articles/10.3389/fphar.2021.675003/full",["Reactive",16],{"main":17,"user":511,"article":512,"articleHub":868,"mainHeader":872},{"ibar":18,"footer":264,"newsletterComponent":-1,"snackbarItem":346,"toggleShowSnackbar":347,"contentfulJournal":348,"graphJournal":412,"settingsFeaturesSwitchers":416,"templateToggleBanner":417,"tenantConfig":476},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":195,"aboutJournal":196,"mainLinks":245,"journalLinks":252,"helpCenterLink":261},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=62&specialtyid=0&entitytype=2&entityid=176",{"id":115,"name":116,"slug":117,"sections":118},176,"Frontiers in Pharmacology","pharmacology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191],{"id":120,"name":121,"slug":122},182,"Cardiovascular and Smooth Muscle Pharmacology","cardiovascular-and-smooth-muscle-pharmacology",{"id":124,"name":125,"slug":126},199,"Drug Metabolism and Transport","drug-metabolism-and-transport",{"id":128,"name":129,"slug":130},202,"Drugs Outcomes Research and Policies","drugs-outcomes-research-and-policies",{"id":132,"name":133,"slug":134},184,"Ethnopharmacology","ethnopharmacology",{"id":136,"name":137,"slug":138},183,"Experimental Pharmacology and Drug Discovery","experimental-pharmacology-and-drug-discovery",{"id":140,"name":141,"slug":142},186,"Gastrointestinal and Hepatic Pharmacology","gastrointestinal-and-hepatic-pharmacology",{"id":144,"name":145,"slug":146},188,"Inflammation Pharmacology","inflammation-pharmacology",{"id":148,"name":149,"slug":150},178,"Integrative and Regenerative Pharmacology","integrative-and-regenerative-pharmacology",{"id":152,"name":153,"slug":154},26,"Neuropharmacology","neuropharmacology",{"id":156,"name":157,"slug":158},196,"Obstetric and Pediatric Pharmacology","obstetric-and-pediatric-pharmacology",{"id":160,"name":161,"slug":162},2186,"Pharmacoepidemiology","pharmacoepidemiology",{"id":164,"name":165,"slug":166},198,"Pharmacogenetics and Pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":168,"name":169,"slug":170},192,"Pharmacology of Anti-Cancer Drugs","pharmacology-of-anti-cancer-drugs",{"id":172,"name":173,"slug":174},2216,"Pharmacology of Infectious Diseases","pharmacology-of-infectious-diseases",{"id":176,"name":177,"slug":178},179,"Pharmacology of Ion Channels and Channelopathies","pharmacology-of-ion-channels-and-channelopathies",{"id":180,"name":181,"slug":182},195,"Predictive Toxicology","predictive-toxicology",{"id":184,"name":185,"slug":186},1357,"Renal Pharmacology","renal-pharmacology",{"id":188,"name":189,"slug":190},190,"Respiratory Pharmacology","respiratory-pharmacology",{"id":192,"name":193,"slug":194},1251,"Translational Pharmacology","translational-pharmacology","Sections",[197,221],{"title":198,"links":199},"Scope",[200,203,206,209,212,215,218],{"text":201,"url":202,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/pharmacology/about#about-editors",{"text":204,"url":205,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/pharmacology/about#about-scope",{"text":207,"url":208,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/pharmacology/about#about-facts",{"text":210,"url":211,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/pharmacology/about#about-submission",{"text":213,"url":214,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/pharmacology/about#about-open",{"text":216,"url":217,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/pharmacology/about#copyright-statement",{"text":219,"url":220,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/pharmacology/about#about-quality",{"title":222,"links":223},"For authors",[224,227,230,233,236,239,242],{"text":225,"url":226,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit",{"text":228,"url":229,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/pharmacology/for-authors/article-types",{"text":231,"url":232,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines",{"text":234,"url":235,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines",{"text":237,"url":238,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees",{"text":240,"url":241,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist",{"text":243,"url":244,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office",[246,249],{"text":247,"url":248,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":250,"url":251,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[253,256,258],{"text":254,"url":255,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":257,"target":27,"ariaLabel":28},"research-topics",{"text":259,"url":260,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":262,"url":263,"target":77,"ariaLabel":262},"Help center","https://helpcenter.frontiersin.org",{"blocks":265,"socialLinks":319,"copyright":343,"termsAndConditionsUrl":344,"privacyPolicyUrl":345},[266,280,290,304],{"title":267,"links":268},"Guidelines",[269,271,274,277,279],{"text":231,"url":270,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":272,"url":273,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":275,"url":276,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":234,"url":278,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":281,"links":282},"Explore",[283,284,287,289],{"text":254,"url":251,"target":27,"ariaLabel":28},{"text":285,"url":286,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":288,"url":248,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":291,"links":292},"Outreach",[293,296,299,303],{"text":294,"url":92,"target":77,"ariaLabel":295},"Frontiers Forum ","Frontiers Forum website",{"text":297,"url":298,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":300,"url":301,"target":77,"ariaLabel":302},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":305,"links":306},"Connect",[307,308,312,315,318],{"text":262,"url":263,"target":77,"ariaLabel":262},{"text":309,"url":310,"target":77,"ariaLabel":311},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":313,"url":111,"target":27,"ariaLabel":314},"Contact us ","Subscribe to newsletter",{"text":316,"url":317,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[320,328,333,338],{"link":321,"type":324,"color":325,"icon":326,"size":327,"hiddenText":13},{"text":322,"url":323,"target":77,"ariaLabel":322},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":329,"type":324,"color":325,"icon":332,"size":327,"hiddenText":13},{"text":330,"url":331,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":334,"type":324,"color":325,"icon":337,"size":327,"hiddenText":13},{"text":335,"url":336,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":339,"type":324,"color":325,"icon":342,"size":327,"hiddenText":13},{"text":340,"url":341,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":349,"identifier":115,"name":116,"slug":117,"banner":350,"description":405,"mission":406,"palette":407,"impactFactor":408,"citeScore":409,"citations":410,"showTagline":28,"twitter":411},"Journal",[351],{"id":352,"src":353,"name":354,"tags":355,"type":363,"width":364,"height":365,"idHash":366,"archive":367,"brandId":368,"limited":367,"fileSize":369,"isPublic":370,"original":371,"copyright":372,"extension":373,"thumbnails":375,"dateCreated":383,"description":384,"orientation":385,"userCreated":386,"watermarked":367,"dateModified":383,"datePublished":387,"ecsArchiveFiles":388,"propertyOptions":389,"property_Channel":394,"property_Sub-Type":396,"property_Asset_Type":398,"activeOriginalFocusPoint":400,"property_Office_Department":403},"754E12A9-443F-4EA8-AB01E0811E45131D","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/webimage-9D720582-24AD-4D2E-9205AB9D241919DA.jpg","FPHAR_Main Visual_Purple_Website",[356,357,358,359,360,361,362],"pain","medical","pharmaceutical","antibiotic","concept","capsule","treatment","image",5844,3896,"79b643019a2651e0",0,"22C10171-81B3-4DA6-99342F272A32E8BB",8675243,1,"https://brand.frontiersin.org/m/79b643019a2651e0/original/FPHAR_Main-Visual_Purple_Website.jpeg","Copyright (c) 2017 Marian Weyo/Shutterstock.  No use without permission.",[374],"jpeg",{"mini":376,"thul":377,"webimage":353,"Guidelines":378,"WebsiteJpg_XL":379,"WebsiteWebP_L":380,"WebsiteWebP_M":381,"WebsiteWebP_XL":382},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/mini-97EEF455-249B-43BD-9D8F02FEE86046D3.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/thul-B2DBD910-1DDF-4ED3-B1500DF973953144.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/Guidelines-FPHAR_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/WebsiteJpg_XL-FPHAR_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/WebsiteWebP_L-FPHAR_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/WebsiteWebP_M-FPHAR_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/754E12A9-443F-4EA8-AB01E0811E45131D/F3882BDE-513E-4D16-8DB695504865E7B8/WebsiteWebP_XL-FPHAR_Main Visual_Purple_Website.webp","2022-06-27T10:00:45Z","Pills Tablets Capsule or Medicament freely laid on glass background.","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[390,391,392,393],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[395],"frontiersin_org",[397],"Main_Visual",[399],"Photography",{"x":401,"y":402},2922,1948,[404],"Publishing","The world's most cited pharmacology and pharmacy journal, advancing global pharmacological discoveries to prevent and treat human disease.","\u003Cp>Frontiers in Pharmacology is an interdisciplinary journal that publishes research on the interactions between drugs and living beings to prevent and cure human disease.\u003C/p>\n\n\u003Cp>Led by Field Chief Editor Heike Wulff (University of California, Davis, US), Frontiers in Pharmacology explores basic and clinical pharmacology, medicinal chemistry, pharmacy, and toxicology to clarify the fundamental processes of disease treatment and drug effects. Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, the journal welcomes academic, industrial, and clinical work focused on pharmacology.\u003C/p>\n\n\u003Cp>Topics include, but are not limited to:\u003C/p>\n\u003Cul>\n  \u003Cli>cardiovascular and smooth muscle pharmacology\u003C/li>\n  \u003Cli>drug metabolism and transport\u003C/li>\n  \u003Cli>drugs outcomes research and policies\u003C/li>\n  \u003Cli>ELSI in science and genetics\u003C/li>\n  \u003Cli>ethnopharmacology\u003C/li>\n  \u003Cli>experimental pharmacology and drug discovery\u003C/li>\n  \u003Cli>gastrointestinal and hepatic pharmacology\u003C/li>\n  \u003Cli>inflammation pharmacology\u003C/li>\n  \u003Cli>integrative and regenerative pharmacology\u003C/li>\n  \u003Cli>neuropharmacology\u003C/li>\n  \u003Cli>obstetric and pediatric pharmacology\u003C/li>\n  \u003Cli>pharmacoepidemiology\u003C/li>\n  \u003Cli>pharmacogenetics and pharmacogenomics\u003C/li>\n  \u003Cli>pharmacology of anti-cancer drugs\u003C/li>\n  \u003Cli>pharmacology of infectious diseases\u003C/li>\n  \u003Cli>pharmacology of ion channels and channelopathies\u003C/li>\n  \u003Cli>predictive toxicology\u003C/li>\n  \u003Cli>renal pharmacology\u003C/li>\n  \u003Cli>respiratory pharmacology\u003C/li>\n  \u003Cli>translational pharmacology.\u003C/li>\n\u003C/ul>\n\n\u003Cp>All submissions to the journal involving natural products, including plant extracts or preparations, must adhere to \u003Ci>'The Four Pillars of Ethnopharmacology'\u003C/i> to be considered for peer review, regardless of the specialty section, as a baseline standard for sample characterization. These are a set of mandatory guidelines designed to maintain the scientific, cultural, and ethical integrity of the Journal, and describe what the leading journals in the field consider as the basic aspects of good research (full ConPhyMP statement available \u003Ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.953205/full\" target=\"_blank\">here\u003C/a>, ConPhyMP statement overview \u003Ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1338710/full\" target=\"_blank\">here\u003C/a>, and GA-tool \u003Ca href=\"https://ga-online.org/best-practice/\" target=\"_blank\">here\u003C/a>). Please refer to the \u003Ca href=\"https://assets.ctfassets.net/41vi7p4898pd/63DCrRxGncG4B1stfaYeh8/1b87b9a742b0610ace5b19fd11f62359/Four_pillars_ethnopharmacology_2025.pdf\" target=\"_blank\">FULL VERSION\u003C/a> of these guidelines before submitting a manuscript to the journal.\u003C/p> \n\u003Cp>To be considered for publication in Frontiers in Pharmacology, studies incorporating complementary or alternative medicine must be based on a set of data linked to local or traditional uses that can be evaluated pharmacologically. A clear and plausible set of pharmacological data must be generated in these studies. Similarly, the journal endorses protocols including a minimum of 2 cell-lines in vitro as an evidential basis to demonstrate proposed anti-cancer effects in all relevant studies submitted to all specialty sections in the journal.\u003C/p>\n\u003Cp>Isolated data mining studies using disproportionality analyses of databases containing spontaneously reported adverse events, frequently lead to misinterpretation due to various reporting biases, lack of structured control, and insufficient demographic details. Presenting such analyses in isolation typically does not yield clinically actionable safety findings without the broader context of a comprehensive signal evaluation. To ensure rigor and relevance, all submissions to the journal must be complemented by a proper systematic review and/or thorough analyses of reported cases, and adhere to the READUS-PV guidelines (\u003Ca href=\"https://www.equator-network.org/reporting-guidelines/the-reporting-of-a-disproportionality-analysis-for-drug-safety-signal-detection-using-individual-case-safety-reports-in-pharmacovigilance-readus-pv-development-and-statement/\" target=\"_blank\">The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance\u003C/a>). Authors are expected to ensure compliance with the corresponding \u003Ca href=\"https://readus-statement.org/wp-content/uploads/2024/03/readus-checklist.pdf\" target=\"_blank\">checklist\u003C/a> before proceeding with submission to the journal. Full publication of the READUS-PV guidelines is available \u003Ca href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11116242/pdf/40264_2024_Article_1421.pdf\" target=\"_blank\">here\u003C/a>.\u003C/p>\n\n\u003Cp>Frontiers journals require that manuscripts primarily comprising computational studies of public data, such as NHANES or Mendelian Randomization studies, must include appropriate validation. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a>, for more information. Manuscripts not adhering to these standards will not be considered.\u003Cp>\n\n\u003Cp>Further unique criteria for the conception and review of submissions may apply, where appropriate, for individual specialty sections.\u003C/p>\n\n\u003Cp>The journal welcomes submissions that support and advance the \u003Ca href=\"https://www.globalgoals.org/goals/\" target=\"_blank\">UN Sustainable Development Goals\u003C/a> (SDGs), notably the \u003Ca href=\"https://www.globalgoals.org/goals/3-good-health-and-well-being/\" target=\"_blank\">SDG 3: Good Health and Well-being\u003C/a>.\u003C/p>\n\n\u003Cp>Manuscripts that focus solely on clinical trials, patient management, or conventional therapies without a focus on pharmacological research are not suitable for publication in this journal. Additionally, studies that are purely statistical or predictive in nature, without providing novel insights into pharmacological mechanisms or drug development, are not within the scope of this journal.\u003C/p>\n\n\u003Cp>Frontiers in Pharmacology is committed to advancing developments in the field of pharmacological discoveries by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>\n\n\u003Cb>\u003Cp>Ethics Information\u003C/p>\u003C/b>\n\u003Cp>Research involving human subjects should comply with the ethical guidelines outlined in the \u003Ca href= https://www.wma.net/policies-post/wma-declaration-of-helsinki/ target=_blank>World Medical Associations Declaration of Helsinki\u003C/a>.\u003C/p>\n\u003Cp>Similarly, authors are required to specify the institutional and national standards adhered to for the care and use of laboratory animals. Transparent and accurate reporting of animal studies is required, with references to guidelines such as \u003Ca href=\"https://arriveguidelines.org/arrive-guidelines\" target=\"_blank\">ARRIVE\u003C/a> and \u003Ca href=\"https://nc3rs.org.uk/sites/default/files/2022-01/The%20IMPROVE%20Guidelines%20%28poster%29.pdf\" target=\"_blank\"> IMPROVE\u003C/a>.\u003C/p>\n\u003Cp>Extended information on research ethics can be found under the Frontiers Policies and Publication Ethics page.\u003C/p>","purple","5.6","6.3","531663","@FrontPharmacol",{"id":115,"name":116,"slug":117,"abbreviation":413,"isOnline":13,"isOpenForSubmissions":13,"citeScore":414,"impactFactor":415},"fphar",8.9,4.8,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":347},{"isPublic":13,"allowCompanyUsers":347,"whiteListEmails":418,"enableAllJournals":13,"whiteListJournals":440},[419,420,421,422,423,424,425,426,427,424,428,429,430,431,432,433,434,435,436,437,438,439],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[441,442,443,444,445,446,370,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,115,469,470,471,472,473,474,475],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,1440,403,1239,755,2136,609,1534,{"spaceId":370,"name":370,"availableJournalPages":477,"announcement":481},[255,260,257,478,479,480],"volumes","about","community-reviewers",{"__typename":482,"sys":483,"preHeader":42,"title":485,"description":486,"image":487,"link":509},"Announcement",{"id":484},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[488],{"archive":367,"brandId":368,"copyright":28,"dateCreated":489,"dateModified":490,"datePublished":491,"description":28,"extension":492,"fileSize":494,"height":495,"id":496,"isPublic":367,"limited":367,"name":497,"orientation":385,"original":28,"thumbnails":498,"type":363,"watermarked":367,"width":505,"videoPreviewURLs":506,"tags":507,"textMetaproperties":508,"src":499},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[493],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":499,"thul":500,"mini":501,"WebsiteWebP_L":502,"WebsiteWebP_M":503,"Guidelines":504},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":510,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":513,"isPreviewPage":347,"hasSupplementalData":347,"showCrossmarkWidget":13,"articleTemplate":704,"currentArticlePageMetaInfo":705,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":514,"doi":515,"title":516,"acceptanceDate":517,"receptionDate":518,"publicationDate":519,"lastModifiedDate":520,"isPublished":13,"abstract":521,"researchTopic":28,"articleType":522,"stage":525,"keywords":527,"authors":533,"editors":634,"reviewers":644,"journal":663,"section":670,"impactMetrics":672,"volume":675,"articleVolume":676,"relatedArticles":677,"isPublishedV2":347,"contents":678,"files":681},675003,"10.3389/fphar.2021.675003","Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1",["Date","2021-04-26T11:31:51.000Z"],["Date","2021-03-02T09:54:05.000Z"],["Date","2021-05-07T00:00:00.000Z"],["Date","2025-11-26T05:38:18.908Z"],"Aims The short QT syndrome type 1 (SQT1) is linked to hERG channel mutations (e. g. N588K). Drug effects on hERG channel gating kinetics in SQT1-cells have not been investigated. \nMethods This study used hiPSC-CMs of a healthy donor and a SQT1-patient carrying the N588K mutation and patch clamp to examine the drug effects on hERG channel gating kinetics. \nResults   Ajmaline, amiodarone, ivabradine, flecainide, quinidine, mexiletine and ranolazine inhibited the hERG channel current (IKr) less strongly in hiPSC-CMs from the SQTS1-patient (SQT1-hiPSC-CMs) comparing with cells from the healthy donor (donor-hiPSC-CMs). Quinidine and mexiletine reduced, but ajmaline, amiodarone, ivabradine and ranolazine increased the time to peak of IKr similarly in SQT1-hiPSC-CMs and donor-hiPSC-CMs. Although regarding the shift of activation and inactivation curves, tested drugs showed differential effects in donor- and SQT1-hiPSC-CMs, quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine reduced the window current in SQT1-hiPSC-CMs. Quinidine, ajmaline, ivabradine and mexiletine differentially changed the time constant of recovery from inactivation, but all of them increased the time constant of deactivation in SQT1-hiPSC-CMs. \nConclusion The window current-reducing and deactivation-slowing effects may be important for the antiarrhythmic effect of ajmaline, ivabradine, quinidine and mexiletine in SQT1-cells. This information may be helpful for selecting drugs for treating SQT1-patients with hERG channel mutation.",{"id":523,"name":524},24,"Original Research",{"id":526,"name":19},18,[528,529,530,531,532],"short QT syndrome","arrhythmias","Antiarrhythmic drugs","Human-induced pluripotent stem cell-derived cardiomyocytes","HERG channel",[534,543,552,560,567,576,581,587,596,605,614,621,628],{"id":535,"firstName":536,"middleName":19,"lastName":537,"givenNames":538,"isCorresponding":347,"isProfilePublic":13,"userId":535,"email":-1,"affiliations":539},1251801,"Mengying","Huang","Mengying ",[540],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},"First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg","Germany",{"id":367,"firstName":544,"middleName":19,"lastName":545,"givenNames":546,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":547},"Zhenxing","Liao","Zhenxing ",[548,549],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":550,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"North Sichuan Medical College","China",{"id":367,"firstName":553,"middleName":19,"lastName":554,"givenNames":555,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":556},"Xin","Li","Xin ",[557,558],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":559,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"College of Medical Technology, Chengdu University of Traditional Chinese Medicine",{"id":367,"firstName":561,"middleName":19,"lastName":562,"givenNames":563,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":564},"Zhen","Yang","Zhen ",[565,566],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":550,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"id":568,"firstName":569,"middleName":19,"lastName":570,"givenNames":571,"isCorresponding":347,"isProfilePublic":13,"userId":568,"email":-1,"affiliations":572},1252911,"Xuehui","Fan","Xuehui ",[573,574],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":575,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University",{"id":367,"firstName":577,"middleName":19,"lastName":554,"givenNames":578,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":579},"Yingrui","Yingrui ",[580],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"id":367,"firstName":582,"middleName":19,"lastName":583,"givenNames":584,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":585},"Zhihan","Zhao","Zhihan ",[586],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"id":588,"firstName":589,"middleName":19,"lastName":590,"givenNames":591,"isCorresponding":347,"isProfilePublic":13,"userId":588,"email":-1,"affiliations":592},701611,"Siegfried","Lang","Siegfried ",[593,594],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":595,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},"DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G?ttingen",{"id":597,"firstName":598,"middleName":19,"lastName":599,"givenNames":600,"isCorresponding":347,"isProfilePublic":13,"userId":597,"email":-1,"affiliations":601},822000,"Lukas","Cyganek","Lukas ",[602,603],{"organizationName":595,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":604,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},"Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center G?ttingen",{"id":606,"firstName":607,"middleName":19,"lastName":608,"givenNames":609,"isCorresponding":347,"isProfilePublic":13,"userId":606,"email":-1,"affiliations":610},815918,"Xiaobo","Zhou","Xiaobo ",[611,612,613],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":575,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":595,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"id":367,"firstName":615,"middleName":19,"lastName":616,"givenNames":617,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":618},"Ibrahim","Akin","Ibrahim ",[619,620],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":595,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"id":367,"firstName":622,"middleName":19,"lastName":623,"givenNames":624,"isCorresponding":347,"isProfilePublic":347,"userId":367,"email":-1,"affiliations":625},"Martin","Borggrefe","Martin ",[626,627],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":595,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"id":629,"firstName":615,"middleName":19,"lastName":630,"givenNames":617,"isCorresponding":347,"isProfilePublic":13,"userId":629,"email":-1,"affiliations":631},368363,"El-Battrawy",[632,633],{"organizationName":541,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":595,"countryName":542,"cityName":19,"stateName":19,"zipCode":19},[635],{"id":636,"firstName":637,"middleName":19,"lastName":638,"givenNames":639,"isCorresponding":347,"isProfilePublic":13,"userId":636,"email":-1,"affiliations":640},29508,"Eleonora","Grandi","Eleonora ",[641],{"organizationName":642,"countryName":643,"cityName":19,"stateName":19,"zipCode":19},"University of California, Davis","United States",[645,654],{"id":646,"firstName":647,"middleName":19,"lastName":648,"givenNames":649,"isCorresponding":347,"isProfilePublic":13,"userId":646,"email":-1,"affiliations":650},466033,"Michelangelo","Paci","Michelangelo ",[651],{"organizationName":652,"countryName":653,"cityName":19,"stateName":19,"zipCode":19},"Tampere University","Finland",{"id":655,"firstName":656,"middleName":19,"lastName":657,"givenNames":658,"isCorresponding":347,"isProfilePublic":13,"userId":655,"email":-1,"affiliations":659},649436,"Luca","Sala","Luca ",[660],{"organizationName":661,"countryName":662,"cityName":19,"stateName":19,"zipCode":19},"Department of Biotechnology and Biosciences, University of Milano - Bicocca","Italy",{"id":115,"slug":117,"name":116,"shortName":664,"electronicISSN":665,"field":666,"specialtyId":28,"journalSectionPaths":668},"Front. Pharmacol.","1663-9812",{"id":667,"domainId":370},62,[669],{"section":670},{"id":176,"name":177,"slug":178,"specialtyId":671},862,{"views":673,"downloads":674,"citations":675},2961,1563,12,"Volume 12 - 2021",[],{"titleHtml":516,"fullTextHtml":679,"menuHtml":680},"\u003Cdiv class=\"JournalAbstract\">\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1251801\" class=\"user-id-1251801\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1251801/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Mengying Huang&#x;\">Mengying Huang\u003C/a>\u003Csup>1\u003C/sup>\u003Csup>&#x02020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Zhenxing Liao,&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Zhenxing Liao\u003Csup>1,2\u003C/sup>\u003Csup>&#x02020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Xin Li,&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Xin Li\u003Csup>1,3\u003C/sup>\u003Csup>&#x02020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Zhen Yang,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Zhen Yang\u003Csup>1,2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1252911\" class=\"user-id-1252911\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1252911/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Xuehui Fan,\">Xuehui Fan\u003C/a>\u003Csup>1,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Yingrui Li\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Yingrui Li\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Zhihan Zhao\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Zhihan Zhao\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/701611\" class=\"user-id-701611\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/701611/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Siegfried Lang,\">Siegfried Lang\u003C/a>\u003Csup>1,5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/822000\" class=\"user-id-822000\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/822000/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Lukas Cyganek,\">Lukas Cyganek\u003C/a>\u003Csup>5,6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/815918\" class=\"user-id-815918\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/815918/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Xiaobo Zhou,,&#xa;\">Xiaobo Zhou\u003C/a>\u003Csup>1,4,5\u003C/sup>&#x0002a;\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Ibrahim Akin,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Ibrahim Akin\u003Csup>1,5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Martin Borggrefe,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Martin Borggrefe\u003Csup>1,5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/368363\" class=\"user-id-368363\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/368363/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Ibrahim El-Battrawy,\">Ibrahim El-Battrawy\u003C/a>\u003Csup>1,5\u003C/sup>\u003C/span>\u003C/div>\u003Cul class=\"notes\">\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Mannheim, Germany\u003C/li>\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>North Sichuan Medical College, Nanchong, China\u003C/li>\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China\u003C/li>\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China\u003C/li>\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G&#x000f6;ttingen, Mannheim, Germany\u003C/li>\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center G&#x000f6;ttingen, G&#x000f6;ttingen, Germany\u003C/li>\u003C/ul>\u003Cp class=\"mb15\">\u003Cstrong>Aims:\u003C/strong> The short QT syndrome type 1 (SQT1) is linked to hERG channel mutations (e.g., N588K). Drug effects on hERG channel gating kinetics in SQT1-cells have not been investigated.\u003C/p>\u003Cp class=\"mb15\">\u003Cstrong>Methods:\u003C/strong> This study used hiPSC-CMs of a healthy donor and a SQT1-patient carrying the N588K mutation and patch clamp to examine the drug effects on hERG channel gating kinetics.\u003C/p>\u003Cp class=\"mb15\">\u003Cstrong>Results:\u003C/strong> Ajmaline, amiodarone, ivabradine, flecainide, quinidine, mexiletine and ranolazine inhibited the hERG channel current (I\u003Csub>Kr\u003C/sub>) less strongly in hiPSC-CMs from the SQTS1-patient (SQT1-hiPSC-CMs) comparing with cells from the healthy donor (donor-hiPSC-CMs). Quinidine and mexiletine reduced, but ajmaline, amiodarone, ivabradine and ranolazine increased the time to peak of I\u003Csub>Kr\u003C/sub> similarly in SQT1-hiPSC-CMs and donor-hiPSC-CMs. Although regarding the shift of activation and inactivation curves, tested drugs showed differential effects in donor- and SQT1-hiPSC-CMs, quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine reduced the window current in SQT1-hiPSC-CMs. Quinidine, ajmaline, ivabradine and mexiletine differentially changed the time constant of recovery from inactivation, but all of them increased the time constant of deactivation in SQT1-hiPSC-CMs.\u003C/p>\u003Cp class=\"mb15\">\u003Cstrong>Conclusion:\u003C/strong> The window current-reducing and deactivation-slowing effects may be important for the antiarrhythmic effect of ajmaline, ivabradine, quinidine and mexiletine in SQT1-cells. This information may be helpful for selecting drugs for treating SQT1-patients with hERG channel mutation.\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>\u003Cdiv class=\"JournalFullText\">\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\u003Cp class=\"mb15\">Short QT syndrome (SQTS), described initially by Gussak et al., in 2000 (\u003Ca href=\"#B30\">Gussak et al., 2000\u003C/a>), is a rare, inheritable heart disease associated with abbreviated corrected QT interval (QTc) and sudden cardiac death (SCD). So far, genes reported to be associated with SQTS include KCNH2 (SQTS1), KCNQ1 (SQTS2) and KCNJ2 (SQTS3) (\u003Ca href=\"#B11\">Campuzano et al., 2018\u003C/a>). In addition, a mutation in the cardiac Cl/HCO3 exchanger AE3 has also been reported in patients with SQTS (\u003Ca href=\"#B68\">Thorsen et al., 2017\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">The therapeutic approaches for SQTS are challenging for physicians because of the low prevalence and rare cases. Until now, a small number of drugs including disopyramide, nifekalant, quinidine, flecainide, sotalol, ibutilide and propafenone have been tested by \u003Cem>in vivo\u003C/em> studies on SQTS1 (\u003Ca href=\"#B1\">Abriel and Rougier, 2013\u003C/a>), among which only quinidine has shown profit effect in the treatment (\u003Ca href=\"#B50\">Mizobuchi et al., 2008\u003C/a>; \u003Ca href=\"#B27\">Giustetto et al., 2011\u003C/a>; \u003Ca href=\"#B42\">Mazzanti et al., 2017\u003C/a>; \u003Ca href=\"#B19\">El-Battrawy et al., 2018\u003C/a>; \u003Ca href=\"#B20\">El-Battrawy et al., 2019\u003C/a>). In human-induced stem cell-derived cardiomyocytes (hiPSC-CMs) from a patient with SQTS type 1, besides quinidine, disopyramide, ajmaline, ivabradine and mexiletine but not sotalol, amiodarone, flecainide and ranolazine showed profitable (APD-prolonging and antiarrhythmic) effects (\u003Ca href=\"#B65\">Shinnawi et al., 2019\u003C/a>; \u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>; \u003Ca href=\"#B39\">Lan et al., 2020\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Since SQT1 is caused by an enhanced (a gain-of-function) hERG channel current, hERG channel blockers should be effective for prolonging QT interval or reducing the chance of arrhythmias in SQT1-patients. Surprisingly, some classical hERG channel blockers like sotalol and ibutilide failed to prolong QTc interval in SQT1-patients (\u003Ca href=\"#B26\">Gaita et al., 2004\u003C/a>; \u003Ca href=\"#B20\">El-Battrawy et al., 2019\u003C/a>), suggesting that the mutation in the hERG channel changed the sensitivity of the channel to drugs. Indeed, it was found that some drugs mainly affect hERG channels in the inactivated state and the SQTS1 is caused by a mutation in the hERG channel, which impairs inactivation of the channel and hence reduce the channel sensitivity to those drugs (\u003Ca href=\"#B43\">McPate et al., 2008\u003C/a>). Quinidine affects both the open and inactivated hERG channels and can still inhibit hERG channels even when the inactivation is impaired. This could be an explanation for the failure of some drugs in treating SQTS1. Therefore, numerous studies focused on influences of mutations on channel sensitivity and/or affinity of hERG channels to drugs. However, the sensitivity change cannot explain some phenomena, for example, amiodarone, propafenone and quinidine inhibited N588K-hERG channels in a similar intensity, but only quinidine is effective in prolonging QTc or action potential duration (APD) and suppressing arrhythmic events in SQT1-patients or SQT1-cells (\u003Ca href=\"#B43\">McPate et al., 2008\u003C/a>; \u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>). This suggests other mechanisms may also play important roles for the efficacy of drugs for SQTS-patients. In our recent studies, using hiPSC-CMs from a patient carrying N588K mutation in hERG channels, we tested the APD-prolonging and antiarrhythmic effects of quinidine, sotalol, ajmaline, amiodarone, ivabradine, flecainide, mexiletine and ranolazine, which are known to be able to inhibit hERG channels. We found that quinidine, ajmaline, ivabradine and mexiletine but not sotalol, amiodarone, flecainide and ranolazine prolonged APD and reduced arrhythmic events in SQT1-hiPSC-CMs (\u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>; \u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>), although all of them could inhibit hERG channel currents. Therefore, we hypothesize that not only the channel sensitivity bot also the channel gating kinetics in presence of a drug is important for the efficacy of the drug and the observed differential drug effects may also result from different effects on hERG channel gating kinetics in SQT1-cells. The current study was designed to analyze in detail the effects of quinidine, ajmaline, amiodarone, ivabradine, flecainide, mexiletine and ranolazine on hERG channel gating kinetics in SQT1-hiPSC-CMs.\u003C/p>\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Methods\u003C/h2>\u003Ch3 class=\"pt0\">Ethics Statement and Clinical Data\u003C/h3>\u003Cp class=\"mb0\">A skin biopsy from a SQTS1 patient was obtained with written informed consent from the patient and the Ethics Committee of the Medical Faculty Mannheim, University of Heidelberg (approval numbers: 2018-565N-MA) and the Ethics Committee of University Medical Center G&#x000f6;ttingen (approval number: 10/9/15). The study was carried out in accordance with the Helsinki Declaration of 1975 (\u003Ca href=\"https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/\">https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/\u003C/a>), revised in 2013.\u003C/p>\u003Ch3 class=\"pt0\">Generation of Human iPS Cells\u003C/h3>\u003Cp class=\"mb0\">The patient with familial SQTS1 carries the N588K mutation in hERG channel. The clinical data of the patient has been provided in our recent publication (\u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>).\u003C/p>\u003Cp class=\"mb0\">The methods for the generation of iPS cells (hiPSCs) have been described in our previous study (\u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>). Briefly, skin fibroblasts from a skin biopsy of the patient and a healthy subject (here defined as donor) were reprogrammed into hiPSC cell line in feeder free culture conditions using the integration-free CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific, &#x00023;A16517) and the reprogramming factors OCT4, KLF4, SOX2 and c-MYC. The pluripotency and \u003Cem>in vitro\u003C/em> differentiation potential of generated hiPSCs were examined as described before (\u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>). The detailed information is provided in the \u003Ca href=\"#SM1\">Supplementary Material\u003C/a>.\u003C/p>\u003Ch3 class=\"pt0\">Generation of hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">The hiPSCs were differentiated into cardiomyocytes (hiPSC-CMs) as described in our previous studies (\u003Ca href=\"#B13\">Cyganek et al., 2018\u003C/a>; \u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>; \u003Ca href=\"#B18\">El-Battrawy et al., 2018\u003C/a>). Briefly (the detailed information is provided in the \u003Ca href=\"#SM1\">Supplementary Material\u003C/a>), culture dishes were coated with Matrigel (Corning). The medium of TeSR-E8 (Stemcell Technologies) was used for hiPSCs culture and the medium of RPMI1640 Glutamax (Life Technologies) consisting of 1% sodium pyruvate, 1% Penicillin/Streptomycin, ascorbic acid (Sigma Aldrich) and B27 (Life Technologies) was used for hiPSC-CM culture (basic cardiac medium). In the first two weeks, CHIR99021 (Stemgent), BMP-4 (R&#x00026;DSystems), FGF-2 (MiltenyiBiotec), Activin A (R&#x00026;D Systems), and IWP-4 (Stemgent) were applied to induce hiPSCs to differentiate into hiPSC-CMs. Normally, on day 8 of differentiation some cells start to beat. In the third week, a selection medium containing sodium lactate (Sigma, Germany) and RPMI medium without glucose and glutamine (WKS, Germany) was used to select cardiomyocytes. Afterward, the selected cells were cultured with basic cardiac medium. After 40 to 60 days of differentiation, the cardiomyocytes were dissociated from 6 well plates and plated on Matrigel-coated 3.5&#x000a0;cm petri dishes as single cells for patch clamp tests. In our lab, the differentiation of hiPS cells into iPSC-CMs is regularly carried out every 2&#x02013;3&#x000a0;weeks. The hiPSC-CMs from several differentiations were used for studies and the data were combined. Two clones of the hiPSCs were alternately differentiated into hiPSC-CMs.\u003C/p>\u003Ch3 class=\"pt0\">Patch-Clamp\u003C/h3>\u003Cp class=\"mb0\">Standard patch-clamp whole-cell recording techniques were used to measure the hERG channel currents at room temperature. Patch electrodes were pulled from borosilicate glass capillaries (MTW 150F; world Precision Instruments, Inc., Sarasota, FL) using a DMZ-Universal Puller (Zeitz-Instrumente Vertriebs GmbH, Martinsried, Germany) and filled with pre-filtered pipette solution (see below). Pipette resistance ranged from 1&#x02013;2&#x000a0;M&#x003a9;. Signals were acquired at 10&#x000a0;kHz and filtered at 2&#x000a0;kHz with the EPC10 Patch-master digitizer hardware (HEKA Germany) and Fit-master software (HEKA Germany).\u003C/p>\u003Cp class=\"mb0\">To separate the hERG channel current from other currents, the Cs\u003Csup>&#x0002b;\u003C/sup> currents conducted by hERG channels (I\u003Csub>Kr\u003C/sub>) were measured. External solution contains (mM): 140 CsCl, 2 MgCl2, 10 HEPES, 10 Glucose, pH &#x0003d; 7.4 (CsOH). Pipette solution: 140 CsCl, 2 MgCl2, 10 HEPES, 10 EGTA, pH&#x0003d;7.2 (CsOH).\u003C/p>\u003Ch3 class=\"pt0\">Drugs\u003C/h3>\u003Cp class=\"mb0\">Ivabradine, flecainide, amiodarone, mexiletine, quinidine, and ranolazine were from Sigma, ajmaline from MP Biomedicals. The tested concentrations were selected according to literatures and our previous studies in hiPSC-CMs (\u003Ca href=\"#B76\">Wu et al., 2004\u003C/a>; \u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>; \u003Ca href=\"#B59\">Salvage et al., 2018\u003C/a>; \u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>). Our previous studies showed that 10&#x000a0;&#x000b5;M quinidine, 10&#x000a0;&#x000b5;M ivabradine, 30&#x000a0;&#x000b5;M ajmaline, 100&#x000a0;&#x000b5;M mexiletine, prolonged APD, 10&#x000a0;&#x000b5;M amiodarone inhibited I\u003Csub>Kr\u003C/sub> (\u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>; \u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>). Ranolazine (5&#x02013;30&#x000a0;&#x000b5;M) significantly reduced episodes of EADs and VT produced by ATX-II (\u003Ca href=\"#B76\">Wu et al., 2004\u003C/a>). Flecainide of 3&#x02013;30&#x000a0;&#x000b5;M was shown to inhibit Na and K channel currents (\u003Ca href=\"#B59\">Salvage et al., 2018\u003C/a>). Therefore, the concentrations of 10&#x000a0;&#x000b5;M quinidine, 30&#x000a0;&#x000b5;M ajmaline, 10&#x000a0;&#x000b5;M amiodarone, 10&#x000a0;&#x000b5;M ivabradine, 30&#x000a0;&#x000b5;M flecainide, 100&#x000a0;&#x000b5;M mexiletine and 30&#x000a0;&#x000b5;M ranolazine were chosen for the study. Of note, all these drugs can affect other channel currents besides hERG channel currents (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>).\u003C/p>\u003Ch3 class=\"pt0\">Statistical Analysis\u003C/h3>\u003Cp class=\"mb0\">Data are shown as mean &#x000b1; SEM and were analyzed using InStat\u003Csup>&#x000a9;\u003C/sup> (GraphPad, San Diego, United States) and SigmaPlot 11.0 (Systat GmbH, Germany). The t-test was used for comparison between two independent groups. Paired t-test was used for comparisons of data in the same cells before and after application of a drug. One way ANOVA was used for comparison among multiple groups (more than two groups). \u003Cem>p\u003C/em> &#x0003c; 0.05 (two-tailed) was considered significant.\u003C/p>\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\u003Ch3 class=\"pt0\">Drug Effects on hERG Channel Currents in hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">In our recent study, we demonstrated that quinidine, ajmaline, amiodarone, ivabradine, and mexiletine but not amiodarone, flecainide and ranolazine prolonged APD and reduced epinephrine induced arrhythmic events in hiPSC-CMs from the SQT1-patient (SQT1-hiPSC-CMs) (\u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>).To check whether these drugs affect hERG channel currents (I\u003Csub>Kr\u003C/sub>) differentially in hiPSC-CMs from healthy donor and the SQTS1-patient, drug effects on I\u003Csub>Kr\u003C/sub> were analyzed in both the healthy and diseased cells. I\u003Csub>Kr\u003C/sub> amplitudes and current-voltage relationship (I-V) curves in the same cells before and after application of a drug were analyzed. \u003Ca href=\"#F1\">Figures 1A&#x02013;D\u003C/a> showed effects of quinidine as examples of drug effects. Quinidine reduced the peak and steady state current of I\u003Csub>Kr\u003C/sub> (\u003Ca href=\"#F1\">Figures 1,B\u003C/a>) at different potentials (\u003Ca href=\"#F1\">Figures 1C,D\u003C/a>). All the tested seven drugs inhibited I\u003Csub>Kr\u003C/sub> in both donor- and SQT1-hiPSC-CMs. However, the inhibition induced by drugs was reduced in SQT1-hiPSC-CMs. Especially, the effect of amiodarone, flecainide, mexiletine and ranolazine was more severely reduced in SQT1-hiPSC-CMs (\u003Ca href=\"#F1\">Figure 1E\u003C/a>, \u003Ca href=\"#T1\">Table 1\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg\" name=\"Figure1\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg\" alt=\"www.frontiersin.org\" id=\"F1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>FIGURE 1\u003C/strong>. Drug effects on I\u003Csub>Kr\u003C/sub> in SQTS1-hiPSC-CMs. I\u003Csub>Kr\u003C/sub> was evoked by 2&#x000a0;s pulses from &#x02212;80 to 60&#x000a0;mV (10&#x000a0;mV increments) with a holding potential of &#x02212;80&#x000a0;mV. The steady state currents were measured at the end of pulses as indicated by arrows in \u003Cstrong>(A)\u003C/strong> and \u003Cstrong>(B)\u003C/strong> in the same cells before and after application of a drug. \u003Cstrong>(A)\u003C/strong> The protocol \u003Cstrong>(right side)\u003C/strong> and representative I\u003Csub>Kr\u003C/sub> traces \u003Cstrong>(left side)\u003C/strong> in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a SQT1-hiPSC-CM (SQT). \u003Cstrong>(B)\u003C/strong> Representative I\u003Csub>Kr\u003C/sub> traces in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a donor-hiPSC-CM (Healthy). \u003Cstrong>(C)\u003C/strong> Current-voltage relationship (I-V) curves of I\u003Csub>Kr\u003C/sub> in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in SQT1-hiPSC-CMs (SQT). \u003Cstrong>(D)\u003C/strong> I-V curves of I\u003Csub>Kr\u003C/sub> in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in donor-hiPSC-CMs (Healthy). \u003Cstrong>(E)\u003C/strong> Averaged values of percent inhibition of I\u003Csub>Kr\u003C/sub> at 40&#x000a0;mV by quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M) in hiPSC-CMs from a healthy subject (Donor) and the patient (SQT). The inhibition was calculated by: Inhibition &#x0003d; (I\u003Csub>ctr\u003C/sub>&#x02212;I\u003Csub>drug\u003C/sub>)/I\u003Csub>ctr\u003C/sub>&#x0002a;100, where I\u003Csub>ctr\u003C/sub> is the current before application of a drug, I\u003Csub>drug\u003C/sub> is the steady state current in presence of a drug. Shown are mean &#x000b1; SEM, \u003Cem>n\u003C/em> represents number of measured cells. The statistical significance was examined by paired t-test \u003Cstrong>(C, D)\u003C/strong> or unpaired t-test \u003Cstrong>(E)\u003C/strong>, &#x0002a;\u003Cem>p\u003C/em> &#x0003c; 0.05.\u003C/p>\u003C/div>\u003Cdiv class=\"clear\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE 1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg\" name=\"Table1\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>TABLE 1\u003C/strong>. Summary of drug effects on I\u003Csub>Kr\u003C/sub> and APD/QT.\u003C/p>\u003C/div>\u003Cdiv class=\"clear\">\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3 class=\"pt0\">Drug Effects on Activation of I\u003Csub>Kr\u003C/sub> in hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">To examine the effects of drugs on I\u003Csub>Kr\u003C/sub> activation, the time to peak (T-p) and activation curves were analyzed (\u003Ca href=\"#T1\">Table 1\u003C/a>). Quinidine (\u003Ca href=\"#F2\">Figures 2A,H,I,P\u003C/a>) and mexiletine (\u003Ca href=\"#F2\">Figures 2F,H,N,P\u003C/a>) accelerated (T-p was reduced), while ajmaline (\u003Ca href=\"#F2\">Figures 2B,H,J,P\u003C/a>), amiodarone (\u003Ca href=\"#F2\">Figures 2C,H,K,P\u003C/a>), ivabradine (\u003Ca href=\"#F2\">Figures 2D,H,L,P\u003C/a>) and ranolazine (\u003Ca href=\"#F2\">Figures 2G,H,O,P\u003C/a>) decelerated (T-p was increased) the I\u003Csub>Kr\u003C/sub> activation in donor- and SQTS1-hiPSC-CMs. Flecainide showed no effect in SQT1-hiPSC-CMs (\u003Ca href=\"#F2\">Figures 2E,H\u003C/a>), but increased T-p in donor-hiPSC-CMs (\u003Ca href=\"#F2\">Figures 2M,P\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg\" name=\"Figure2\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g002.jpg\" alt=\"www.frontiersin.org\" id=\"F2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>FIGURE 2\u003C/strong>. Drug effects on the time to peak of I\u003Csub>Kr\u003C/sub> in SQTS1-hiPSC-CMs. The time to peak (the time between the start of a pulse to the highest peak current point) of I\u003Csub>Kr\u003C/sub> was measured in current traces from 10 to 80&#x000a0;mV and plotted against voltages. The same cells before and after application of a drug were measured. \u003Cstrong>(A&#x02013;G)\u003C/strong> Representative curves of time to peak in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(H)\u003C/strong> Averaged values of time to peak at 20&#x000a0;mV in SQT1-hiPSC-CMs in absence (Ctr) and presence of drugs. \u003Cstrong>(I&#x02013;O)\u003C/strong> Representative curves of time to peak in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(P)\u003C/strong> Averaged values of time to peak at 20&#x000a0;mV in donor-hiPSC-CMs in absence (Ctr) and presence of drugs. Shown are mean &#x000b1; SEM, \u003Cem>n\u003C/em> represents number of cells. The statistical significance was examined by paired t-test, &#x0002a;\u003Cem>p\u003C/em> &#x0003c; 0.05 versus Control.\u003C/p>\u003C/div>\u003Cdiv class=\"clear\">\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb0\">In SQT1-hiPSC-CMs, quinidine, ajmaline and ivabradine shifted the activation curve of I\u003Csub>Kr\u003C/sub> to more positive potentials (\u003Ca href=\"#F3\">Figures 3A,B,D,H\u003C/a>), whereas ranolazine shifted the activation curve to more negative potentials (\u003Ca href=\"#F3\">Figures 3G,H\u003C/a>). Amiodarone, flecainide and mexiletine showed no effect (\u003Ca href=\"#F3\">Figures 3C,E&#x02013;H\u003C/a>). In donor cells, quinidine, ajmaline, amiodarone, ivabradine and mexiletine shifted the activation curves to more positive potentials (\u003Ca href=\"#F3\">Figures 3I&#x02013;L,N,P\u003C/a>), while ranolazine showed an opposite effect (\u003Ca href=\"#F3\">Figures 3O,P\u003C/a>). Flecainide showed no significant effect (\u003Ca href=\"#F3\">Figures 3M,P\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg\" name=\"Figure3\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g003.jpg\" alt=\"www.frontiersin.org\" id=\"F3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>FIGURE 3\u003C/strong>. Drug effects on voltage-dependent activation of I\u003Csub>Kr\u003C/sub> in SQTS1-hiPSC-CMs. I\u003Csub>Kr\u003C/sub> was evoked by 2&#x000a0;s pulses from &#x02212;80 to 60&#x000a0;mV (10&#x000a0;mV increments) with a holding potential of &#x02212;80&#x000a0;mV. The steady state currents were measured at the end of pulses as indicated by arrows in \u003Ca href=\"#F1\">Figures 1A,B\u003C/a> before and after application of a drug. The conductance was calculated with the equation: G &#x0003d; I/V, where I is the measured current, V is the voltage of pulses and G is the conductance. The conductance was normalized to the maximum (G/Gmax) and plotted against voltage to obtain the activation (G-V) curves. The curves were fitted by Boltzmann equation to obtain the voltage value at half maximal activation (V0.5). \u003Cstrong>(A&#x02013;G)\u003C/strong> Activation curves of I\u003Csub>Kr\u003C/sub> in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(H)\u003C/strong> Averaged values of half maximal activation potential (V0.5) in SQT1-hiPSC-CMs in absence (Ctr) and presence of drugs. \u003Cstrong>(I&#x02013;O)\u003C/strong> Activation curves of I\u003Csub>Kr\u003C/sub> in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(P)\u003C/strong> Averaged values of half maximal activation potential (V0.5) in donor-hiPSC-CMs in absence (Ctr) and presence of drugs. Shown are mean &#x000b1; SEM, \u003Cem>n\u003C/em> represents number of cells. The statistical significance was examined by paired t-test, &#x0002a;\u003Cem>p\u003C/em> &#x0003c; 0.05 versus Control.\u003C/p>\u003C/div>\u003Cdiv class=\"clear\">\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3 class=\"pt0\">Drug Effects on Inactivation of I\u003Csub>Kr\u003C/sub> in hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">To examine drug effects on I\u003Csub>Kr\u003C/sub> inactivation, the inactivation curves of I\u003Csub>Kr\u003C/sub> and the time constant (&#x003c4;) of the current decay due to channel inactivation were analyzed (\u003Ca href=\"#T1\">Table 1\u003C/a>). The inactivation curves were shifted to more negative potentials by quinidine (\u003Ca href=\"#F4\">Figures 4A,H\u003C/a>), ajmaline (\u003Ca href=\"#F4\">Figures 4B,H\u003C/a>), ivabradine (\u003Ca href=\"#F4\">Figures 4D,H\u003C/a>), mexiletine (\u003Ca href=\"#F4\">Figures 4F,H\u003C/a>), and ranolazine (\u003Ca href=\"#F4\">Figures 4G,H\u003C/a>) but not significantly influenced by amiodarone (\u003Ca href=\"#F4\">Figures 4C,H\u003C/a>) and flecainide (\u003Ca href=\"#F4\">Figures 4E,H\u003C/a>) in SQT1-hiPSC-CMs. In donor cells, the inactivation curves were shifted to more negative potentials by quinidine (\u003Ca href=\"#F4\">Figures 4I,P\u003C/a>), ajmaline (\u003Ca href=\"#F4\">Figures 4J,P\u003C/a>), flecainide (\u003Ca href=\"#F4\">Figures 4M,P\u003C/a>), mexiletine (\u003Ca href=\"#F4\">Figures 4N,P\u003C/a>) and ranolazine (\u003Ca href=\"#F4\">Figures 4O,P\u003C/a>) and to more positive potentials by amiodarone (\u003Ca href=\"#F4\">Figures 4K,P\u003C/a>) and ivabradine (\u003Ca href=\"#F4\">Figures 4L,P\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 4\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg\" name=\"Figure4\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g004.jpg\" alt=\"www.frontiersin.org\" id=\"F4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>FIGURE 4\u003C/strong>. Drug effects on voltage-dependent inactivation of I\u003Csub>Kr\u003C/sub> in SQTS1-hiPSC-CMs. I\u003Csub>Kr\u003C/sub> was evoked by the protocol shown in A \u003Cstrong>(right panel)\u003C/strong>. A pre-pulse of 1&#x000a0;s from &#x02212;80&#x000a0;mV (the holding potential) to &#x0002b;60&#x000a0;mV followed by a short (20&#x000a0;ms) repolarization to &#x02212;100&#x000a0;mV was given for channel activation, inactivation and recovery of inactivated channels to open state. Before deactivation occurs, test pulses of 1&#x000b0;s from &#x02212;50 to &#x0002b;80&#x000a0;mV (10&#x000a0;mV increments) were started to evaluate the inactivation of channels. I\u003Csub>Kr\u003C/sub> was measured at the beginning (peak current, a) and end (steady current, b) of test pulses as shown in A \u003Cstrong>(right panel)\u003C/strong>. The currents in same cells before and after application of a drug were measured. The current of inactivated channels (I\u003Csub>inact\u003C/sub>) was calculated as: I\u003Csub>inact\u003C/sub> &#x0003d;Ia-Ib, where Ia is the peak current, Ib is the steady current. When I\u003Csub>inact\u003C/sub> is larger than zero, it means inactivation occurred. When I\u003Csub>inact\u003C/sub> equals or is smaller than zero, it means no inactivation occurred. I\u003Csub>inact\u003C/sub> at different potentials were measured and normalized to the maximal current (I\u003Csub>inactMax\u003C/sub>). To plot the inactivation curves as usually shown (the curve decays with increasing voltages), the relative current was calculated by I&#x0003d;1 &#x02212; I\u003Csub>inact\u003C/sub>/I\u003Csub>inactMax\u003C/sub>. Finally, I was normalized to the maximal value I\u003Csub>max\u003C/sub> and plotted against voltages to obtain an inactivation curve. The inactivation curves were then fitted by Boltzmann equation to obtain the voltage value at half maximal inactivation (V0.5). \u003Cstrong>(A&#x02013;G)\u003C/strong> Inactivation curves of I\u003Csub>Kr\u003C/sub> in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(H)\u003C/strong> Averaged values of half maximal inactivation potential (V0.5) in SQT1-hiPSC-CMs in absence (Ctr) and presence of drugs. \u003Cstrong>(I&#x02013;O)\u003C/strong> Inactivation curves of I\u003Csub>Kr\u003C/sub> in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(P)\u003C/strong> Averaged values of half maximal inactivation potential (V0.5) in donor-hiPSC-CMs in absence (Ctr) and presence of drugs. Shown are mean &#x000b1; SEM, \u003Cem>n\u003C/em> represents number of cells. The statistical significance was examined by paired t-test, &#x0002a;\u003Cem>p\u003C/em> &#x0003c; 0.05 versus Control.\u003C/p>\u003C/div>\u003Cdiv class=\"clear\">\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb0\">In addition, it was detected that in SQT1-hiPSC-CMs, ajmaline (\u003Ca href=\"#F5\">Figure 5C\u003C/a>), flecainide (\u003Ca href=\"#F5\">Figure 5F\u003C/a>) and ranolazine (\u003Ca href=\"#F5\">Figure 5H\u003C/a>) decelerated the inactivation (time constant was increased), while amiodarone (\u003Ca href=\"#F5\">Figure 5D\u003C/a>) and ivabradine (\u003Ca href=\"#F5\">Figure 5E\u003C/a>) accelerated it. Quinidine (\u003Ca href=\"#F5\">Figure 5B\u003C/a>) and mexiletine (\u003Ca href=\"#F5\">Figure 5G\u003C/a>) had no significant effects. In donor-hiPSC-CMs, quinidine (\u003Ca href=\"#F5\">Figure 5J\u003C/a>), ajmaline (\u003Ca href=\"#F5\">Figure 5K\u003C/a>), amiodarone (\u003Ca href=\"#F5\">Figure 5L\u003C/a>) and flecainide (\u003Ca href=\"#F5\">Figure 5N\u003C/a>) decelerated the inactivation, while ivabradine (\u003Ca href=\"#F5\">Figure 5M\u003C/a>), mexiletine (\u003Ca href=\"#F5\">Figure 5O\u003C/a>) and ranolazine (\u003Ca href=\"#F5\">Figure 5P\u003C/a>) accelerated it. \u003Ca href=\"#F5\">Figures 5A,I\u003C/a> show examples of current inactivation in absence and presence of a drug (quinidine).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 5\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg\" name=\"Figure5\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g005.jpg\" alt=\"www.frontiersin.org\" id=\"F5\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>FIGURE 5\u003C/strong>. Drug effects on the time constant of I\u003Csub>Kr\u003C/sub> inactivation in SQTS1-hiPSC-CMs. To examine drug effects on the fast phase of inactivation, I\u003Csub>Kr\u003C/sub> was evoked by a 1&#x000a0;s-long pre-pulse from &#x02212;80 to 60&#x000a0;mV to let hERG channels be activated and returned to &#x02212;100&#x000a0;mV for 20&#x000a0;ms, and then the pre-pulse was followed by 500&#x000a0;ms test-pulses [P4 in the protocol shown by the inset in \u003Cstrong>(A)\u003C/strong> and \u003Cstrong>(I)\u003C/strong>] from 20 to 80&#x000a0;mV (10&#x000a0;mV increments). Currents evoked by test pulses were fitted by single exponential decay to obtain the time constant (&#x003c4;) of I\u003Csub>Kr\u003C/sub> fast inactivation. \u003Cstrong>(A)\u003C/strong> Representative traces of I\u003Csub>Kr\u003C/sub> evoked by pulses from 20 to 80&#x000a0;mV in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a SQT1-hiPSC-CM. \u003Cstrong>(B&#x02013;H)\u003C/strong> Mean values of time constants (&#x003c4;) of I\u003Csub>Kr\u003C/sub> inactivation in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(I)\u003C/strong> Representative traces of I\u003Csub>Kr\u003C/sub> evoked by pulses from 20 to 80&#x000a0;mV in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a donor-hiPSC-CM. \u003Cstrong>(J&#x02013;P)\u003C/strong> Mean values of time constants (&#x003c4;) of I\u003Csub>Kr\u003C/sub> inactivation in donor-hiPSC-CMs in absence (Ctr) and presence of each drug. Shown are mean &#x000b1; SEM, \u003Cem>n\u003C/em> represents number of cells. The statistical significance was examined by paired t-test, &#x0002a;\u003Cem>p\u003C/em> &#x0003c; 0.05 versus Control.\u003C/p>\u003C/div>\u003Cdiv class=\"clear\">\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3 class=\"pt0\">Drug Effects on I\u003Csub>Kr\u003C/sub> Window Currents in hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">Since the shift of activation or inactivation curves may change the window current, we assessed the I\u003Csub>Kr\u003C/sub> window current in the same cells in absence and presence of a drug. Quinidine, ivabradine, ajmaline and mexiletine reduced the I\u003Csub>Kr\u003C/sub> window current, but amiodarone, flecainide and ranolazine failed to do so in SQTS1-hiPSC-CMs (\u003Ca href=\"#F6\">Figures 6A&#x02013;G\u003C/a>). In donor cells, quinidine, ajmaline and mexiletine also reduced the window current, whereas ivabradine, ranolazine, amiodarone and flecainide showed no effects (\u003Ca href=\"#F6\">Figures 6 H&#x02013;N\u003C/a>) (\u003Ca href=\"#T1\">Table 1\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 6\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg\" name=\"Figure6\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g006.jpg\" alt=\"www.frontiersin.org\" id=\"F6\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>FIGURE 6\u003C/strong>. Drug effects on window currents of I\u003Csub>Kr\u003C/sub> in SQTS1-hiPSC-CMs. The activation and inactivation curves were plotted in the same figure. The window current was defined as the current under the crossover of activation and inactivation curves. The activation curves are the same curves as in \u003Ca href=\"#F3\">Figure 3\u003C/a>. To obtain the inactivation curves, a pulse of 1&#x000a0;s from &#x02212;80 to &#x0002b;60&#x000a0;mV was applied to activate and inactivate hERG channels. Then, the pulse was set to &#x02212;100&#x000a0;mV for 20&#x000a0;ms to let the inactivated channels recover to open state. Before the deactivation occurs, a test pulse to &#x0002b;60&#x000a0;mV for 500&#x000a0;ms was applied and the peak current at the test potential was measured. The voltage of recovery pulses was changed from &#x02212;100 to &#x0002b;80&#x000a0;mV. The currents at test pulse versus respective voltages of the recovery pulses were normalized to the maximal current and plotted against voltages of the recovery pulses to obtain the inactivation curves (availability-voltage curves). The cell numbers of activation curves are same as that in \u003Ca href=\"#F3\">Figure 3\u003C/a>. The cells numbers of inactivation curves are nine for each drug experiments. For comparison, the window currents in absence (black points and lines) and presence (grey points and lines) of drugs were overlapped in the same plot. \u003Cstrong>(A&#x02013;G)\u003C/strong> Overlapped activation and inactivation curves showing the widow currents in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(H&#x02013;N)\u003C/strong> Overlapped activation and inactivation curves showing the widow currents in donor-hiPSC-CMs in absence (Ctr) and presence of each drug.\u003C/p>\u003C/div>\u003Cdiv class=\"clear\">\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3 class=\"pt0\">Drug Effects on Recovery From Inactivation of I\u003Csub>Kr\u003C/sub> in hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">To examine drug effect on the recovery of hERG channel from inactivation, the time constant (&#x003c4;) of tail currents representing recovery of hERG channels from inactivation was analyzed (\u003Ca href=\"#F7\">Figures 7E,F\u003C/a>) (\u003Ca href=\"#T1\">Table 1\u003C/a>). In SQTS1-hiPSC-CMs, ajmaline, amiodarone and mexiletine speeded up the recovery, whereas flecainide and quinidine slowed it down. Ivabradine and ranolazine showed no significant effect (\u003Ca href=\"#F7\">Figure 7E\u003C/a>). In donor cells, the recovery speed was reduced by quinidine (\u003Ca href=\"#F7\">Figures 7B,F\u003C/a>), ivabradine and ranolazine, increased by amiodarone but not significantly affected by ajmaline, flecainide and mexiletine (\u003Ca href=\"#F7\">Figure 7F\u003C/a>). \u003Ca href=\"#F7\">Figures 7A,D\u003C/a> show examples of current recovery from inactivation in absence and presence of a drug (quinidine).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 7\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg\" name=\"Figure7\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g007.jpg\" alt=\"www.frontiersin.org\" id=\"F7\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>FIGURE 7\u003C/strong>. Drug effects on time constants of I\u003Csub>Kr\u003C/sub> recovery from inactivation and deactivation in SQTS1-hiPSC-CMs. I\u003Csub>Kr\u003C/sub> was evoked by a 1&#x000a0;s-long pre-pulse from &#x02212;80 to 60&#x000a0;mV to let hERG channels be activated and some of them to be inactivated. The pre-pulse was followed by 500&#x000a0;ms test-pulses from &#x02212;20 to &#x02212;100&#x000a0;mV (10&#x000a0;mV increments). The protocol is shown in \u003Cstrong>(B)\u003C/strong> (inset). Currents evoked by test pulses (tail currents) were used for analyzing the recovery from inactivation or deactivation of the currents. When the tail current increased, i.e., &#x0201c;b&#x0201d; is larger (more negative) than &#x0201c;a&#x0201d;, the current was defined as recovered current. The curves were fitted by single exponential decay to obtain time constants of recovery from inactivation. From &#x02212;50 to &#x02212;100&#x000a0;mV, deactivation became obvious. i.e., the current decrease again (the current at &#x0201c;d&#x0201d; is smaller than that at &#x0201c;c&#x0201d;. The change point &#x0201c;b/c&#x0201d; is defined as the end of recovered current and the start of the deactivation. \u003Cstrong>(A)\u003C/strong> Representative traces of I\u003Csub>Kr\u003C/sub> evoked by test pulses from &#x02212;20 to &#x02212;100&#x000a0;mV in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a donor-hiPSC-CM. \u003Cstrong>(B)\u003C/strong> Mean values of time constants (&#x003c4;) of I\u003Csub>Kr\u003C/sub> recovery from inactivation at different voltages in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine. \u003Cstrong>(C)\u003C/strong> Mean values of time constants (&#x003c4;) of I\u003Csub>Kr\u003C/sub> deactivation at different voltages in donor-hiPSC-CMs in absence (Ctr) and presence of quinidine. \u003Cstrong>(D)\u003C/strong> Representative traces of I\u003Csub>Kr\u003C/sub> at &#x02212;60&#x000a0;mV taken as recovered currents from inactivation in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in donor-hiPSC-CMs. \u003Cstrong>(E)\u003C/strong> Mean values of time constants (&#x003c4;) of I\u003Csub>Kr\u003C/sub> recovery from inactivation at &#x02212;60&#x000a0;mV in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(F)\u003C/strong> Mean values of time constants (&#x003c4;) of I\u003Csub>Kr\u003C/sub> recovery from inactivation at &#x02212;60&#x000a0;mV in donor-hiPSC-CMs in absence (Ctr) and presence of each drug. \u003Cstrong>(G)\u003C/strong> Representative traces of I\u003Csub>Kr\u003C/sub> at &#x02212;80&#x000a0;mV taken as deactivated currents in absence (Control) and presence of 10&#x000a0;&#x000b5;M quinidine (Qui) in a donor-hiPSC-CM. \u003Cstrong>(H)\u003C/strong> Mean values of time constants (&#x003c4;) of I\u003Csub>Kr\u003C/sub> deactivation at &#x02212;80&#x000a0;mV in SQT1-hiPSC-CMs in absence (Ctr) and presence of quinidine (Qui, 10&#x000a0;&#x000b5;M), ajmaline (Ajm, 30&#x000a0;&#x000b5;M), amiodarone (Ami, 10&#x000a0;&#x000b5;M), ivabradine (Iva, 10&#x000a0;&#x000b5;M), flecainide (Fle, 30&#x000a0;&#x000b5;M), mexiletine (Mex, 100&#x000a0;&#x000b5;M) and ranolazine (Ran, 30&#x000a0;&#x000b5;M). \u003Cstrong>(I)\u003C/strong> Mean values of time constants (&#x003c4;) of I\u003Csub>Kr\u003C/sub> deactivation at &#x02212;80&#x000a0;mV in donor-hiPSC-CMs in absence (Ctr) and presence of each drug. Shown are mean &#x000b1; SEM, n represents number of cells. The n-numbers given in \u003Cstrong>(F)\u003C/strong> are also for \u003Cstrong>(E)\u003C/strong>, \u003Cstrong>(H)\u003C/strong> and \u003Cstrong>(I)\u003C/strong>. The statistical significance was examined by paired t-test, &#x0002a;\u003Cem>p\u003C/em> &#x0003c; 0.05 \u003Cem>vs.\u003C/em> Control.\u003C/p>\u003C/div>\u003Cdiv class=\"clear\">\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3 class=\"pt0\">Drug Effects on Deactivation of I\u003Csub>Kr\u003C/sub> in hiPSC-CMs\u003C/h3>\u003Cp class=\"mb0\">Finally, the deactivation of I\u003Csub>Kr\u003C/sub> was analyzed in hiPSC-CMs (\u003Ca href=\"#T1\">Table 1\u003C/a>, \u003Ca href=\"#F7\">Figures 7A,G&#x02013;I\u003C/a>). In SQT1-hiPSC-CMs, quinidine, ajmaline, ivabradine and mexiletine reduced the speed of deactivation of hERG channels (the time constant &#x003c4; was increased), but amiodarone, flecainide and ranolazine failed to change it (\u003Ca href=\"#F7\">Figure 7H\u003C/a>). In donor cells, amiodarone accelerated the deactivation (\u003Ca href=\"#F7\">Figure 7I\u003C/a>), while quinidine (\u003Ca href=\"#F7\">Figures 7C,I\u003C/a>), ivabradine and mexiletine decelerated it (\u003Ca href=\"#F7\">Figure 7I\u003C/a>). Ajmaline, flecainide and ranolazine did not influence the channel deactivation (\u003Ca href=\"#F7\">Figure 7I\u003C/a>). \u003Ca href=\"#F7\">Figures 7A,G\u003C/a> show examples of current deactivation in absence and presence of a drug (quinidine).\u003C/p>\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\u003Cp class=\"mb15\">In this study, we investigated the effects of quinidine, ajmaline, amiodarone, ivabradine, flecainide, mexiletine and ranolazine on gating kinetics of hERG channels in hiPSC-CMs from a SQT1-patient with N588k mutation. The study demonstrated that 1) these drugs affected differentially the hERG channel gating kinetics in donor- and SQT1-hiPSC-CMs, 2) quinidine, ajmaline, ivabradine and mexiletine reduced the window current of hERG channels and 3) quinidine, ajmaline, ivabradine and mexiletine decelerated deactivation of hERG channels. The latter two may be important for their antiarrhythmic effects previously observed in SQTS-patients (reduction of the occurrence of life-threatening arrhythmic events) or SQTS-hiPSC-CMs (reduction of epinephrine-induced arrhythmic events) (\u003Ca href=\"#B42\">Mazzanti et al., 2017\u003C/a>; \u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">In our previous study, we generated hiPSC-CMs from a patient with STQS1 carrying the hERG (KCNH2) gene mutation of N588K and characterized the phenotypic features (APD-shortening and arrhythmic events) (\u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>). Using the cellular model of SQT1 (SQT1-hiPSC-CMs) we tested the APD-prolonging and antiarrhythmic effect of different drugs (\u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>; \u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>; \u003Ca href=\"#B39\">Lan et al., 2020\u003C/a>). We have demonstrated that the SQTS1-hiPSC-CMs displayed shortened APD and increased arrhythmic events. Quinidine, disopyramide, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide or ranolazine prolonged APD and reduced the arrhythmic episodes in SQT1-hiPSC-CMs (\u003Ca href=\"#B17\">El-Battrawy et al., 2018\u003C/a>; \u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>; \u003Ca href=\"#B39\">Lan et al., 2020\u003C/a>). Although we found that the inhibition of the N588K-hERG channel current by drugs is different, whether these drugs exert also different effects on N588K-hERG channel gating kinetics, which may help clarify the effect difference of drugs, is so far unknown. The current study was designed to address this open question and look for hints for selecting possible effective drugs for SQT1-treatment.\u003C/p>\u003Cp class=\"mb15\">Quinidine is a multiple channel blocker with a high affinity to hERG and was a frequently used antiarrhythmic drug. It can inhibit I\u003Csub>Na\u003C/sub> (Na channel current), I\u003Csub>Ca-L\u003C/sub> (L-type Ca current), I\u003Csub>to\u003C/sub> (transient outward K current), I\u003Csub>Kr\u003C/sub> (hERG channel current), I\u003Csub>Ks\u003C/sub> (slowly activating delayed rectifier K current), I\u003Csub>K1\u003C/sub> (inward rectifier K current) and I\u003Csub>KATP\u003C/sub> (ATP-sensitive-K channel current) (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>) (\u003Ca href=\"#B55\">Pugsley et al., 2005\u003C/a>; \u003Ca href=\"#B46\">Michel et al., 2002\u003C/a>; \u003Ca href=\"#B52\">Paul et al., 2002\u003C/a>; \u003Ca href=\"#B77\">Yang et al., 2009\u003C/a>; \u003Ca href=\"#B32\">Imaizumi and Giles, 1987\u003C/a>; \u003Ca href=\"#B37\">Koepple et al., 2017\u003C/a>; \u003Ca href=\"#B70\">Undrovinas et al., 1990\u003C/a>). The I\u003Csub>Na\u003C/sub>-inhibiting effect can reduce the speed of depolarization and excitation conduction, and hence reduce occurrence of some arrhythmias. The inhibition of I\u003Csub>Ca-L\u003C/sub> may shorten APD, whereas the inhibition of K currents can prolong APD. In fact, quinidine prolongs APD in wild-type (healthy) and SQTS-cells (\u003Ca href=\"#T1\">Table 1\u003C/a>) (\u003Ca href=\"#B14\">Davidenko et al., 1989\u003C/a>; \u003Ca href=\"#B29\">Guo et al., 2019\u003C/a>), indicating that its effect on K currents is larger than that on I\u003Csub>Ca-L\u003C/sub>. The APD-prolonging effect can be antiarrhythmic and also proarrhythmic. Quinidine was clinically used as an antiarrhythmic drug, but the severe side effects of quinidine reduced its clinical relevance for arrhythmia-treatment. However, when it was shown to be effective for SQT-patients, it absorbed again interests of physicians and researchers. It was found that although the mutation N588K in hERG channel rendered hERG channel resistant to many drugs including typical hERG channel blockers, the channel remains still sensitive to quinidine. One reason for the efficacy of quinidine is that quinidine affects hERG channels in both open and closed (inactivated) state, different from other drugs that affect only or mainly inactivated hERG channels. The N588K mutation reduced the inactivation of hERG channel and hence reduced the effects of inactivation-affecting drugs like E-4031, sotalol, dofetilide and terfenadine (\u003Ca href=\"#B43\">McPate et al., 2008\u003C/a>; \u003Ca href=\"#B53\">Perrin et al., 2008\u003C/a>). Quinidine effect is only partially changed by N588K mutation because its open-channel-affecting effect is not influenced by the mutation. Therefore, quinidine is effective for SQT-patients with N588K mutation and recommended for application in SQT-patients (\u003Ca href=\"#B54\">Priori et al., 2015\u003C/a>). Since previously reported studies focused on the change of channel sensitivity (shift of dose-response curve) induced by N588K-mutation, the influence of N588K on drug effects regarding the hERG channel gating kinetic parameters was not analyzed in detail. In the current study, we found out that the quinidine effects on the time to peak and activation curve, on the time constant of inactivation and inactivation curve, on the time constants of recovery from inactivation and the deactivation as well as on the window current of the hERG channel were similar in donor- and SQT1-hiPSC-CMs, suggesting that quinidine effects on hERG channel gating are not severely changed by N588K.\u003C/p>\u003Cp class=\"mb15\">The class Ia anti-arrhythmic drug ajmaline is frequently applied to induce phenotypic changes of Brugada syndrome (BrS) in ECG for diagnostic aim. Studies reported that ajmaline inhibits various currents, including I\u003Csub>Na\u003C/sub>, I\u003Csub>Ca-L\u003C/sub>, I\u003Csub>to\u003C/sub>, I\u003Csub>Kr\u003C/sub>, I\u003Csub>K1\u003C/sub> and I\u003Csub>KATP\u003C/sub> (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>) (\u003Ca href=\"#B48\">Miller et al., 2017\u003C/a>; \u003Ca href=\"#B5\">B&#x000e9;barov&#x000e1; et al., 2005a\u003C/a>; \u003Ca href=\"#B35\">Khodorov and Zaborovskaya, 1983\u003C/a>; \u003Ca href=\"#B6\">B&#x000e9;barov&#x000e1; et al., 2005b\u003C/a>; \u003Ca href=\"#B36\">Kiesecker et al., 2004\u003C/a>). The inhibition of I\u003Csub>to\u003C/sub>, I\u003Csub>Kr\u003C/sub>, I\u003Csub>K1\u003C/sub> and I\u003Csub>KATP\u003C/sub> can prolong APD and hence APD-prolongation induced by ajmaline was observed in both wild-type cells and an SQT-model (\u003Ca href=\"#T1\">Table 1\u003C/a>) (\u003Ca href=\"#B6\">B&#x000e9;barov&#x000e1; et al., 2005b\u003C/a>; \u003Ca href=\"#B34\">J&#x000e6;ger et al., 2021\u003C/a>). This led us to assume that it may inhibit the hERG channel current in SQTS1-hiPSC-CMs. Indeed, ajmaline inhibited the hERG channel current, prolonged APD and reduced arrhythmic events in SQTS1-cells (\u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>). In HEK cells and Xenopus oocytes expressing hERG channels, ajmaline inhibited the hERG current and the Y652A and F656A mutations abolished the ajmaline effect (\u003Ca href=\"#B36\">Kiesecker et al., 2004\u003C/a>). Ajmaline shifted slightly the half-maximal activation voltage toward more negative potentials but did not significantly influence hERG inactivation curve, although it reduced the &#x003c4; value of inactivation (\u003Ca href=\"#B36\">Kiesecker et al., 2004\u003C/a>). The influence of N588K on ajmaline effects was not examined in that study. Here in the current study, we add novel data about ajmaline effects on the gating parameters of wild-type and N588K-hERG channels in hiPSC-CMs. The effects of ajmaline on hERG channel current data including the time to peak, &#x003c4; of inactivation, activation and inactivation curves and the window current are similar (changes in the same direction) in donor- and SQT1-hiPSC-CMs, while its effects on the time constants of recovery from inactivation and deactivation were observed only in SQT1-hiPSC-CMs. These data may be helpful for understanding the anti- or pro-arrhythmic feature of the drug. Since ajmaline can inhibit other ion channel currents, its inhibitory effect on I\u003Csub>to\u003C/sub>, I\u003Csub>K1\u003C/sub> and I\u003Csub>KATP\u003C/sub> may also contribute its APD-prolonging and antiarrhythmic effects in SQTS.\u003C/p>\u003Cp class=\"mb15\">Amiodarone alone showed no QTc-prolonging effect, but amiodarone together with metoprolol prolonged QTc in a SQTS-patient (\u003Ca href=\"#B27\">Giustetto et al., 2011\u003C/a>). The benefit of amiodarone for SQTS-patients is still questionable. In our hiPS-CMs from the patient with SQTS1, amiodarone failed to prolong APD and to reduce arrhythmic events. Amiodarone is similar to quinidine in inhibiting hERG current conducted by the mutant (N588K) hERG channel (\u003Ca href=\"#B43\">McPate et al., 2008\u003C/a>). Since the influence of N588K on amiodarone effects regarding gating kinetics of hERG channels was not investigated, it is difficult to understand why quinidine but not amiodarone is effective in SQT1-patients. Our current study detected the difference, i.e., quinidine reduced the window current, decelerated the recovery from inactivation and deactivation, while amiodarone showed no or opposite effects on those parameters. Besides hERG current, I\u003Csub>Na\u003C/sub>, I\u003Csub>Ca-L\u003C/sub>, I\u003Csub>NCX\u003C/sub>, I\u003Csub>to\u003C/sub>, I\u003Csub>Ks\u003C/sub>, I\u003Csub>K1\u003C/sub> and I\u003Csub>KATP\u003C/sub> can be inhibited by amiodarone (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>) (\u003Ca href=\"#B51\">Nishida et al., 2011\u003C/a>; \u003Ca href=\"#B67\">Suzuki et al., 2013\u003C/a>; \u003Ca href=\"#B33\">Iwamoto et al., 2007\u003C/a>; \u003Ca href=\"#B75\">Watanabe, 2019\u003C/a>). The inhibition of I\u003Csub>Ca-L\u003C/sub> may shorten APD, while the inhibition of I\u003Csub>to\u003C/sub>, I\u003Csub>Ks\u003C/sub>, I\u003Csub>K1\u003C/sub> and I\u003Csub>KATP\u003C/sub> can prolong APD. In wild-type cells, amiodarone prolonged or showed no effect on APD (\u003Ca href=\"#T1\">Table 1\u003C/a>) (\u003Ca href=\"#B4\">Aomine, 1988\u003C/a>; \u003Ca href=\"#B61\">Sasaki et al., 2014\u003C/a>). In our experiments, amiodarone failed to changed APD significantly, implying that its effects on inward currents and outward currents are similar.\u003C/p>\u003Cp class=\"mb15\">Ivabradine could prolong QT interval and suppress the arrhythmic events in rabbit models of SQTS induced by an ATP-sensitive potassium channel activator pinacidil (\u003Ca href=\"#B24\">Frommeyer et al., 2017\u003C/a>). Ivabradine is a well-known funny channel (I\u003Csub>f\u003C/sub>) blocker. Since it displayed no negative inotropic effects and is useful to maintain stable hemodynamics, it is clinically administered to reduce heart rate in patients with heart failure. Ivabradine also inhibits hERG channel currents (\u003Ca href=\"#B40\">Lees-Miller et al., 2015\u003C/a>). In a study, hERG channels, either WT or mutated, were expressed by transfection into HEK393 cells and ivabradine effects on the channels were investigated (\u003Ca href=\"#B44\">Melgari et al., 2015\u003C/a>). In that study, Melgari et al. demonstrated that ivabradine inhibited the WT- and mutated hERG channel current. N588K and S624A variants slightly reduced ivabradine effect, while Y652A and F656A strongly reduced its effect. In addition, the authors also showed that ivabradine shifted both the activation and inactivation curve to a more negative potential without effect on the speed (&#x003c4;) of inactivation of the WT-hERG channel. In the current study, we demonstrated that the inhibition of hERG current by ivabradine was reduced and the inactivation curve was shifted to a more negative potential, consistent with the previous study. However, we found that ivabradine shifted the activation curve to a more positive potential, which differs from the results of the Melgari study. Moreover, we observed that ivabradine prolonged the time to peak, reduced the time constant of inactivation and increased the time constant of deactivation in both donor and SQT1-cells, reduced the window current in SQT1-cells but not in donor-cells, and increased the time constant of recovery in donor-cells but not in SQT1-cells. These data are new because previous studies including Melgari study did not investigate ivabradine effects on these parameters in N588K-hERG channels or in SQT1-cells. Besides hERG current, I\u003Csub>Na\u003C/sub>, but not I\u003Csub>Ca-L\u003C/sub>, I\u003Csub>Ks\u003C/sub> and I\u003Csub>K1\u003C/sub> can be inhibited by ivabradine (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>) (\u003Ca href=\"#B31\">Haechl et al., 2019\u003C/a>; \u003Ca href=\"#B15\">Demontis et al., 2009\u003C/a>). The inhibition of I\u003Csub>Na\u003C/sub> may contribute to antiarrhythmic but not APD-prolonging effect. In previous studies, ivabradine showed no effect or prolonging or shortening effect on APD in wild type cells (\u003Ca href=\"#T1\">Table 1\u003C/a>) (\u003Ca href=\"#B38\">Koncz et al., 2011\u003C/a>; \u003Ca href=\"#B31\">Haechl et al., 2019\u003C/a>). It seems that ivabradine effect on APD mainly resulted from its effect on I\u003Csub>Kr\u003C/sub>.\u003C/p>\u003Cp class=\"mb15\">Mexiletine, a sodium channel blocker, was shown to be effective for suppressing arrhythmias in a rabbit model of SQTS and atrial fibrillation (AF) (\u003Ca href=\"#B25\">Frommeyer et al., 2018\u003C/a>). In our recent study, using the SQT1-hiPSC-CMs we also observed profitable results of mexiletine, prolonging APD and reducing arrhythmic events. Although mexiletine inhibited I\u003Csub>Kr\u003C/sub> in SQTS1-hiPSC-CMs, its effect on I\u003Csub>Kr\u003C/sub> gating kinetic parameter has not been assessed. In a previous study from Gualdani et al., WT and mutant hERG channels were expressed in HEK293 or CHO cells and mexiletine effects were assessed (\u003Ca href=\"#B28\">Gualdani et al., 2015\u003C/a>). The study demonstrated that i) Mexiletine inhibited the hERG channel current in a time- and voltage-dependent way; ii) Its inhibitory effect was strongly reduced by Y652A and F656A mutants; iii) It reduced the time constant of activation but increased the time constant of deactivation, meaning that it accelerated activation and decelerated deactivation; iv) Mexiletine did not influence the channel inactivation. The effects of mexiletine on gating kinetics of N588K-hERG channels were not investigated. Our current study detected that the inhibitory effect of mexiletine was strongly reduced in SQT1-hiPSC-CMs carrying the N588K mutation. Mexiletine reduced the time to peak in both donor and SQT1-cells, suggesting an increase in activation speed, consistent with the Gualdani study. In our study, mexiletine increased the time constant of deactivation (consistent with the previous study) but reduced the time constant of inactivation (different from the previous study) in both donor and SQT1-cells. The differences between our and the previous study may result from using different cell types. Further, mexiletine reduced the time constant of recovery from inactivation and the window current as well, which have not been shown before. In addition, mexiletine can inhibit I\u003Csub>Na\u003C/sub>, I\u003Csub>Ca-L\u003C/sub>, I\u003Csub>NCX\u003C/sub>, I\u003Csub>Ks\u003C/sub> and I\u003Csub>to,\u003C/sub> and activate I\u003Csub>KATP\u003C/sub> (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>) (\u003Ca href=\"#B72\">Wang et al., 1996\u003C/a>; \u003Ca href=\"#B78\">Yonemizu et al., 2019\u003C/a>; \u003Ca href=\"#B57\">Rahm et al., 2020\u003C/a>; \u003Ca href=\"#B49\">Mitcheson and Hancox, 1997\u003C/a>). The I\u003Csub>Ca-L\u003C/sub>-inhibiting and I\u003Csub>KATP\u003C/sub>-activation can explain the APD-shortening effect of mexiletine in wild-type cardiomyocytes (\u003Ca href=\"#T1\">Table 1\u003C/a>) (\u003Ca href=\"#B41\">Matsuo et al., 1985\u003C/a>; \u003Ca href=\"#B62\">Sato et al., 1995\u003C/a>). The I\u003Csub>Kr\u003C/sub>-, I\u003Csub>Ks\u003C/sub>- and I\u003Csub>to\u003C/sub>-inhibiting effects can be the reason for APD-prolonging effect observed in SQT-cells (\u003Ca href=\"#B25\">Frommeyer et al., 2018\u003C/a>). Whether mexiletine prolongs or shortens APD in cells, probably depends on its net effect on the inward and outward currents. In our hiPSC-CMs, mexiletine prolonged APD, suggesting that its effect on outward current is predominant.\u003C/p>\u003Cp class=\"mb15\">Flecainide has been shown to prolong APD and refractory period but did not reduce the rate of inducibility of ventricular fibrillation in a rabbit model of SQTS (\u003Ca href=\"#B47\">Milberg et al., 2007\u003C/a>). In a clinical study, it was shown to be ineffective for prolonging QT interval and reducing arrhythmias (\u003Ca href=\"#B26\">Gaita et al., 2004\u003C/a>). In our recent study, it inhibited slightly the hERG channel current, but failed to prolong APD or to reduce arrhythmic events in SQT1-hiPSC-CMs (\u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>). Before, it was shown that flecainide inhibited hERG channel currents in HEK cells and N588K reduced flecainide effect (\u003Ca href=\"#B45\">Melgari et al., 2015\u003C/a>). Flecainide did not influence the voltage-dependent inactivation curve but increased the time constant of inactivation of wild-type hERG channels (\u003Ca href=\"#B45\">Melgari et al., 2015\u003C/a>). Flecainide shifted activation curve to a more negative potential but did not influence the time constant of deactivation of wild-type hERG channels (\u003Ca href=\"#B52\">Paul et al., 2002\u003C/a>). Flecainide effects on gating kinetics of N588K-hERG channel have not been reported. Our current study showed that i) The inhibitory effect of flecainide was largely reduced in SQT1-cells, ii) The time to peak of hERG current was prolonged in donor but not in SQT1-cells and iii) The inactivation curve was shifted to a more negative potential in donor but not in SQT1-cells. The latter may help us understand the reduced inhibitory effect of flecainide in SQT1-hiPSC-CMs. Flecainide did not change the window current of hERG channels. It decelerated the recovery from inactivation in SQT1-hiPSC-CMs and showed no effect on the channel deactivation. These data may help explain why flecainide showed no antiarrhythmic effects in SQT1-hiPSC-CMs and SQT-patients because these effects are different from that of quinidine, ajmaline, ivabradine and mexiletine, which prolonged APD and reduced epinephrine-induced arrhythmic events in SQT1-hiPSC-CMs. Flecainide can inhibit I\u003Csub>Na\u003C/sub>, I\u003Csub>Ca-L\u003C/sub>, I\u003Csub>to\u003C/sub>, I\u003Csub>KATP\u003C/sub>, and enhance I\u003Csub>NCX\u003C/sub> and I\u003Csub>K1\u003C/sub> but has no effect on I\u003Csub>Ks\u003C/sub> (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>) (\u003Ca href=\"#B75\">Watanabe, 2019\u003C/a>; \u003Ca href=\"#B72\">Wang et al., 1996\u003C/a>; \u003Ca href=\"#B71\">Wang et al., 1993\u003C/a>; \u003Ca href=\"#B21\">Follmer and Colatsky, 1990\u003C/a>; \u003Ca href=\"#B10\">Caballero et al., 2010\u003C/a>; \u003Ca href=\"#B80\">Yunoki et al., 2001\u003C/a>). The inhibition of I\u003Csub>to\u003C/sub> and I\u003Csub>KATP\u003C/sub> can prolong APD, which may contribute to the APD-prolongation observed in healthy cardiomyocytes (\u003Ca href=\"#T1\">Table 1\u003C/a>) (\u003Ca href=\"#B8\">Borchard and Boisten, 1982\u003C/a>; \u003Ca href=\"#B71\">Wang et al., 1993\u003C/a>). In the current study, we did not examine the effect of flecainide on these currents. The fact that flecainide failed to prolong APD in SQT1-hiPSC-CMs suggests that its effect on I\u003Csub>to\u003C/sub> and I\u003Csub>KATP\u003C/sub> is probably also attenuated in SQT1-cells.\u003C/p>\u003Cp class=\"mb15\">Ranolazine, an antianginal drug, possesses also antiarrhythmic effects (\u003Ca href=\"#B22\">Frommeyer et al., 2012\u003C/a>; \u003Ca href=\"#B9\">Burashnikov et al., 2012\u003C/a>). It showed potent antiarrhythmic properties in the rabbit model of pinacidil-induced SQTS (\u003Ca href=\"#B23\">Frommeyer et al., 2016\u003C/a>). Ranolazine was shown to block I\u003Csub>Kr\u003C/sub> in dog cardiomyocytes (\u003Ca href=\"#B2\">Antzelevitch et al., 2004a\u003C/a>; \u003Ca href=\"#B64\">Schram et al., 2004\u003C/a>). In HEK cells expressing WT- and mutant hERG channels, ranolazine inhibited the hERG channel current and its effect was reduced by different mutants including N588K\u003Csup>69\u003C/sup>. It shifted the activation curve of WT hERG channels to a more negative potential (\u003Ca href=\"#B16\">Du et al., 2014\u003C/a>; \u003Ca href=\"#B58\">Rajamani et al., 2008\u003C/a>). It was also shown that ranolazine reduced the time constant of inactivation and showed no effect on the time constant of recovery from inactivation of hERG channels in HEK cells (\u003Ca href=\"#B58\">Rajamani et al., 2008\u003C/a>). Effects of ranolazine on gating kinetic parameters of mutant hERG channels have not been shown. Our study analyzed in detail the effects of ranolazine on the activation, inactivation, recovery from inactivation and deactivation of hERG channel currents in both healthy donor and SQT1-hiPSC-CMs. The main findings are that both the activation and inactivation curves were shifted in the same direction and hence the window current was not changed. The time to peak and time constant of deactivation were similar in donor and SQT1-hiPSC-CMs. The time constant of inactivation and time constant of recovery from inactivation were differentially affected by ranolazine in donor- and SQT1-hiPSC-CMs. Besides hERG current, ranolazine can inhibit I\u003Csub>Na\u003C/sub>, I\u003Csub>Ca-L\u003C/sub>, I\u003Csub>NCX\u003C/sub>, I\u003Csub>to\u003C/sub> and I\u003Csub>Ks\u003C/sub> without effect onI\u003Csub>K1\u003C/sub> (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>) (\u003Ca href=\"#B3\">Antzelevitch et al., 2004b\u003C/a>; \u003Ca href=\"#B56\">Qian et al., 2012\u003C/a>). Action potential prolongation and shortening induced by ranolazine were observed in wild-type cells (\u003Ca href=\"#T1\">Table 1\u003C/a>) (\u003Ca href=\"#B2\">Antzelevitch et al., 2004a\u003C/a>; \u003Ca href=\"#B76\">Wu et al., 2004\u003C/a>; \u003Ca href=\"#B23\">Frommeyer et al., 2016\u003C/a>). The inhibition of I\u003Csub>Ca-L\u003C/sub> can shorten APD, while inhibition of I\u003Csub>Kr\u003C/sub> and I\u003Csub>Ks\u003C/sub> can explain the APD-prolongation. In our SQT1-hiPSC-CMs, ranolazine did not prolong APD, probably, its effect on I\u003Csub>Ks\u003C/sub> was also attenuated or its inhibitory effect on I\u003Csub>Ca-L\u003C/sub> was enhanced, which counteracted the APD-prolonging effect of inhibition of I\u003Csub>Kr\u003C/sub> and I\u003Csub>Ks\u003C/sub>.\u003C/p>\u003Cp class=\"mb15\">Taking all the data together, all the examined drugs inhibited the hERG channel current in both donor- and SQT1-hiPSC-CMs. The inhibition by each drug was reduced in SQT1-cells. Though the tested drugs displayed some differences regarding effects on the hERG channel gating kinetics in donor or SQT1-hiPSC-CMs, we observed important features, i.e., 1) quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine reduced the window current in SQT1-hiPSC-CMs, 2) quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine increased the time constant of deactivation (the speed of deactivation was reduced). Since quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine showed APD-prolonging and antiarrhythmic effects in SQT1-hiPSC-CMs (\u003Ca href=\"#B84\">Zhao et al., 2019\u003C/a>), we assume that the window current-reducing and deactivation-slowing effect may be important for antiarrhythmic effects of drugs in SQT1-paptient with hERG mutation, at least with a N588K mutation.\u003C/p>\u003Cp class=\"mb15\">Notably, all the seven drugs tested in this study have effects on multiple ion channels (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>). Theoretically, either an enhancement of inward current or a suppression of outward current or both can prolong APD/QTc. Therefore, the effects of quinidine, ajmaline, ivabradine and mexiletine on ion channel currents other than I\u003Csub>Kr\u003C/sub> may also contribute to their APD/QTc-prolonging and antiarrhythmic effects.\u003C/p>\u003Cp class=\"mb15\">The concentrations of drugs used in the study were higher than that used in patients. The concentrations were selected because they showed noticeable effects (either on I\u003Csub>Kr\u003C/sub> or APD or arrhythmic events) in hiPSC-CMs. The reason for requirement of higher concentration is not clear. Probably, the sensitivity of cells to drugs is reduced due to challenges in cell splitting, single cell isolation or unphysiological cell culture. The high concentration may enhance the toxicity or side effects of a drug and limit the drug application in patients. Besides, cells in other systems express also hERG channels, which may be also inhibited when the drug is used in a SQTS-patient. This may further limit the application of hERG-inhibiting drugs in patients. Therefore, the data from our study cannot be directly translated to clinical use, instead, provide information for designing clinical studies. On the other hand, it is possible that in patients lower concentrations of drugs are required to exert effects same with or similar to that observed in our study. Our hiPSC-CM platform for drug testing can provide possible candidate drugs, but the real efficacy and safe concentrations in patients need to be examined in clinical studies\u003Cstrong>.\u003C/strong>\u003C/p>\u003Cp class=\"mb15\">In summary, we analyzed effects of quinidine, ajmaline, amiodarone, ivabradine, flecainide, mexiletine and ranolazine on hERG channel gating kinetic parameters. We observed that all the tested drugs have some effects on hERG gating parameters in donor or SQT1-hiPSC-CMs (\u003Ca href=\"#T1\">Table 1\u003C/a>), but constant effects on hERG window current and deactivation were detected only in the application of quinidine, ajmaline, ivabradine and mexiletine, which may be one of the reasons for their effective antiarrhythmic effects in SQT1-cells.\u003C/p>\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Conclusion\u003C/h2>\u003Cp class=\"mb15\">From the results we conclude that the window current-reducing and deactivation-slowing effects may be important for the antiarrhythmic effects of drugs in SQT1-paptients with a hERG mutation, at least with a N588K mutation. These findings may help us to search for potential candidate drugs for treating SQT1-patients.\u003C/p>\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Study Limitations\u003C/h2>\u003Cp class=\"mb15\">We recruited only one SQT1-patient and one healthy donor for this study. Differences among individuals cannot be ruled out. Due to the hurdle to find more SQT1-patients with the same mutation, the study focused on cell line from single patient. Therefore, the study may be relevant for personalized medicine, e.g., for planning a therapeutical strategy for this specific SQT-hiPSC-CM donor.\u003C/p>\u003Cp class=\"mb15\">Isogenic control cells were not used in the study. The possibility that the different gene background in heathy donor and SQT1 cells influenced the drug effects cannot be completely excluded.\u003C/p>\u003Cp class=\"mb15\">Since the concentration of drugs used in the study was higher than that used in patients, possible drug toxicity \u003Cem>in vivo\u003C/em> needs to be considered when interpreting the data of the current study.\u003C/p>\u003Cp class=\"mb15\">All the measurements were performed at room temperature. The possible influence of temperature on drug effects was not examined in this study. In previously reported studies with respect to hERG channel current or drug effect on the current, some were performed at room temperature (\u003Ca href=\"#B60\">Sanguinetti et al., 1995\u003C/a>; \u003Ca href=\"#B69\">Trudeau et al., 1995\u003C/a>; \u003Ca href=\"#B66\">Snyders and Chaudhary, 1996\u003C/a>; \u003Ca href=\"#B73\">Wang et al., 1997\u003C/a>; \u003Ca href=\"#B81\">Zhang et al., 1999\u003C/a>; \u003Ca href=\"#B36\">Kiesecker et al., 2004\u003C/a>; \u003Ca href=\"#B12\">Cordeiro et al., 2005\u003C/a>; \u003Ca href=\"#B58\">Rajamani et al., 2008\u003C/a>), some at physiological temperature (37&#x000b0;C) (\u003Ca href=\"#B52\">Paul et al., 2002\u003C/a>; \u003Ca href=\"#B43\">McPate et al., 2008\u003C/a>; \u003Ca href=\"#B44\">Melgari et al., 2015\u003C/a>; \u003Ca href=\"#B45\">Melgari et al., 2015\u003C/a>). It has been shown that hERG channel current is temperature-sensitive (\u003Ca href=\"#B85\">Zhou et al., 1998\u003C/a>; \u003Ca href=\"#B74\">Wang et al., 2003\u003C/a>). This may suggest a possible influence of temperature on drug effects. On the other hand, it is also possible that the temperature influence on drug effects is minor because the temperature-sensitivity of the channel does not mean the drug effect is also temperature-sensitive. The temperature may underestimate or overestimate (amplify) drug effects, but it is also possible that temperature does not change drug effect when temperature changes at certain range. Cs\u003Csup>&#x0002b;\u003C/sup> instead of K\u003Csup>&#x0002b;\u003C/sup> was used as the charge carrier for recording hERG current since Cs\u003Csup>&#x0002b;\u003C/sup> can be conducted by hERG channel but not by other K\u003Csup>&#x0002b;\u003C/sup> channels and hence can separate hERG channel current from other K\u003Csup>&#x0002b;\u003C/sup> currents (\u003Ca href=\"#B63\">Sch&#x000f6;nherr and Heinemann, 1996\u003C/a>; \u003Ca href=\"#B79\">Youm et al., 2004\u003C/a>; \u003Ca href=\"#B83\">Zhang, 2006\u003C/a>). It was reported that Cs\u003Csup>&#x0002b;\u003C/sup> can slow hERG channel inactivation but has no effect on the channel activation (\u003Ca href=\"#B82\">Zhang et al., 2003\u003C/a>). This suggests a possibility that Cs\u003Csup>&#x0002b;\u003C/sup> may influence some drug effects. It is possible that Cs\u003Csup>&#x0002b;\u003C/sup> may reduce or enhance drug effects, but it is also possible that it has no influence on some drug effects. Taken together, the drug effects shown in this study were detected under unphysiological conditions and therefore need to be examined in more physiological studies in future.\u003C/p>\u003Cp class=\"mb15\">Another limitation may be the immaturity of hiPSC-CMs. The immature hiPSC-CMs possess similarities but also differences compared with adult human cardiomyocytes. As shown before, the expression profile of some ion channels in hiPSC-CMs may be different from that in adult cardiomyocytes and even more, hiPSC-CMs from different cell lines may also show different expression profile of ion channels (\u003Ca href=\"#B7\">Blinova et al., 2017\u003C/a>), which may influence drug effects in hiPSC-CMs. This should be taken into account when interpreting the data.\u003C/p>\u003Cp class=\"mb15\">I\u003Csub>NCX\u003C/sub> is known to have both an inward and an outward component at different phases of APs. Although we reported in \u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a> the drug effects on I\u003Csub>NCX\u003C/sub>, it is not simple speculating on how its activation/inhibition could affect APD following drug administration. This would require a more detailed analysis that is out of the scope of this manuscript.\u003C/p>\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Data Availability Statement\u003C/h2>\u003Cp class=\"mb15\">The original contributions presented in the study are included in the article/\u003Ca href=\"#SM1\">Supplementary Material\u003C/a>, further inquiries can be directed to the corresponding author.\u003C/p>\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Author Contributions\u003C/h2>\u003Cp class=\"mb0\">MH, XL, ZL, XF, ZY, YL and ZZ performed experiments. SL analyzed data. LC, MB, XZ, IA and IE designed the study and wrote the paper.\u003C/p>\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Funding\u003C/h2>\u003Cp class=\"mb0\">This study was supported by the Post-doc of German Center for Cardiovascular Research (DZHK) (81Z0500204) and shared expertise (81X2500208).\u003C/p>\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Conflict of Interest\u003C/h2>\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\u003Cp class=\"mb0\">We gratefully thank C. Liebetrau for excellent technical assistance. We thank the Chinese Scholarship Council (CSC) for the financial support for Mengying Huang, Zhihan Zhao, Xin Li and Xuehui Fan. Excellent technical support by the Stem Cell Unit G&#x000f6;ttingen is acknowledged.\u003C/p>\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\u003Ch2>Supplementary Material\u003C/h2>\u003Cp class=\"mb15\" id=\"SM1\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fphar.2021.675003/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fphar.2021.675003/full&#x00023;supplementary-material\u003C/a>\u003C/p>\u003Ca id=\"h14\" name=\"h14\">\u003C/a>\u003Ch2>References\u003C/h2>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a>Abriel, H., and Rougier, J. S. (2013). &#x003b2;-Blockers in Congenital Short-QT Syndrome as Ion Channel Blockers. \u003Cem>J. Cardiovasc. Electrophysiol.\u003C/em> 24, 1172&#x02013;1174. doi:10.1111/jce.12204\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23890274/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/jce.12204\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=-Blockers+in+Congenital+Short-QT+Syndrome+as+Ion+Channel+Blockers&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a>Antzelevitch, C., Belardinelli, L., Wu, L., Fraser, H., Zygmunt, A. C., Burashnikov, A., et al. (2004a). Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent. \u003Cem>J. Cardiovasc. Pharmacol. Ther.\u003C/em> 9 (Suppl. 1), S65&#x02013;S83. doi:10.1177/107424840400900106\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15378132/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1177/107424840400900106\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Electrophysiologic+Properties+and+Antiarrhythmic+Actions+of+a+Novel+Antianginal+Agent&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a>Antzelevitch, C., Belardinelli, L., Zygmunt, A. C., Burashnikov, A., Di Diego, J. M., Fish, J. M., et al. (2004b). Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent with Antiarrhythmic Properties. \u003Cem>Circulation\u003C/em> 110, 904&#x02013;910. doi:10.1161/01.cir.0000139333.83620.5d\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15302796/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1161/01.cir.0000139333.83620.5d\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Electrophysiological+Effects+of+Ranolazine,+a+Novel+Antianginal+Agent+with+Antiarrhythmic+Properties&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a>Aomine, M. (1988). Does Acute Exposure to Amiodarone Prolong Cardiac Action Potential Duration? \u003Cem>Gen. Pharmacol. Vasc. Syst.\u003C/em> 19, 615&#x02013;619. doi:10.1016/0306-3623(88)90173-5\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1016/0306-3623(88)90173-5\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Does+Acute+Exposure+to+Amiodarone+Prolong+Cardiac+Action+Potential+Duration?&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a>B&#x000e9;barov&#x000e1;, M., Matejovic, P., P&#x000e1;sek, M., Simurdov&#x000e1;, M., and Simurda, J. (2005a). Effect of Ajmaline on Transient Outward Current in Rat Ventricular Myocytes. \u003Cem>Gen. Physiol. Biophys.\u003C/em> 24, 27&#x02013;45. doi:10.1113/expphysiol.2004.029439 \u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effect+of+Ajmaline+on+Transient+Outward+Current+in+Rat+Ventricular+Myocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a>B&#x000e9;barov&#x000e1;, M., Matejovic, P., P&#x000e1;sek, M., Simurdov&#x000e1;, M., and Simurda, J. (2005b). Effect of Ajmaline on Action Potential and Ionic Currents in Rat Ventricular Myocytes. \u003Cem>Gen. Physiol. Biophys.\u003C/em> 24, 311&#x02013;325. doi:10.1113/expphysiol.2005.031096 \u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effect+of+Ajmaline+on+Action+Potential+and+Ionic+Currents+in+Rat+Ventricular+Myocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a>Blinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre, M. P., et al. (2017). Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. \u003Cem>Toxicol. Sci.\u003C/em> 155, 234&#x02013;247. doi:10.1093/toxsci/kfw200\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27701120/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1093/toxsci/kfw200\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Comprehensive+Translational+Assessment+of+Human-Induced+Pluripotent+Stem+Cell+Derived+Cardiomyocytes+for+Evaluating+Drug-Induced+Arrhythmias&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a>Borchard, U., and Boisten, M. (1982). Effect of Flecainide on Action Potentials and Alternating Current-Induced Arrhythmias in Mammalian Myocardium. \u003Cem>J. Cardiovasc. Pharmacol.\u003C/em> 4, 205&#x02013;212. doi:10.1097/00005344-198203000-00007\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/6175802/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1097/00005344-198203000-00007\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effect+of+Flecainide+on+Action+Potentials+and+Alternating+Current-Induced+Arrhythmias+in+Mammalian+Myocardium&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a>Burashnikov, A., Belardinelli, L., and Antzelevitch, C. (2012). Atrial-selective Sodium Channel Block Strategy to Suppress Atrial Fibrillation: Ranolazine versus Propafenone. \u003Cem>J. Pharmacol. Exp. Ther.\u003C/em> 340, 161&#x02013;168. doi:10.1124/jpet.111.186395\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22005044/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1124/jpet.111.186395\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Atrial-selective+Sodium+Channel+Block+Strategy+to+Suppress+Atrial+Fibrillation:+Ranolazine+versus+Propafenone&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a>Caballero, R., Dolz-Gait&#x000f3;n, P., G&#x000f3;mez, R., Amor&#x000f3;s, I., Barana, A., Gonz&#x000e1;lez de la Fuente, M., et al. (2010). Flecainide Increases Kir2.1 Currents by Interacting with Cysteine 311, Decreasing the Polyamine-Induced Rectification. \u003Cem>Proc. Natl. Acad. Sci.\u003C/em> 107, 15631&#x02013;15636. doi:10.1073/pnas.1004021107\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20713726/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1073/pnas.1004021107\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Flecainide+Increases+Kir2.1+Currents+by+Interacting+with+Cysteine+311,+Decreasing+the+Polyamine-Induced+Rectification&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a>Campuzano, O., Sarquella-Brugada, G., Cesar, S., Arbelo, E., Brugada, J., and Brugada, R. (2018). Recent Advances in Short QT Syndrome. \u003Cem>Front. Cardiovasc. Med.\u003C/em> 5, 149. doi:10.3389/fcvm.2018.00149\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30420954/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.3389/fcvm.2018.00149\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Recent+Advances+in+Short+QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a>Cordeiro, J., Brugada, R., Wu, Y., Hong, K., and Dumaine, R. (2005). Modulation of Inactivation by Mutation N588K in KCNH2: A Link to Arrhythmogenesis in Short QT Syndrome. \u003Cem>Cardiovasc. Res.\u003C/em> 67, 498&#x02013;509. doi:10.1016/j.cardiores.2005.02.018\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16039272/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.cardiores.2005.02.018\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modulation+of+Inactivation+by+Mutation+N588K+in+KCNH2:+A+Link+to+Arrhythmogenesis+in+Short+QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a>Cyganek, L., Tiburcy, M., Sekeres, K., Gerstenberg, K., Bohnenberger, H., Lenz, C., et al. (2018). Deep Phenotyping of Human Induced Pluripotent Stem Cell-Derived Atrial and Ventricular Cardiomyocytes. \u003Cem>JCI insight\u003C/em> 3, e99941. doi:10.1172/jci.insight.99941\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29925689/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1172/jci.insight.99941\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Deep+Phenotyping+of+Human+Induced+Pluripotent+Stem+Cell-Derived+Atrial+and+Ventricular+Cardiomyocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a>Davidenko, J. M., Cohen, L., Goodrow, R., and Antzelevitch, C. (1989). Quinidine-induced Action Potential Prolongation, Early Afterdepolarizations, and Triggered Activity in Canine Purkinje Fibers. Effects of Stimulation Rate, Potassium, and Magnesium. \u003Cem>Circulation\u003C/em> 79, 674&#x02013;686. doi:10.1161/01.cir.79.3.674\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/2917391/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1161/01.cir.79.3.674\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Quinidine-induced+Action+Potential+Prolongation,+Early+Afterdepolarizations,+and+Triggered+Activity+in+Canine+Purkinje+Fibers.+Effects+of+Stimulation+Rate,+Potassium,+and+Magnesium&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a>Demontis, G. C., Gargini, C., Paoli, T. G., and Cervetto, L. (2009). Selective Hcn1 Channels Inhibition by Ivabradine in Mouse Rod Photoreceptors. \u003Cem>Invest. Ophthalmol. Vis. Sci.\u003C/em> 50, 1948&#x02013;1955. doi:10.1167/iovs.08-2659\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19060291/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1167/iovs.08-2659\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Selective+Hcn1+Channels+Inhibition+by+Ivabradine+in+Mouse+Rod+Photoreceptors&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a>Du, C., Zhang, Y., El Harchi, A., Dempsey, C. E., and Hancox, J. C. (2014). Ranolazine Inhibition of hERG Potassium Channels: Drug-Pore Interactions and Reduced Potency against Inactivation Mutants. \u003Cem>J. Mol. Cell. Cardiol.\u003C/em> 74, 220&#x02013;230. doi:10.1016/j.yjmcc.2014.05.013\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24877995/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.yjmcc.2014.05.013\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ranolazine+Inhibition+of+hERG+Potassium+Channels:+Drug-Pore+Interactions+and+Reduced+Potency+against+Inactivation+Mutants&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a>El-Battrawy, I., Lan, H., Cyganek, L., Zhao, Z., Li, X., Buljubasic, F., et al. (2018). Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. \u003Cem>J. Am. Heart Assoc.\u003C/em> 7. doi:10.1161/JAHA.117.007394\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29574456/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1161/JAHA.117.007394\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modeling+Short+QT+Syndrome+Using+Human-Induced+Pluripotent+Stem+Cell-Derived+Cardiomyocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a>El-Battrawy, I., Zhao, Z., Lan, H., Sch&#x000fc;nemann, J.-D., Sattler, K., Buljubasic, F., et al. (2018). Estradiol Protection against Toxic Effects of Catecholamine on Electrical Properties in Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes. \u003Cem>Int. J. Cardiol.\u003C/em> 254, 195&#x02013;202. doi:10.1016/j.ijcard.2017.11.007\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29407091/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.ijcard.2017.11.007\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Estradiol+Protection+against+Toxic+Effects+of+Catecholamine+on+Electrical+Properties+in+Human-Induced+Pluripotent+Stem+Cell+Derived+Cardiomyocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a>El-Battrawy, I., Besler, J., Liebe, V., Schimpf, R., T&#x000fc;l&#x000fc;men, E., Rudic, B., et al. (2018). Long-Term Follow-Up of Patients with Short QT Syndrome: Clinical Profile and Outcome. \u003Cem>J. Am. Heart Assoc.\u003C/em> 7, e010073. doi:10.1161/JAHA.118.010073\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30571592/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1161/JAHA.118.010073\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Long-Term+Follow-Up+of+Patients+with+Short+QT+Syndrome:+Clinical+Profile+and+Outcome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a>El-Battrawy, I., Besler, J., Li, X., Lan, H., Zhao, Z., Liebe, V., et al. (2019). Impact of Antiarrhythmic Drugs on the Outcome of Short QT Syndrome. \u003Cem>Front. Pharmacol.\u003C/em> 10, 771. doi:10.3389/fphar.2019.00771\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31427960/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.3389/fphar.2019.00771\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Impact+of+Antiarrhythmic+Drugs+on+the+Outcome+of+Short+QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a>Follmer, C. H., and Colatsky, T. J. (1990). Block of Delayed Rectifier Potassium Current, Ik, by Flecainide and E-4031 in Cat Ventricular Myocytes. \u003Cem>Circulation\u003C/em> 82, 289&#x02013;293. doi:10.1161/01.cir.82.1.289\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/2114236/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1161/01.cir.82.1.289\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Block+of+Delayed+Rectifier+Potassium+Current,+Ik,+by+Flecainide+and+E-4031+in+Cat+Ventricular+Myocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a>Frommeyer, G., Schmidt, M., Clauss, C., Kaese, S., Stypmann, J., Pott, C., et al. (2012). Further Insights into the Underlying Electrophysiological Mechanisms for Reduction of Atrial Fibrillation by Ranolazine in an Experimental Model of Chronic Heart Failure. \u003Cem>Eur. J. Heart Fail.\u003C/em> 14, 1322&#x02013;1331. doi:10.1093/eurjhf/hfs163\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23099358/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1093/eurjhf/hfs163\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Further+Insights+into+the+Underlying+Electrophysiological+Mechanisms+for+Reduction+of+Atrial+Fibrillation+by+Ranolazine+in+an+Experimental+Model+of+Chronic+Heart+Failure&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a>Frommeyer, G., Ellermann, C., Dechering, D. G., Kochh&#x000e4;user, S., B&#x000f6;geholz, N., G&#x000fc;ner, F., et al. (2016). Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome. \u003Cem>J. Cardiovasc. Electrophysiol.\u003C/em> 27, 1214&#x02013;1219. doi:10.1111/jce.13029\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27283775/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/jce.13029\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ranolazine+and+Vernakalant+Prevent+Ventricular+Arrhythmias+in+an+Experimental+Whole-Heart+Model+of+Short+QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a>Frommeyer, G., Weller, J., Ellermann, C., Kaese, S., Kochh&#x000e4;user, S., Lange, P. S., et al. (2017). Antiarrhythmic Properties of Ivabradine in an Experimental Model of Short-QT- Syndrome. \u003Cem>Clin. Exp. Pharmacol. Physiol.\u003C/em> 44, 941&#x02013;945. doi:10.1111/1440-1681.12790\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28556923/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/1440-1681.12790\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Antiarrhythmic+Properties+of+Ivabradine+in+an+Experimental+Model+of+Short-QT-+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a>Frommeyer, G., Garthmann, J., Ellermann, C., Dechering, D. G., Kochh&#x000e4;user, S., Reinke, F., et al. (2018). Broad Antiarrhythmic Effect of Mexiletine in Different Arrhythmia Models. \u003Cem>Electrophysiol. Eur. Soc. Cardiol.\u003C/em> 20, 1375&#x02013;1381. doi:10.1093/europace/eux221\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1093/europace/eux221\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Broad+Antiarrhythmic+Effect+of+Mexiletine+in+Different+Arrhythmia+Models&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a>Gaita, F., Giustetto, C., Bianchi, F., Schimpf, R., Haissaguerre, M., Cal&#x000f2;, L., et al. (2004). Short QT Syndrome: Pharmacological Treatment. \u003Cem>J. Am. Coll. Cardiol.\u003C/em> 43, 1494&#x02013;1499. doi:10.1016/j.jacc.2004.02.034\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15093889/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.jacc.2004.02.034\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Short+QT+Syndrome:+Pharmacological+Treatment&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a>Giustetto, C., Schimpf, R., Mazzanti, A., Scrocco, C., Maury, P., Anttonen, O., et al. (2011). Long-term Follow-Up of Patients with Short QT Syndrome. \u003Cem>J. Am. Coll. Cardiol.\u003C/em> 58, 587&#x02013;595. doi:10.1016/j.jacc.2011.03.038\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21798421/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.jacc.2011.03.038\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Long-term+Follow-Up+of+Patients+with+Short+QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a>Gualdani, R., Tadini-Buoninsegni, F., Roselli, M., Defrenza, I., Contino, M., Colabufo, N. A., et al. (2015). Inhibition of hERG Potassium Channel by the Antiarrhythmic Agent Mexiletine and its Metabolite M-Hydroxymexiletine. \u003Cem>Pharmacol. Res. Perspect.\u003C/em> 3, e00160. doi:10.1002/prp2.160\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26516576/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1002/prp2.160\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibition+of+hERG+Potassium+Channel+by+the+Antiarrhythmic+Agent+Mexiletine+and+its+Metabolite+M-Hydroxymexiletine&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a>Guo, F., Sun, Y., Wang, X., Wang, H., Wang, J., Gong, T., et al. (2019). Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome. \u003Cem>Circ. Res.\u003C/em> 124, 66&#x02013;78. doi:10.1161/circresaha.118.313518\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30582453/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1161/circresaha.118.313518\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Patient-Specific+and+Gene-Corrected+Induced+Pluripotent+Stem+Cell-Derived+Cardiomyocytes+Elucidate+Single-Cell+Phenotype+of+Short+QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a>Gussak, I., Brugada, P., Brugada, J., Wright, R. S., Kopecky, S. L., Chaitman, B. R., et al. (2000). Idiopathic Short QT Interval:A New Clinical Syndrome? \u003Cem>Cardiology\u003C/em> 94, 99&#x02013;102. doi:10.1159/000047299\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11173780/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1159/000047299\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Idiopathic+Short+QT+Interval:A+New+Clinical+Syndrome?&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a>Haechl, N., Ebner, J., Hilber, K., Todt, H., and Koenig, X. (2019). Pharmacological Profile of the Bradycardic Agent Ivabradine on Human Cardiac Ion Channels. \u003Cem>Cell Physiol Biochem\u003C/em> 53, 36&#x02013;48. doi:10.33594/000000119\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31169990/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.33594/000000119\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Pharmacological+Profile+of+the+Bradycardic+Agent+Ivabradine+on+Human+Cardiac+Ion+Channels&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a>Imaizumi, Y., and Giles, W. R. (1987). Quinidine-induced Inhibition of Transient Outward Current in Cardiac Muscle. \u003Cem>Am. J. Physiology-Heart Circulatory Physiol.\u003C/em> 253, H704&#x02013;H708. doi:10.1152/ajpheart.1987.253.3.h704\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1152/ajpheart.1987.253.3.h704\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Quinidine-induced+Inhibition+of+Transient+Outward+Current+in+Cardiac+Muscle&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a>Iwamoto, T., Watanabe, Y., Kita, S., and Blaustein, M. (2007). Na&#x0002b;/Ca2&#x0002b; Exchange Inhibitors: a New Class of Calcium Regulators. \u003Cem>Chddt\u003C/em> 7, 188&#x02013;198. doi:10.2174/187152907781745288\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.2174/187152907781745288\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Na+/Ca2++Exchange+Inhibitors:+a+New+Class+of+Calcium+Regulators&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a>J&#x000e6;ger, K. H., Wall, S., and Tveito, A. (2021). Computational Prediction of Drug Response in Short QT Syndrome Type 1 Based on Measurements of Compound Effect in Stem Cell-Derived Cardiomyocytes. \u003Cem>Plos Comput. Biol.\u003C/em> 17, e1008089. doi:10.1371/journal.pcbi.1008089\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33591962/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1371/journal.pcbi.1008089\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Computational+Prediction+of+Drug+Response+in+Short+QT+Syndrome+Type+1+Based+on+Measurements+of+Compound+Effect+in+Stem+Cell-Derived+Cardiomyocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a>Khodorov, B. I., and Zaborovskaya, L. D. (1983). Blockade of Sodium and Potassium Channels in the Node of Ranvier by Ajmaline and N-Propyl Ajmaline. \u003Cem>Gen. Physiol. Biophys.\u003C/em> 2, 233&#x02013;268.\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/6088360/\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Blockade+of+Sodium+and+Potassium+Channels+in+the+Node+of+Ranvier+by+Ajmaline+and+N-Propyl+Ajmaline&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a>Kiesecker, C., Zitron, E., L&#x000fc;ck, S., Bloehs, R., Scholz, E. P., Kath&#x000f6;fer, S., et al. (2004). Class Ia Anti-arrhythmic Drug Ajmaline Blocks HERG Potassium Channels: Mode of Action. \u003Cem>Naunyn-schmiedeberg&#x00027;s Arch. Pharmacol.\u003C/em> 370, 423&#x02013;435. doi:10.1007/s00210-004-0976-8\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15599706/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1007/s00210-004-0976-8\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Class+Ia+Anti-arrhythmic+Drug+Ajmaline+Blocks+HERG+Potassium+Channels:+Mode+of+Action&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a>Koepple, C., Scherer, D., Seyler, C., Scholz, E., Thomas, D., Katus, H. A., et al. (2017). Dual Mechanism for Inhibition of Inwardly Rectifying Kir2.X Channels by Quinidine Involving Direct Pore Block and PIP2-Interference. \u003Cem>J. Pharmacol. Exp. Ther.\u003C/em> 361, 209&#x02013;218. doi:10.1124/jpet.116.238287\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28188270/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1124/jpet.116.238287\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Dual+Mechanism+for+Inhibition+of+Inwardly+Rectifying+Kir2.X+Channels+by+Quinidine+Involving+Direct+Pore+Block+and+PIP2-Interference&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a>Koncz, I., Sz&#x000e9;l, T., Bitay, M., Cerbai, E., Jaeger, K., F&#x000fc;l&#x000f6;p, F., et al. (2011). Electrophysiological Effects of Ivabradine in Dog and Human Cardiac Preparations: Potential Antiarrhythmic Actions. \u003Cem>Eur. J. Pharmacol.\u003C/em> 668, 419&#x02013;426. doi:10.1016/j.ejphar.2011.07.025\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21821019/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.ejphar.2011.07.025\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Electrophysiological+Effects+of+Ivabradine+in+Dog+and+Human+Cardiac+Preparations:+Potential+Antiarrhythmic+Actions&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a>Lan, H., Xu, Q., El-Battrawy, I., Zhong, R., Li, X., Lang, S., et al. (2020). Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1. \u003Cem>Front. Pharmacol.\u003C/em> 11, 554422. doi:10.3389/fphar.2020.554422\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33154722/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.3389/fphar.2020.554422\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ionic+Mechanisms+of+Disopyramide+Prolonging+Action+Potential+Duration+in+Human-Induced+Pluripotent+Stem+Cell-Derived+Cardiomyocytes+from+a+Patient+with+Short+QT+Syndrome+Type+1&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a>Lees-Miller, J. P., Guo, J., Wang, Y., Perissinotti, L. L., Noskov, S. Y., and Duff, H. J. (2015). Ivabradine Prolongs Phase 3 of Cardiac Repolarization and Blocks the hERG1 (KCNH2) Current over a Concentration-Range Overlapping with that Required to Block HCN4. \u003Cem>J. Mol. Cell. Cardiol.\u003C/em> 85, 71&#x02013;78. doi:10.1016/j.yjmcc.2015.05.009\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25986146/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.yjmcc.2015.05.009\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ivabradine+Prolongs+Phase+3+of+Cardiac+Repolarization+and+Blocks+the+hERG1+(KCNH2)+Current+over+a+Concentration-Range+Overlapping+with+that+Required+to+Block+HCN4&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a>Matsuo, S., Kishida, H., Munakata, K., and Atarashi, H. (1985). The Effects of Mexiletine on Action Potential Duration and its Restitution in guinea Pig Ventricular Muscles. \u003Cem>Jpn. Heart J.\u003C/em> 26, 271&#x02013;287. doi:10.1536/ihj.26.271\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/4009969/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1536/ihj.26.271\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=The+Effects+of+Mexiletine+on+Action+Potential+Duration+and+its+Restitution+in+guinea+Pig+Ventricular+Muscles&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a>Mazzanti, A., Maragna, R., Vacanti, G., Kostopoulou, A., Marino, M., Monteforte, N., et al. (2017). Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients with Short QT Syndrome. \u003Cem>J. Am. Coll. Cardiol.\u003C/em> 70, 3010&#x02013;3015. doi:10.1016/j.jacc.2017.10.025\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29241489/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.jacc.2017.10.025\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Hydroquinidine+Prevents+Life-Threatening+Arrhythmic+Events+in+Patients+with+Short+QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a>McPate, M. J., Duncan, R. S., Hancox, J. C., and Witchel, H. J. (2008). Pharmacology of the Short QT Syndrome N588K-hERG K&#x0002b; Channel Mutation: Differential Impact on Selected Class I and Class III Antiarrhythmic Drugs. \u003Cem>Br. J. Pharmacol.\u003C/em> 155, 957&#x02013;966. doi:10.1038/bjp.2008.325\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18724381/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1038/bjp.2008.325\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Pharmacology+of+the+Short+QT+Syndrome+N588K-hERG+K++Channel+Mutation:+Differential+Impact+on+Selected+Class+I+and+Class+III+Antiarrhythmic+Drugs&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a>Melgari, D., Brack, K. E., Zhang, C., Zhang, Y., El Harchi, A., Mitcheson, J. S., et al. (2015). hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine. \u003Cem>J. Am. Heart Assoc.\u003C/em> 4, e001813. doi:10.1161/jaha.115.001813\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25911606/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1161/jaha.115.001813\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=hERG+Potassium+Channel+Blockade+by+the+HCN+Channel+Inhibitor+Bradycardic+Agent+Ivabradine&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a>Melgari, D., Zhang, Y., El Harchi, A., Dempsey, C. E., and Hancox, J. C. (2015). Molecular Basis of hERG Potassium Channel Blockade by the Class Ic Antiarrhythmic Flecainide. \u003Cem>J. Mol. Cell. Cardiol.\u003C/em> 86, 42&#x02013;53. doi:10.1016/j.yjmcc.2015.06.021\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26159617/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.yjmcc.2015.06.021\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Molecular+Basis+of+hERG+Potassium+Channel+Blockade+by+the+Class+Ic+Antiarrhythmic+Flecainide&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a>Michel, D., Wegener, J. W., and Nawrath, H. (2002). Effects of Quinine and Quinidine on the Transient Outward and on the L-type Ca2&#x0002b; Current in Rat Ventricular Cardiomyocytes. \u003Cem>Pharmacology\u003C/em> 65, 187&#x02013;192. doi:10.1159/000064342\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12180412/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1159/000064342\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effects+of+Quinine+and+Quinidine+on+the+Transient+Outward+and+on+the+L-type+Ca2++Current+in+Rat+Ventricular+Cardiomyocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B47\" id=\"B47\">\u003C/a>Milberg, P., Tegelkamp, R., Osada, N., Schimpf, R., Wolpert, C., Breithardt, G., et al. (2007). Reduction of Dispersion of Repolarization and Prolongation of Postrepolarization Refractoriness Explain the Antiarrhythmic Effects of Quinidine in a Model of Short QT Syndrome. \u003Cem>J. Cardiovasc. Electrophysiol.\u003C/em> 18, 658&#x02013;664. doi:10.1111/j.1540-8167.2007.00813.x\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17521304/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/j.1540-8167.2007.00813.x\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Reduction+of+Dispersion+of+Repolarization+and+Prolongation+of+Postrepolarization+Refractoriness+Explain+the+Antiarrhythmic+Effects+of+Quinidine+in+a+Model+of+Short+QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B48\" id=\"B48\">\u003C/a>Miller, D. C., Harmer, S. C., Poliandri, A., Nobles, M., Edwards, E. C., Ware, J. S., et al. (2017). Ajmaline Blocks I Na and I Kr without Eliciting Differences between Brugada Syndrome Patient and Control Human Pluripotent Stem Cell-Derived Cardiac Clusters. \u003Cem>Stem Cel. Res.\u003C/em> 25, 233&#x02013;244. doi:10.1016/j.scr.2017.11.003\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1016/j.scr.2017.11.003\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ajmaline+Blocks+I+Na+and+I+Kr+without+Eliciting+Differences+between+Brugada+Syndrome+Patient+and+Control+Human+Pluripotent+Stem+Cell-Derived+Cardiac+Clusters&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B49\" id=\"B49\">\u003C/a>Mitcheson, J. S., and Hancox, J. C. (1997). Modulation by Mexiletine of Action Potentials, L-type Ca Current and Delayed Rectifier K Current Recorded from Isolated Rabbit Atrioventricular Nodal Myocytes. \u003Cem>Pflugers Archiv Eur. J. Physiol.\u003C/em> 434, 855&#x02013;858. doi:10.1007/s004240050476\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/9306023/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1007/s004240050476\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modulation+by+Mexiletine+of+Action+Potentials,+L-type+Ca+Current+and+Delayed+Rectifier+K+Current+Recorded+from+Isolated+Rabbit+Atrioventricular+Nodal+Myocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B50\" id=\"B50\">\u003C/a>Mizobuchi, M., Enjoji, Y., Yamamoto, R., Ono, T., Funatsu, A., Kambayashi, D., et al. (2008). Nifekalant and Disopyramide in a Patient with Short QT Syndrome: Evaluation of Pharmacological Effects and Electrophysiological Properties. \u003Cem>Pacing Clin. Electrophysiol. : PACE\u003C/em> 31, 1229&#x02013;1232. doi:10.1111/j.1540-8159.2008.01169.x\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18834480/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/j.1540-8159.2008.01169.x\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Nifekalant+and+Disopyramide+in+a+Patient+with+Short+QT+Syndrome:+Evaluation+of+Pharmacological+Effects+and+Electrophysiological+Properties&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B51\" id=\"B51\">\u003C/a>Nishida, A., Takizawa, T., Matsumoto, A., Miki, T., Seino, S., and Nakaya, H. (2011). Inhibition of ATP-Sensitive K&#x0002b; Channels and L-type Ca2&#x0002b; Channels by Amiodarone Elicits Contradictory Effect on Insulin Secretion in MIN6 Cells. \u003Cem>J. Pharmacol. Sci.\u003C/em> 116, 73&#x02013;80. doi:10.1254/jphs.10294fp\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21512308/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1254/jphs.10294fp\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibition+of+ATP-Sensitive+K++Channels+and+L-type+Ca2++Channels+by+Amiodarone+Elicits+Contradictory+Effect+on+Insulin+Secretion+in+MIN6+Cells&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B52\" id=\"B52\">\u003C/a>Paul, A. A., Witchel, H. J., and Hancox, J. C. (2002). Inhibition of the Current of Heterologously Expressed HERG Potassium Channels by Flecainide and Comparison with Quinidine, Propafenone and Lignocaine. \u003Cem>Br. J. Pharmacol.\u003C/em> 136, 717&#x02013;729. doi:10.1038/sj.bjp.0704784\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12086981/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1038/sj.bjp.0704784\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibition+of+the+Current+of+Heterologously+Expressed+HERG+Potassium+Channels+by+Flecainide+and+Comparison+with+Quinidine,+Propafenone+and+Lignocaine&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B53\" id=\"B53\">\u003C/a>Perrin, M. J., Kuchel, P. W., Campbell, T. J., and Vandenberg, J. I. (2008). Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-&#x000c0;-Go-Go-Related Gene Channels. \u003Cem>Mol. Pharmacol.\u003C/em> 74, 1443&#x02013;1452. doi:10.1124/mol.108.049056\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18701618/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1124/mol.108.049056\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Drug+Binding+to+the+Inactivated+State+Is+Necessary+but+Not+Sufficient+for+High-Affinity+Binding+to+Human+Ether--Go-Go-Related+Gene+Channels&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B54\" id=\"B54\">\u003C/a>Priori, S. G., Blomstr&#x000f6;m-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., et al. (2015). 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). \u003Cem>Europace\u003C/em> 17, 1601&#x02013;1687. doi:10.1093/europace/euv319\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26318695/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1093/europace/euv319\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=2015+ESC+Guidelines+for+the+Management+of+Patients+with+Ventricular+Arrhythmias+and+the+Prevention+of+Sudden+Cardiac+Death:+The+Task+Force+for+the+Management+of+Patients+with+Ventricular+Arrhythmias+and+the+Prevention+of+Sudden+Cardiac+Death+of+the+European+Society+of+Cardiology+(ESC)Endorsed+by:+Association+for+European+Paediatric+and+Congenital+Cardiology+(AEPC)&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B55\" id=\"B55\">\u003C/a>Pugsley, M. K., Walker, M. J., and Saint, D. A. (2005). Block of NA&#x0002b; and K&#x0002b; Currents in Rat Ventricular Myocytes by Quinacainol and Quinidine. \u003Cem>Clin. Exp. Pharmacol. Physiol.\u003C/em> 32, 60&#x02013;65. doi:10.1111/j.1440-1681.2005.04149.x\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15730436/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/j.1440-1681.2005.04149.x\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Block+of+NA++and+K++Currents+in+Rat+Ventricular+Myocytes+by+Quinacainol+and+Quinidine&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B56\" id=\"B56\">\u003C/a>Qian, C., Ma, J., Zhang, P., Luo, A., Wang, C., Ren, Z., et al. (2012). Resveratrol Attenuates the Na(&#x0002b;)-dependent Intracellular Ca(2&#x0002b;) Overload by Inhibiting H(2)O(2)-induced Increase in Late Sodium Current in Ventricular Myocytes. \u003Cem>PloS one\u003C/em> 7, e51358. doi:10.1371/journal.pone.0051358\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23272101/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1371/journal.pone.0051358\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Resveratrol+Attenuates+the+Na(+)-dependent+Intracellular+Ca(2+)+Overload+by+Inhibiting+H(2)O(2)-induced+Increase+in+Late+Sodium+Current+in+Ventricular+Myocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B57\" id=\"B57\">\u003C/a>Rahm, A.-K., M&#x000fc;ller, M. E., Gramlich, D., Lugenbiel, P., Uludag, E., Rivinius, R., et al. (2020). Inhibition of Cardiac Kv4.3 (Ito) Channel Isoforms by Class I Antiarrhythmic Drugs Lidocaine and Mexiletine. \u003Cem>Eur. J. Pharmacol.\u003C/em> 880, 173159. doi:10.1016/j.ejphar.2020.173159\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32360350/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.ejphar.2020.173159\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibition+of+Cardiac+Kv4.3+(Ito)+Channel+Isoforms+by+Class+I+Antiarrhythmic+Drugs+Lidocaine+and+Mexiletine&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B58\" id=\"B58\">\u003C/a>Rajamani, S., Shryock, J. C., and Belardinelli, L. (2008). Rapid Kinetic Interactions of Ranolazine with HERG K&#x0002b; Current. \u003Cem>J. Cardiovasc. Pharmacol.\u003C/em> 51, 581&#x02013;589. doi:10.1097/fjc.0b013e3181799690\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18520952/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1097/fjc.0b013e3181799690\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Rapid+Kinetic+Interactions+of+Ranolazine+with+HERG+K++Current&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B59\" id=\"B59\">\u003C/a>Salvage, S. C., Chandrasekharan, K. H., Jeevaratnam, K., Dulhunty, A. F., Thompson, A. J., Jackson, A. P., et al. (2018). Multiple Targets for Flecainide Action: Implications for Cardiac Arrhythmogenesis. \u003Cem>Br. J. Pharmacol.\u003C/em> 175, 1260&#x02013;1278. doi:10.1111/bph.13807\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28369767/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/bph.13807\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Multiple+Targets+for+Flecainide+Action:+Implications+for+Cardiac+Arrhythmogenesis&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B60\" id=\"B60\">\u003C/a>Sanguinetti, M. C., Jiang, C., Curran, M. E., and Keating, M. T. (1995). A Mechanistic Link between an Inherited and an Acquird Cardiac Arrthytmia: HERG Encodes the IKr Potassium Channel. \u003Cem>Cell\u003C/em> 81, 299&#x02013;307. doi:10.1016/0092-8674(95)90340-2\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7736582/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/0092-8674(95)90340-2\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=A+Mechanistic+Link+between+an+Inherited+and+an+Acquird+Cardiac+Arrthytmia:+HERG+Encodes+the+IKr+Potassium+Channel&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B61\" id=\"B61\">\u003C/a>Sasaki, N., Watanabe, I., Kogawa, R., Sonoda, K., Takahashi, K., Okumura, Y., et al. (2014). Effects of Intravenous Amiodarone and Ibutilide on Action Potential Duration and Atrial Conduction Kinetics in Patients with Persistent Atrial Fibrillation. \u003Cem>Int. Heart J.\u003C/em> 55, 244&#x02013;248. doi:10.1536/ihj.13-254\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24806377/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1536/ihj.13-254\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Effects+of+Intravenous+Amiodarone+and+Ibutilide+on+Action+Potential+Duration+and+Atrial+Conduction+Kinetics+in+Patients+with+Persistent+Atrial+Fibrillation&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B62\" id=\"B62\">\u003C/a>Sato, T., Shigematsu, S., and Arita, M. (1995). Mexiletine-induced Shortening of the Action Potential Duration of Ventricular Muscles by Activation of ATP-Sensitive K&#x0002b; Channels. \u003Cem>Br. J. Pharmacol.\u003C/em> 115, 381&#x02013;382. doi:10.1111/j.1476-5381.1995.tb16342.x\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7582444/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/j.1476-5381.1995.tb16342.x\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Mexiletine-induced+Shortening+of+the+Action+Potential+Duration+of+Ventricular+Muscles+by+Activation+of+ATP-Sensitive+K++Channels&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B63\" id=\"B63\">\u003C/a>Sch&#x000f6;nherr, R., and Heinemann, S. H. (1996). Molecular Determinants for Activation and Inactivation of HERG, a Human Inward Rectifier Potassium Channel. \u003Cem>J. Physiol.\u003C/em> 493 (Pt 3), 635&#x02013;642. doi:10.1113/jphysiol.1996.sp021410\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/8799887/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1113/jphysiol.1996.sp021410\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Molecular+Determinants+for+Activation+and+Inactivation+of+HERG,+a+Human+Inward+Rectifier+Potassium+Channel&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B64\" id=\"B64\">\u003C/a>Schram, G., Zhang, L., Derakhchan, K., Ehrlich, J. R., Belardinelli, L., and Nattel, S. (2004). Ranolazine: Ion-Channel-Blocking Actions and In Vivo Electrophysiological Effects. \u003Cem>Br. J. Pharmacol.\u003C/em> 142, 1300&#x02013;1308. doi:10.1038/sj.bjp.0705879\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15277312/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1038/sj.bjp.0705879\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Ranolazine:+Ion-Channel-Blocking+Actions+and+In+Vivo+Electrophysiological+Effects&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B65\" id=\"B65\">\u003C/a>Shinnawi, R., Shaheen, N., Huber, I., Shiti, A., Arbel, G., Gepstein, A., et al. (2019). Modeling Reentry in the Short QT Syndrome with Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets. \u003Cem>J. Am. Coll. Cardiol.\u003C/em> 73, 2310&#x02013;2324. doi:10.1016/j.jacc.2019.02.055\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31072576/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.jacc.2019.02.055\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modeling+Reentry+in+the+Short+QT+Syndrome+with+Human-Induced+Pluripotent+Stem+Cell-Derived+Cardiac+Cell+Sheets&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B66\" id=\"B66\">\u003C/a>Snyders, D. J., and Chaudhary, A. (1996). High Affinity Open Channel Block by Dofetilide of HERG Expressed in a Human Cell Line. \u003Cem>Mol. Pharmacol.\u003C/em> 49, 949&#x02013;955.\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/8649354/\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=High+Affinity+Open+Channel+Block+by+Dofetilide+of+HERG+Expressed+in+a+Human+Cell+Line&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B67\" id=\"B67\">\u003C/a>Suzuki, T., Morishima, M., Kato, S., Ueda, N., Honjo, H., and Kamiya, K. (2013). Atrial Selectivity in Na&#x0002b;channel Blockade by Acute Amiodarone. \u003Cem>Cardiovasc. Res.\u003C/em> 98, 136&#x02013;144. doi:10.1093/cvr/cvt007\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23341577/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1093/cvr/cvt007\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Atrial+Selectivity+in+Na+channel+Blockade+by+Acute+Amiodarone&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B68\" id=\"B68\">\u003C/a>Thorsen, K., Dam, V. S., Kjaer-Sorensen, K., Pedersen, L. N., Skeberdis, V. A., Jurevicius, J., et al. (2017). Loss-of-activity-mutation in the Cardiac Chloride-Bicarbonate Exchanger AE3 Causes Short QT Syndrome. \u003Cem>Nat. Commun.\u003C/em> 8, 1696. doi:10.1038/s41467-017-01630-0\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29167417/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1038/s41467-017-01630-0\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Loss-of-activity-mutation+in+the+Cardiac+Chloride-Bicarbonate+Exchanger+AE3+Causes+Short+QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B69\" id=\"B69\">\u003C/a>Trudeau, M., Warmke, J., Ganetzky, B., and Robertson, G. (1995). HERG, a Human Inward Rectifier in the Voltage-Gated Potassium Channel Family. \u003Cem>Science\u003C/em> 269, 92&#x02013;95. doi:10.1126/science.7604285\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7604285/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1126/science.7604285\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=HERG,+a+Human+Inward+Rectifier+in+the+Voltage-Gated+Potassium+Channel+Family&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B70\" id=\"B70\">\u003C/a>Undrovinas, A. I., Burnashev, N., Eroshenko, D., Fleidervish, I., Starmer, C. F., Makielski, J. C., et al. (1990). Quinidine Blocks Adenosine 5&#x00027;-Triphosphate-Sensitive Potassium Channels in Heart. \u003Cem>Am. J. Physiology-Heart Circulatory Physiol.\u003C/em> 259, H1609&#x02013;H1612. doi:10.1152/ajpheart.1990.259.5.h1609\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1152/ajpheart.1990.259.5.h1609\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Quinidine+Blocks+Adenosine+5'-Triphosphate-Sensitive+Potassium+Channels+in+Heart&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B71\" id=\"B71\">\u003C/a>Wang, Z., Fermini, B., and Nattel, S. (1993). Mechanism of Flecainide&#x00027;s Rate-dependent Actions on Action Potential Duration in Canine Atrial Tissue. \u003Cem>J. Pharmacol. Exp. Ther.\u003C/em> 267, 575&#x02013;581.\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/8246130/\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Mechanism+of+Flecainide's+Rate-dependent+Actions+on+Action+Potential+Duration+in+Canine+Atrial+Tissue&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B72\" id=\"B72\">\u003C/a>Wang, D., Kiyosue, T., Sato, T., and Arita, M. (1996). Comparison of the Effects of Class I Anti-arrhythmic Drugs, Cibenzoline, Mexiletine and Flecainide, on the Delayed Rectifier K&#x0002b;Current of Guinea-pig Ventricular Myocytes. \u003Cem>J. Mol. Cell. Cardiol.\u003C/em> 28, 893&#x02013;903. doi:10.1006/jmcc.1996.0084\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/8762029/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1006/jmcc.1996.0084\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Comparison+of+the+Effects+of+Class+I+Anti-arrhythmic+Drugs,+Cibenzoline,+Mexiletine+and+Flecainide,+on+the+Delayed+Rectifier+K+Current+of+Guinea-pig+Ventricular+Myocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B73\" id=\"B73\">\u003C/a>Wang, S., Liu, S., Morales, M. J., Strauss, H. C., and Rasmusson, R. L. (1997). A Quantitative Analysis of the Activation and Inactivation Kinetics of HERG Expressed in \u003Cem>Xenopus\u003C/em> Oocytes. \u003Cem>J. Physiol.\u003C/em> 502 (Pt 1), 45&#x02013;60. doi:10.1111/j.1469-7793.1997.045bl.x\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/9234196/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/j.1469-7793.1997.045bl.x\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=A+Quantitative+Analysis+of+the+Activation+and+Inactivation+Kinetics+of+HERG+Expressed+in+Xenopus+Oocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B74\" id=\"B74\">\u003C/a>Wang, J., Della Penna, K., Wang, H., Karczewski, J., Connolly, T. M., Koblan, K. S., et al. (2003). Functional and Pharmacological Properties of Canine ERG Potassium Channels. \u003Cem>Am. J. Physiology-Heart Circulatory Physiol.\u003C/em> 284, H256&#x02013;H267. doi:10.1152/ajpheart.00220.2002\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12388285/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1152/ajpheart.00220.2002\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Functional+and+Pharmacological+Properties+of+Canine+ERG+Potassium+Channels&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B75\" id=\"B75\">\u003C/a>Watanabe, Y. (2019). Cardiac Na&#x0002b;/Ca2&#x0002b; Exchange Stimulators Among Cardioprotective Drugs. \u003Cem>J. Physiol. Sci.\u003C/em> 69, 837&#x02013;849. doi:10.1007/s12576-019-00721-5\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31664641/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1007/s12576-019-00721-5\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Cardiac+Na+/Ca2++Exchange+Stimulators+Among+Cardioprotective+Drugs&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B76\" id=\"B76\">\u003C/a>Wu, L., Shryock, J. C., Song, Y., Li, Y., Antzelevitch, C., and Belardinelli, L. (2004). Antiarrhythmic Effects of Ranolazine in a guinea Pig In Vitro Model of Long-QT Syndrome. \u003Cem>J. Pharmacol. Exp. Ther.\u003C/em> 310, 599&#x02013;605. doi:10.1124/jpet.104.066100\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15031300/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1124/jpet.104.066100\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Antiarrhythmic+Effects+of+Ranolazine+in+a+guinea+Pig+In+Vitro+Model+of+Long-QT+Syndrome&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B77\" id=\"B77\">\u003C/a>Yang, T., Kanki, H., Zhang, W., and Roden, D. M. (2009). Probing the Mechanisms Underlying Modulation of Quinidine Sensitivity to Cardiac IKsblock by Protein Kinase A-Mediated IKsphosphorylation. \u003Cem>Br. J. Pharmacol.\u003C/em> 157, 952&#x02013;961. doi:10.1111/j.1476-5381.2009.00293.x\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19522859/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1111/j.1476-5381.2009.00293.x\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Probing+the+Mechanisms+Underlying+Modulation+of+Quinidine+Sensitivity+to+Cardiac+IKsblock+by+Protein+Kinase+A-Mediated+IKsphosphorylation&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B78\" id=\"B78\">\u003C/a>Yonemizu, S., Masuda, K., Kurata, Y., Notsu, T., Higashi, Y., Fukumura, K., et al. (2019). Inhibitory Effects of Class I Antiarrhythmic Agents on Na&#x0002b; and Ca2&#x0002b; Currents of Human iPS Cell-Derived Cardiomyocytes. \u003Cem>Regenerative Ther.\u003C/em> 10, 104&#x02013;111. doi:10.1016/j.reth.2018.12.002\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30766898/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/j.reth.2018.12.002\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Inhibitory+Effects+of+Class+I+Antiarrhythmic+Agents+on+Na++and+Ca2++Currents+of+Human+iPS+Cell-Derived+Cardiomyocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B79\" id=\"B79\">\u003C/a>Youm, J. B., Earm, Y. E., and Ho, W. K. (2004). Modulation of HERG Channel Inactivation by External Cations. \u003Cem>Eur. Biophys. J. : EBJ\u003C/em> 33, 360&#x02013;369. doi:10.1007/s00249-003-0367-y\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/14586519/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1007/s00249-003-0367-y\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modulation+of+HERG+Channel+Inactivation+by+External+Cations&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B80\" id=\"B80\">\u003C/a>Yunoki, T., Teramoto, N., Naito, S., and Ito, Y. (2001). The Effects of Flecainide on ATP-Sensitive K&#x0002b; Channels in Pig Urethral Myocytes. \u003Cem>Br. J. Pharmacol.\u003C/em> 133, 730&#x02013;738. doi:10.1038/sj.bjp.0704109\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11429398/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1038/sj.bjp.0704109\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=The+Effects+of+Flecainide+on+ATP-Sensitive+K++Channels+in+Pig+Urethral+Myocytes&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B81\" id=\"B81\">\u003C/a>Zhang, S., Zhou, Z., Gong, Q., Makielski, J. C., and January, C. T. (1999). Mechanism of Block and Identification of the Verapamil Binding Domain to HERG Potassium Channels. \u003Cem>Circ. Res.\u003C/em> 84, 989&#x02013;998. doi:10.1161/01.res.84.9.989\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/10325236/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1161/01.res.84.9.989\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Mechanism+of+Block+and+Identification+of+the+Verapamil+Binding+Domain+to+HERG+Potassium+Channels&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B82\" id=\"B82\">\u003C/a>Zhang, S., Kehl, S. J., and Fedida, D. (2003). Modulation of Human Ether-A-Go-Go-Related K&#x0002b; (HERG) Channel Inactivation by Cs&#x0002b; and K&#x0002b;. \u003Cem>J. Physiol.\u003C/em> 548, 691&#x02013;702. doi:10.1113/jphysiol.2003.039198\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12626667/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1113/jphysiol.2003.039198\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Modulation+of+Human+Ether-A-Go-Go-Related+K++(HERG)+Channel+Inactivation+by+Cs++and+K+&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B83\" id=\"B83\">\u003C/a>Zhang, S. (2006). Isolation and Characterization of IKr in Cardiac Myocytes by Cs&#x0002b; Permeation. \u003Cem>Am. J. Physiology-Heart Circulatory Physiol.\u003C/em> 290, H1038&#x02013;H1049. doi:10.1152/ajpheart.00679.2005\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1152/ajpheart.00679.2005\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Isolation+and+Characterization+of+IKr+in+Cardiac+Myocytes+by+Cs++Permeation&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B84\" id=\"B84\">\u003C/a>Zhao, Z., Li, X., El&#x02010;Battrawy, I., Lan, H., Zhong, R., Xu, Q., et al. (2019). Drug Testing in Human&#x02010;Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1. \u003Cem>Clin. Pharmacol. Ther.\u003C/em> 106, 642&#x02013;651. doi:10.1002/cpt.1449\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30947366/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1002/cpt.1449\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Drug+Testing+in+Human%90Induced+Pluripotent+Stem+Cell-Derived+Cardiomyocytes+from+a+Patient+with+Short+QT+Syndrome+Type+1&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\">\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B85\" id=\"B85\">\u003C/a>Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J. C., Robertson, G. A., et al. (1998). Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature. \u003Cem>Biophysical J.\u003C/em> 74, 230&#x02013;241. doi:10.1016/s0006-3495(98)77782-3\u003C/p>\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/9449325/\">PubMed Abstract\u003C/a> &#x0007c; \u003Ca href=\"https://doi.org/10.1016/s0006-3495(98)77782-3\">CrossRef Full Text\u003C/a> &#x0007c; \u003Ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2C5&amp;q=Properties+of+HERG+Channels+Stably+Expressed+in+HEK+293+Cells+Studied+at+Physiological+Temperature&amp;btnG=\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003C/div>\u003Cdiv class=\"thinLineM20\">\u003C/div>\u003Cdiv class=\"AbstractSummary\">\u003Cp>\u003Cspan>Keywords:\u003C/span> short QT syndrome, arrhythmias, antiarrhythmic drugs, human-induced pluripotent stem cell-derived cardiomyocytes, hERG channel\u003C/p>\u003Cp>\u003Cspan>Citation:\u003C/span> Huang M, Liao Z, Li X, Yang Z, Fan X, Li Y, Zhao Z, Lang S, Cyganek L, Zhou X, Akin I, Borggrefe M and El-Battrawy I (2021) Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. \u003Cem>Front. Pharmacol.\u003C/em> 12:675003. doi: 10.3389/fphar.2021.675003\u003C/p>\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 02 March 2021; \u003Cspan>Accepted:\u003C/span> 26 April 2021;\u003Cbr>\u003Cspan>Published:\u003C/span> 07 May 2021.\u003C/p>\u003Cdiv>\u003Cp>Edited by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/29508/overview\">Eleonora Grandi\u003C/a>, University of California, Davis, United States\u003C/div>\u003Cdiv>\u003Cp>Reviewed by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/649436/overview\">Luca Sala\u003C/a>, Istituto Auxologico Italiano, Italy\u003Cbr>\u003Ca href=\"https://loop.frontiersin.org/people/466033/overview\">Michelangelo Paci\u003C/a>, Tampere University, Finland\u003C/div>\u003Cp>\u003Cspan>Copyright\u003C/span> &#x000a9; 2021 Huang, Liao, Li, Yang, Fan, Li, Zhao, Lang, Cyganek, Zhou, Akin, Borggrefe and El-Battrawy. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY).\u003C/a> The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\u003Cp>\u003Cspan>&#x0002a;Correspondence:\u003C/span> Xiaobo Zhou, \u003Ca id=\"encmail\">WGlhb2JvLnpob3VAbWVkbWEudW5pLWhlaWRlbGJlcmcuZGU=\u003C/a>\u003C/p>\u003Cp>\u003Cspan>\u003Csup>&#x02020;\u003C/sup>\u003C/span>These authors have contributed equally to this work\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>\r\n","\u003Cul class=\"flyoutJournal\">\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h3\">Methods\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h6\">Conclusion\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h7\">Study Limitations\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h8\">Data Availability Statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h9\">Author Contributions\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h10\">Funding\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h11\">Conflict of Interest\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h12\">Acknowledgments\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h13\">Supplementary Material\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h14\">References\u003C/a>\u003C/li>\u003C/ul>",[682,687,692,695,700],{"name":683,"fileServerPackageEntryId":19,"fileServerId":684,"fileServerVersionNumber":370,"type":685},"EPUB.epub","675003/epub",{"code":686,"name":686},"EPUB",{"name":688,"fileServerPackageEntryId":688,"fileServerId":689,"fileServerVersionNumber":370,"type":690},"fphar-12-675003.pdf","675003/pubmed-zip",{"code":691,"name":691},"PDF",{"name":688,"fileServerPackageEntryId":19,"fileServerId":693,"fileServerVersionNumber":370,"type":694},"675003/publishers-proof/pdf",{"code":691,"name":691},{"name":696,"fileServerPackageEntryId":696,"fileServerId":689,"fileServerVersionNumber":370,"type":697},"fphar-12-675003.xml",{"code":698,"name":699},"NLM_XML","XML",{"name":701,"fileServerPackageEntryId":19,"fileServerId":702,"fileServerVersionNumber":370,"type":703},"Provisional PDF.pdf","675003/provisional-pdf",{"code":691,"name":691},"v3",{"title":706,"link":707,"meta":711,"script":856},"Frontiers | Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1",[708],{"rel":709,"href":710},"canonical","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/full",[712,715,718,720,723,727,730,734,737,740,743,745,747,749,751,753,756,759,761,764,767,769,772,775,778,781,784,788,792,795,797,800,802,805,807,810,812,815,817,820,822,825,827,830,833,836,838,841,843,846,848,851,853],{"hid":713,"property":713,"name":713,"content":714},"description","Aims The short QT syndrome type 1 (SQT1) is linked to hERG channel mutations (e. g. N588K). Drug effects on hERG channel gating kinetics in SQT1-cells have n...",{"hid":716,"property":716,"name":717,"content":706},"og:title","title",{"hid":719,"property":719,"name":713,"content":714},"og:description",{"hid":721,"name":721,"content":722},"keywords","short QT syndrome,arrhythmias,Antiarrhythmic drugs,Human-induced pluripotent stem cell-derived cardiomyocytes,HERG channel",{"hid":724,"property":724,"name":725,"content":726},"og:site_name","site_name","Frontiers",{"hid":728,"property":728,"name":363,"content":729},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/675003/fphar-12-675003-HTML/image_m/fphar-12-675003-g001.jpg",{"hid":731,"property":731,"name":732,"content":733},"og:type","type","article",{"hid":735,"property":735,"name":736,"content":710},"og:url","url",{"hid":738,"name":738,"content":739},"twitter:card","summary_large_image",{"hid":741,"name":741,"content":742},"citation_volume","12",{"hid":744,"name":744,"content":116},"citation_journal_title",{"hid":746,"name":746,"content":726},"citation_publisher",{"hid":748,"name":748,"content":664},"citation_journal_abbrev",{"hid":750,"name":750,"content":665},"citation_issn",{"hid":752,"name":752,"content":515},"citation_doi",{"hid":754,"name":754,"content":755},"citation_firstpage","675003",{"hid":757,"name":757,"content":758},"citation_language","English",{"hid":760,"name":760,"content":516},"citation_title",{"hid":762,"name":762,"content":763},"citation_keywords","short QT syndrome; arrhythmias; Antiarrhythmic drugs; Human-induced pluripotent stem cell-derived cardiomyocytes; HERG channel",{"hid":765,"name":765,"content":766},"citation_abstract","Aims The short QT syndrome type 1 (SQT1) is linked to hERG channel mutations (e. g. N588K). Drug effects on hERG channel gating kinetics in SQT1-cells have not been investigated. Methods This study used hiPSC-CMs of a healthy donor and a SQT1-patient carrying the N588K mutation and patch clamp to examine the drug effects on hERG channel gating kinetics. Results   Ajmaline, amiodarone, ivabradine, flecainide, quinidine, mexiletine and ranolazine inhibited the hERG channel current (IKr) less strongly in hiPSC-CMs from the SQTS1-patient (SQT1-hiPSC-CMs) comparing with cells from the healthy donor (donor-hiPSC-CMs). Quinidine and mexiletine reduced, but ajmaline, amiodarone, ivabradine and ranolazine increased the time to peak of IKr similarly in SQT1-hiPSC-CMs and donor-hiPSC-CMs. Although regarding the shift of activation and inactivation curves, tested drugs showed differential effects in donor- and SQT1-hiPSC-CMs, quinidine, ajmaline, ivabradine and mexiletine but not amiodarone, flecainide and ranolazine reduced the window current in SQT1-hiPSC-CMs. Quinidine, ajmaline, ivabradine and mexiletine differentially changed the time constant of recovery from inactivation, but all of them increased the time constant of deactivation in SQT1-hiPSC-CMs. Conclusion The window current-reducing and deactivation-slowing effects may be important for the antiarrhythmic effect of ajmaline, ivabradine, quinidine and mexiletine in SQT1-cells. This information may be helpful for selecting drugs for treating SQT1-patients with hERG channel mutation.",{"hid":768,"name":768,"content":524},"citation_article_type",{"hid":770,"name":770,"content":771},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/pdf",{"hid":773,"name":773,"content":774},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675003/xml",{"hid":776,"name":776,"content":777},"citation_fulltext_world_readable","yes",{"hid":779,"name":779,"content":780},"citation_online_date","2021/04/26",{"hid":782,"name":782,"content":783},"citation_publication_date","2021/05/07",{"hid":785,"name":786,"content":787},"citation_author_0","citation_author","Huang, Mengying ",{"hid":789,"name":790,"content":791},"citation_author_institution_0","citation_author_institution","First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Germany",{"hid":793,"name":786,"content":794},"citation_author_1","Liao, Zhenxing ",{"hid":796,"name":790,"content":791},"citation_author_institution_1",{"hid":798,"name":786,"content":799},"citation_author_2","Li, Xin ",{"hid":801,"name":790,"content":791},"citation_author_institution_2",{"hid":803,"name":786,"content":804},"citation_author_3","Yang, Zhen ",{"hid":806,"name":790,"content":791},"citation_author_institution_3",{"hid":808,"name":786,"content":809},"citation_author_4","Fan, Xuehui ",{"hid":811,"name":790,"content":791},"citation_author_institution_4",{"hid":813,"name":786,"content":814},"citation_author_5","Li, Yingrui ",{"hid":816,"name":790,"content":791},"citation_author_institution_5",{"hid":818,"name":786,"content":819},"citation_author_6","Zhao, Zhihan ",{"hid":821,"name":790,"content":791},"citation_author_institution_6",{"hid":823,"name":786,"content":824},"citation_author_7","Lang, Siegfried ",{"hid":826,"name":790,"content":791},"citation_author_institution_7",{"hid":828,"name":786,"content":829},"citation_author_8","Cyganek, Lukas ",{"hid":831,"name":790,"content":832},"citation_author_institution_8","DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and G?ttingen, Germany",{"hid":834,"name":786,"content":835},"citation_author_9","Zhou, Xiaobo ",{"hid":837,"name":790,"content":791},"citation_author_institution_9",{"hid":839,"name":786,"content":840},"citation_author_10","Akin, Ibrahim ",{"hid":842,"name":790,"content":791},"citation_author_institution_10",{"hid":844,"name":786,"content":845},"citation_author_11","Borggrefe, Martin ",{"hid":847,"name":790,"content":791},"citation_author_institution_11",{"hid":849,"name":786,"content":850},"citation_author_12","El-Battrawy, Ibrahim ",{"hid":852,"name":790,"content":791},"citation_author_institution_12",{"hid":854,"name":854,"content":855},"dc.identifier","doi:10.3389/fphar.2021.675003",[857,860,862,864,866],{"src":858,"body":13,"type":859,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":861,"body":13,"type":859,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":863,"body":13,"type":859,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":865,"body":13,"type":859,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fphar.2021.675003?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":867,"body":13,"type":859,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":869,"articleHubArticlesList":870,"canJournalHasArticleHub":347,"articleDoiList":871},{},[],[],{"title":19,"image":-1,"breadcrumbs":873,"linksCollection":874,"metricsCollection":876},[],{"total":367,"items":875},[],{"total":367,"items":877},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fphar.2021.675003?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>